Fused heterocyclic compound, pyrazole-ring-containing fused heterocyclic compound, agricultural composition containing thereof, and method of using the composition

Information

  • Patent Grant
  • 11401271
  • Patent Number
    11,401,271
  • Date Filed
    Friday, November 2, 2018
    6 years ago
  • Date Issued
    Tuesday, August 2, 2022
    2 years ago
  • Inventors
    • Xu; Hanhong
    • Jiang; Xunyuan
    • Wei; Xiaoyi
    • Zhang; Zhixiang
    • Lin; Fei
    • Yao; Guangkai
    • Deng; Chengju
    • Zhao; Chen
    • Yang; Shuai
    • Zhao; Weijing
  • Original Assignees
  • Examiners
    • Carcanague; Daniel R
    Agents
    • JCIPRNET
Abstract
A fused tricyclic compound, an optical isomer, cis and trans isomers or an agromedically acceptable salt thereof, and insecticidal use thereof in agroforestry. A pyrazole-ring-contained fused heterocyclic compound, an agricultural composition, and a method of using the agricultural composition are also provided.
Description
CROSS-REFERENCE TO RELATED APPLICATION

This application is a 371 of international application of PCT application serial no. PCT/CN2018/113811, filed on Nov. 2, 2018, which claims the priority benefit of China application no. 201711069917.7, filed on Nov. 3, 2017 and China application no. 201810219338.4, filed on Mar. 16, 2018. The entirety of each of the above mentioned patent applications is hereby incorporated by reference herein and made a part of this specification.


TECHNICAL FIELD

The present invention belongs to the field of heterocyclic compounds, and more particularly, relates to a fused heterocyclic compound, and an optical isomer, cis and trans isomers or an agromedically acceptable salt thereof, as well as a preparation method and use thereof.


BACKGROUND

New heterocyclic pesticides represented by nitrogen-containing heterocycles have the advantages of high insecticidal activity, wide insecticidal spectrum, low toxicity to mammals and appropriate field stability, so that heterocyclic compounds have become an important hotspot field in the development of new pesticides. In recent years, newly developed pesticides such as Flupyrimin, flupyradifurone, cycloxaprid, sulfoxaflor, flonicamid, spirotetramat, cyflumetofen, cyenopyrafen, cyantraniliprole and the like, all belong to the nitrogen-containing heterocyclic compounds (with reference to patents US2013150414, CN103960242, CN103254125, CN102892290, DE102006015467, WO2010069266, WO2007095229, EP580374, WO9805638, WO2002014263, JP2003201280 and WO2004067528).


However, the problems of serious resistance and cross resistance are caused due to excessive and frequent use of a single pesticide and a high toxicity of the existing insecticide to the environment while killing pests, which reduces an efficacy of the pesticide and greatly restricts use of the pesticide, thus restricting the development of agriculture and forestry. Therefore, how to develop a new pesticide that is more efficient and environmentally friendly and how to solve the problem of resistance become technical problems to be urgently solved in this field.


New structural molecules with big structural differences from previous pesticide molecules are believed to have no cross resistance with the existing pesticides, and may be used to control the development of pest resistance (Pestide Biochemistry and Physiology, 2015, 121: 22). In recent years, multiple series of fused heterocyclic compounds have been synthesized and reported to have an extensive bioactivity (such as Computational Biology and Chemistry, 2018, 74: 218; Bioorganic & Medicinal Chemistry Letters, 2017, 27: 3201; Journal of Medicinal Chemistry, 2017, 60: 9691; Journal of Heterocyclic Chemistry, 2017, 54: 2788; Organic & Biomolecular Chemistry, 2016, 14: 8721; Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 31: 195; New Journal of Chemistry, 2015, 39: 1060; Chemistry-A European Journal, 2015, 21: 16859; Bioorganic & Medicinal Chemistry Letters, 2014, 24: 2693; Journal of Medicinal Chemistry, 2013, 56: 7458; Bioorganic & Medicinal Chemistry Letters, 2009, 19: 4196; Chemistry & Biology, 2007, 14: 153; Journal of Biological Chemistry, 2003, 278: 25990; and Journal of Medicinal Chemistry, 2002, 45: 1035). Based on this, a large number of new fused heterocyclic compounds have been designed, synthesized and screened in this study. These compounds with novel structures have excellent control effects on a variety of pests and even on pests with resistance.


SUMMARY

According to an aspect of the invention, there is provided a nitrogen-containing fused tricyclic compound, and an optical isomer, cis and trans isomers or an agromedically acceptable salt thereof. The fused heterocyclic compound and the optical isomer, the cis and trans isomers or the agromedically acceptable salt thereof have a high killing activity on agroforestry pests and sanitary insect pests and sanitary pests, and more surprisingly, have a delayed working effect on pests such as Solenopsis invicta, thereby having a better killing effect.


According to another aspect of the invention, there is provided a method for preparing the fused tricyclic compound, and the optical isomer, the cis and trans isomers or the agromedically acceptable salt thereof.


According to another aspect of the invention, these is provided a method of using the fused heterocyclic compound and the optical isomer, the cis and trans isomers or the agromedically acceptable salt thereof in preparing an insecticide.


In order to achieve the above objects, the technical solutions adopted by the present invention are as follows.


A fused heterocyclic compound, and an optical isomer, cis and trans isomers or an agromedically acceptable salt thereof, wherein the fused heterocyclic compound has a structure shown in formula (I):




embedded image


wherein R11 and R12 are each independently hydrogen, halogen, —NO2, —CN, —COR17, —CO2R17, —CONR17R18, —S(O) R17, —S(O)2 R17, —N R17 R18, —N R17CO R18, —N R17CON R18R19, —N R17CO2 R18, —N R17S(O)2 R18, alkyl, heteroalkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl; wherein the alkyl, the alkenyl, the cycloalkyl, the cycloalkenyl, the aryl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10; and


R13 is hydrogen, —COR17, —CO2 R17, —S(O)2 R17, —CONR17R18, alkyl, heteroalkyl, alkenyl, cycloalkyl, cycloalkenyl and aryl; wherein the alkyl, the alkenyl, the cycloalkyl, the cycloalkenyl and the aryl are unsubstituted or substituted with one or more substituents R10;


R14 and R15 are each independently hydrogen, halogen, —CN, —OH, —N R17 R18, —O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CON R18R19, —NR17CO2R18, —NR17S(O)2R18, —S(O)R17, —S(O)2R17, alkyl, heteroalkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl; wherein the alkyl, the alkenyl, the cycloalkyl, the cycloalkenyl, the aryl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10, and R14 and R15 are not hydrogen at the same time;


Y is N or CH;


Z1, Z2, Z3 and Z4 are each independently C or N, under conditions that at most two of Z1 to Z4 are N, and a ring containing Z1 to Z4 is aromatic;


R16 represents a substituent on the ring containing Z1 to Z4, one or more R16 are provided, and each R16 is independently hydrogen, halogen, —CN, alkyl, heteroalkyl, —CO R17, —CO2 R17, —N R17 R18, —CONR17R18, —N R17CO R18, —NR17CON R18R19, —NR17CO2R18 or —NR17S(O)2R18;


R17, R18 and R19 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl or heteroaryl; wherein the alkyl, the alkenyl, the cycloalkyl, the cycloalkenyl, the aryl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10; and


R10 is halogen, C1-C6 alkyl, C2-C6 alkenyl, substituted or unsubstituted cycloalkyl, cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, —CN, —NH2, —OR′″, —NR′″R″″, —COR′″, —CO2R′″, —CONR′″R″″, —NR′″COR″″, —NR′″CONR′″R″″, —NR′″CO2R″″, —S(O)2R′″ or —NR′″S(O)2R″″, wherein R′″ and R″″ are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocyclyl.


Preferably, when Y is N or CH;


R11 is halogen, —CN, —COR17, —CONR17R18, —S(O) R17, —N R17 R18, —N R17CO R18, aryl, heterocyclyl or heteroaryl; wherein the alkyl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;


R12 is hydrogen, —COR17, —CONR17R18, —S(O)R17, —S(O)2R17, —N R17 R18, —N R17CO R18, —NR17CONR18R19, —NR17CO2R18, aryl, heterocyclyl or heteroaryl; wherein the alkyl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;


R13 is hydrogen, —COR17, alkyl, heteroalkyl or alkenyl;


R14 is halogen, —CN, —N R17 R18, —O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl, the heteroalkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10; and


R15 is hydrogen, halogen, —CN, —N R17 R18, —O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl, the heteroalkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10.


Preferably, when Z1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently hydrogen, halogen, alkyl, heteroalkyl, alkenyl, —S(O) R17, —S(O)2 R17, —COR17, —N R17 R18, —CONR17R18, —N R17CO R18 or —NR17S(O)2R18;


R11 is halogen, —CN, —COR17, —CONR17R18, —S(O) R17, —N R17 R18, —N R17CO R18, aryl, heterocyclyl or heteroaryl; wherein the alkyl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;


R12 is —CONR17R18, —S(O) R17, —S(O)2 R17, —N R17 R18, —N R17CO R18, —N R17CON R18R19, aryl, heterocyclyl or heteroaryl; wherein the alkyl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;


R13 is hydrogen, —COR17, alkyl or alkenyl; and


R14 and R15 are each independently halogen, —CN, —N R17 R18, —O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CO2R18, alkyl, heteroalkyl and alkenyl; wherein the alkyl, the heteroalkyl and the alkenyl are unsubstituted or substituted with one or more substituents R10.


More preferably,


when Y is N or CH;


R11 is halogen, —CN, —COR17, —CONR17R18, —S(O) R17, —N R17 R18 or —N R17CO R18;


R12 is —S(O) R17, —S(O)2 R17, —N R17 R18, —N R17CO R18, aryl or heteroaryl; wherein the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;


R13 is hydrogen, —COR17, alkyl or alkenyl;


R14 and R15 are each independently halogen, —CN, —N R17 R18, —O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10; and


Z1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently halogen, alkyl, heteroalkyl, —S(O) R17, —S(O)2 R17, —COR17, —N R17 R18, —N R17CO R18 or —NR17S(O)2R18.


More preferably,


R11 is halogen, —CN, —COR17 or —CONR17R18;


R12 is —S(O)R17, —S(O)2R17, —NR17COR18, aryl or heteroaryl; wherein the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;


R13 is hydrogen, —COR17 or alkyl; and


Z1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently halogen, heteroalkyl, —S(O)R17, —NR17R18 or —NR17COR18.


More preferably,


R11 is —CN or —COR17;


R12 is —S(O)R17 or aryl; wherein the aryl is substituted with one or more substituents R10;


R13 is hydrogen, —COR17, methyl or ethyl;


R14 and R15 are each independently halogen, —OR17, —COR17, —CO2R17, —CONR17R18, —NR17COR18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10; and


Z1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently halogen or heteroalkyl.


More preferably,


R11 is —CN or —COR17, and R17 is alkyl or heteroalkyl;


R12 is —S(O)R17, and R17 is alkyl or heteroalkyl;


R13 is hydrogen, —COR17, methyl or ethyl, and R17 is alkyl;


R14 and R15 are each independently halogen, —OR17, —COR17, —CO2R17, —CONR17R18, —NR17COR18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10; and


Z1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently halogen or heteroalkyl.


The present invention further discloses a pyrazole-ring-containing fused heterocyclic compound, and an optical isomer, cis and trans isomers or an agromedically acceptable salt thereof, wherein the pyrazole-ring-containing fused heterocyclic compound has a structure shown in formula (II):




embedded image


wherein R1 is hydrogen, halogen, —CN, alkyl, heteroalkyl, aryl or heteroaryl; wherein the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9; and


R2 is hydrogen, halogen, —CN, —S(O)R7, —S(O)2R7, alkyl, heteroalkyl, aryl or heteroaryl; wherein the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9; and


R3 is hydrogen, —COR7, alkyl or heteroalkyl;


R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted by one or more substituents R9, and R4 and R5 are not hydrogen at the same time;


Z1 and Z2 are independently C or N, and are not N at the same time, and a ring containing Z1 and Z2 is an aromatic ring;


R6 represents a substituent on the ring containing Z1 and Z2, one or more R6 are provided, and each R6 is independently hydrogen, halogen, —NO2, —CN, alkyl, heteroalkyl, —OR7, —COR7, —CO2R7 or —NR7R8;


R7 and R8 are each independently hydrogen, hydroxyl, amino, C1-C6 alkyl, heteroalkyl, aryl or heteroaryl; wherein the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9; and


R9 is halogen, C1-C6 alkyl, heteroalkyl, —CN, —NH2, —OH, —COR′, —CO2R′ or —CONR′R11, wherein R′ and R″ are each independently hydrogen, C1-C6 alkyl or heteroalkyl.


Preferably, when Z1 is N and Z2 is C, R6 is a monosubstituent —CF3 at a 5-position of a pyridine ring, and a general formula of the compound is shown in formula (a):




embedded image



wherein R3 is hydrogen, methyl or chloromethyl; R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9;


or,


when Z2 is N and Z1 is C, R6 is a monosubstituent chlorine at a 5-position of the pyridine ring, and a general formula of the compound is shown in formula (b):




embedded image



wherein R3 is hydrogen, methyl or chloromethyl; R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9;


or,


when Z1 and Z2 are both C, and R6 is disubstituents at a 3-position and a 5-position of a benzene ring, a general formula of the compound is shown in formula (c):




embedded image



wherein R1 is —CN or —CF3, and R2 is —CN, —CF3, —OCF3, —SOCF3 or —SOCH2CH3; R3 is hydrogen, —CH3, —Ac or —CH2CH2Cl; a substituent of R6 at the 3-position of the benzene ring is —Cl, —Br, —CF3, —CH3, —CN, —CO2CH3 or —NO2, and a substituent of R6 at the 5-position of the benzene ring is —Cl, —CF3, —OCF3 or —NO2; R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9;


or,


when Z1 and Z2 are both C, R6 is disubstituents at a 4-position and a 6-position of the benzene ring, and R3 is hydrogen, the general formula of the compound is shown in formula (d):




embedded image



wherein R1 is —CN, —CF3, —COCH3 or —CH2NH2, and R2 is —OCF3, —CF3, —CN, —SOCF3, —SOCH3, —SOCH2CH3, —SOPh, —SOCH2Ph, —SOC6H13,




embedded image



R6 is —Cl or —CF3; R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9;


or,


when Z1 and Z2 are both C, R6 is disubstituents at the 3-position and the 6-position, or at the 3-position and the 4-position, or at the 4-position and the 5-position, or at the 5-position and the 6-position of the benzene ring, and R3 is hydrogen, the general formula of the compound is shown in formula (e):




embedded image



wherein R1 is —CN, and R2 is —SOCF3; R6 is —Cl or —CF3; R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9; and R4 and R5 are not hydrogen at the same time.


Preferably, R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein R7 is hydrogen, halogen, hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkenyl, C1-4 haloalkenyl, amino or substituted amino.


Preferably, when the compound is shown in the formula (a) or the formula (b), and any one of R4 and R5 is hydrogen, R1 is —CN, and R2 is —SOCF3 or —OCF3; or R1 is —CF3, and R2 is —SOCF3;


or, when neither R4 nor R5 is hydrogen, R1 is —CN or —CF3; and R2 is —SOCF3, —SOCH2CH3, —OCF3, —CF3, —CN or halogen.


Preferably, when the compound is shown in the formula (c), R3 is —CH3, —Ac or —CH2CH2Cl, R2 is —SOCF3, R1 is —CN, and both R4 and R5 are —CO2Me;


or, when R3 is hydrogen, R2 is —SOCF3, and R1 is —COCH3 or —CH2NH2, R4 and R5 are independently —CO2Me or —CO2CH2Me;


or, when R3 is hydrogen, and R2 is —OCF3 or —SOCF3, R1 is —CN or —CF3, R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9.


Preferably, when the compound is shown in the formula (d), R3 is hydrogen, and R2 is —CN, —CF3, —SOPh, —SOCH2Ph, —SOC6H13,




embedded image



R1 is —CN, and R4 and R5 are independently —CO2Me or —CO2CH2Me;


or, when R3 is hydrogen, R2 is —SOCF3, and R1 is —COCH3 or —CH2NH2, R4 and R5 are independently —CO2Me or —CO2CH2Me;


or, when R3 is hydrogen, and R2 is —OCF3 or —SOCF3, R1 is —CN or —CF3, R4 and R5 are independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9.


Preferably, when the compound is shown in the formula (e), R6 is 3-Cl and 6-CF3, 3-Cl and 4-CF3, 4-Cl and 5-CF3, or 5-Cl and 6-CF3 on the benzene ring; and R4 and R5 are each independently —CO2Me, —CH2CO2Me, —CO2Et, —CH2CO2Et, —CH2CO2CH2CF3 or —CH2CO2CH2CHF2.


An agricultural composition includes:


(a) 0.001 to 99.99% by weight of the compound above, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt thereof, or a combination thereof; and


(b) an agromedically acceptable carrier and/or excipient.


A method of using the agricultural composition according to the present invention in preparing an insecticide for killing or preventing agroforestry pests, sanitary insect pests and pests harmful to animal health.


A specific method of using is that the insecticide is directly applied to the pests or places contacted by the pests (for example, plants suffering from or probably suffering from pest damages, soil or environment therearound).


Compared with the prior art, the present invention has the following beneficial effects.


The present invention discloses the fused heterocyclic compounds with a new structure and the pyrazole-ring-containing fused heterocyclic compound. The fused heterocyclic compound and the pyrazole-ring-containing fused heterocyclic compound, and the optical isomer, cis and trans isomers or the agromedically acceptable salt thereof have high killing activity on agroforestry pests and sanitary insect pests and the like, and the compound according to the present invention has a delayed effect on pests such as Solenopsis invicta and the like, which enables the pests to carry the compound to a nest, thereby having a better killing effect on the whole Solenopsis invicta nest and a queen Solenopsis invicta. The compound according to the present invention has a good application prospect in pest control. The compound according to the present invention has lower toxicity to environmental organisms such as bees, Bombyx mori L. and the like, thus having a good application prospect.







DETAILED DESCRIPTION

The inventor of the present invention designs, synthesizes and screens a new fused heterocyclic compound and a pyrazole-ring-containing fused heterocyclic compound based on the problems of increasingly serious resistance and harmness to the environment and the like of the existing heterocyclic pesticides upon long-term and in-depth research. An insecticidal activity of the compound is obviously improved, and the compound has an expanded insecticidal spectrum. The present invention is further illustrated hereinafter with reference to the specific embodiments, but the embodiments are not intended to limit the present invention in any form. Unless otherwise specified, all the reagents and methods involved in the embodiments are frequently-used reagents and methods in the field.


In the present invention, unless otherwise specified in the context, meanings expressed by words, phrases and symbols to be used below are regulated as follows. The meanings of the following abbreviations and terms are used throughout the text.


The term “halogen” refers to fluorine, chlorine, bromine and iodine, and the term “halogen” in front of a group name refers to that the group is partially or completely halogenated, i.e., the group is substituted by F, Cl, Br or I in any combination, for example, monofluorodichloromethyl, difluoromethyl, trichloromethyl, pentafluoroethyl, or similar groups.


The term “alkyl” refers to hydrocarbyl, and the hydrocarbyl is selected from a saturated linear-chain or branched-chain hydrocarbyl. The alkyl preferably includes 1 to 12 carbon atoms, and more preferably includes 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or similar groups.


The term “alkenyl” refers to a hydrocarbyl selected from a linear-chain or a branched-chain, and includes at least one C═C double bond. The alkenyl preferably includes 2 to 12 carbon atoms, and more preferably includes 2 to 6 carbon atoms, such as vinyl, prop-1-alkenyl, prop-2-alkenyl, 2-methylprop-1-alkenyl, buta-1,3-dialkylene, 2-methyl-1,3-butadiene, hex-1,3-dialkylene, or similar groups.


The term “cycloalkyl” refers to be selected from to a saturated cyclohydrocarbyl, and includes a monocyclic or polycyclic group. The cycloalkyl preferably has 3 to 12 carbon atoms. For example, the cycloalkyl may be a monocyclic group having 3 to 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl, or similar groups. The cycloalkyl may also be a bicyclic group having 4 to 12 carbon atoms, such as a bicyclic group in [4,5], [5,5], [5,6] and [6,6] ring systems, a bridged bicyclic group selected from bicyclic[2.2.1]heptane, bicyclic[2.2.2]octane and bicyclic[3.2.2]nonane, or similar groups.


The term “cycloalkenyl” refers to be selected from an unsaturated cyclohydrocarbyl, and contains at least one C═C double bond, but is not completely conjugated, and the cycloalkenyl does not belong to an aromatic series (the aromatic series as defined herein), and includes a monocyclic or polycyclic group. The cycloalkenyl preferably has 3 to 12 carbon atoms, such as cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene, cycloheptene, cyclooctene, and cyclopentadiene, or similar groups.


The term “aryl” refers to be selected from the groups as follows: (a) 5 membered and 6 membered carbocyclic aromatic rings, such as phenyl, furan ring or thiophene ring; (b) bicyclic systems such as 7 to 12 membered bicyclic systems, wherein at least one ring is a carboatomic ring and an aromatic ring, such as naphthalene or 1,2,3,4-tetrahydroquinoline; (c) tricyclic systems, such as a 10 to 15 membered tricyclic systems, wherein at least one ring is a carboatomic ring and an aromatic ring, such as fluorene.


For example, the aryl is selected from 5-membered and 6-membered carbocyclic aromatic rings, wherein the carbocyclic aromatic ring is fused to 5 to 7 membered cycloalkyl or a heterocycle optionally containing at least one heteroatom selected from N, O and S, under the conditions that a connection point is on the carbocyclic aromatic ring when the carbocyclic aromatic ring is fused to the heterocycle, and the connection point may be on the carbocyclic aromatic ring or on the cycloalkyl when the carbocyclic aromatic ring is fused to the cycloalkyl. A divalent group formed from a substituted benzene derivative and having a free valence on a ring atom is called a substituted phenylene group. A divalent group derived from a monovalent polycyclic hydrocarbon with a name ended with “yl” by removing a hydrogen atom from a carbon atom having a free valence is named by adding “subunit” to the name of the corresponding monovalent group, for example, a naphthyl having two connection points is called a naphthylene. However, the aryl does not include heterocyclyl or overlaps with heteroaryl, which are defined separately below. Therefore, if one or more carbocyclic aromatic rings are fused with a heterocyclic aromatic ring, a resulting ring system is the heteroaryl as defined herein, rather than the aryl.


The term “heteroalkyl” refers to an alkyl including at least one heteroatom, and the heteroatom refers to a non-C atom. The heteroatom is preferably N, O, S, P or Se, etc.


The term “heteroaryl” refers to be selected from the groups as follows:


5 to 7 membered aromatic monocyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, and the rest ring atoms being carbon;


8 to 12 membered bicyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring;


11 to 14 membered bicyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring;


For example, the heteroaryl includes a 5 to 7 membered heterocyclic aromatic ring fused to a 5 to 7 membered cycloalkyl ring. For the fused bicyclic heteroaryl ring system, only one ring therein contains at least one heteroatom, and a connection point may be located on the heterocyclic aromatic ring or the cycloalkyl ring.


When a total number of Sand O atoms in the heteroaryl exceeds 1, these heteroatoms are not adjacent to each other.


The term “heterocyclyl” refers to be selected from the rings as follows: saturated and partially unsaturated rings of 4 to 12 membered monocyclic, bicyclic and tricyclic rings, which contain at least one carbon atom in addition to 1, 2, 3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen. The term “heterocyclyl” also refers to an aliphatic spiro ring containing at least one heteroatom selected from N, O and S under the condition that a connection point is located on a heterocycle. The ring may be saturated or contain at least one double bond. The heterocycle may be oxidatively substituted. A connection point may be a carbon atom or a heteroatom in the heterocycle.


The term “alkoxy” refers to a hydrocarbonoxy selected from saturated linear or branched hydrocarbonoxy. The alkoxy includes 1 to 12 carbon atoms, and preferably includes 1 to 6 carbon atoms, such as methoxyl, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, or similar groups.


The substituents are selected from halogen, —R′″″, —OR′″″, ═, ═NR′″″, ═N—OR″″″—, —NR′″″R″″″, SR′″″, —OC(O)R′″″, —C(O)R′″″, —NR′″″—SO2NR″″″, —NR″″″CO2R′″″—NH—C(NH2)═NH, —NR′″″C(NH2)═NH, —NH—C(NH2)═NR′″″, —S(O)R′″″, —SO2R′″″, —SO2NR′″″R″″″, —NR″″″SO2R′″″, —CN and —NO2, —CH(Ph)2, halogenated (C1-C4) alkoxy and halogenated (C1-C4)alkyl. A number of the substituents ranges from 0 to 3, and preferably, 0, 1 or 2 substituents are provided. R′″″ and R″″″ are independently selected from hydrogen, unsubstituted (C1-C6) alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1 to 3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy, or aryl-(C1-C4) alkyl. When being connected to the same nitrogen atom, R′″″ and R″″″ can combine with the nitrogen atom to form a 5, 6 or 7 membered ring. Therefore, —NR′″″R′″″ includes 1-pyrrolidinyl and 4-morpholinyl. The “alkyl” includes, for example, trihaloalkyl (e.g., —CF3 and —CH2CF3).


Preferably, the substituents are selected from halogen, —R′″″, —OR′″″, ═O, —NR′″″R″″″, —SR′″″, —OC(O)R′″″, —C(O)R′″″, —CO2R′″″, —CONR′″″R″″″, —OC(O)NR′″″R″″″, —NR″″″C(O)R′″″, —NR″″″CO2R′″″, —S(O)R′″″, —SO2R′″″, —SO2NR′″″R″″″, —NR″″″SO2R′41 ″ —CN and —NO2, halogenated (C1-C4) alkoxy and halogenated (C1-C4) alkyl, wherein R′″″ and R″″″ are defined as above.


The term“fused heterocycle” herein refers to a following cyclic system, such as a bicyclic or tricyclic system, in which two rings share only two ring atoms and one bond, and the ring atoms thereof contain at least one non-C atom. Examples of the fused heterocycle may include fused bi-heterocycloalkyl, such as bi-heterocycles selected from the above [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems composed by arrangement of 7 to 12 ring atoms; fused bicyclic heteroaryl rings, such as the 8 to 12 membered bicyclic heteroaryl rings described above; fused tricyclic heteroaryl rings, such as the 11 to 14 membered tricyclic heteroaryl rings described above, for example, pyrazolo[1,5-a]quinazoline, pyrazolo[1,5-c]quinazoline, pyrrolo[1,2-a]quinazoline, pyrazolo[1,5-a]pyrido[3,2-e]pyrimidine, pyrazolo[1,5-a]pyrido[3,4-e]pyrimidine, pyrazolo[1,5-a]pyrido[2,3-e]pyrimidine, and pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine, etc.; and the fused bicyclic or tricyclic heterocyclic rings.


The compound may contain an asymmetric center, and thus may exist as an enantiomer. When the compound has two or more asymmetric centers, they may additionally exist as diastereomers. The enantiomers and the diastereomers belong to a broader category of stereomers. All these possible stereomers include substantially pure resolved enantiomers (meaning that a target stereomer contains no more than 10% by weight of any other stereomer), racemic mixtures thereof, and diastereomeric mixtures thereof. Unless otherwise stated, one of the mentioned isomers applies to any possible isomer. When isomer components are not specified, all possible isomers are included.


When the compound contains olefinic double bonds, these double bonds refer to geometric isomers containing E and Z, unless otherwise stated.


Some compounds may have different hydrogen connection points, which are called tautomers. For example, a compound containing a carbonyl-CH2C(O)-group (keto form) may undergo tautomerism to form a hydroxyl-CH═C(OH)-group (enol form). During application, the compound also includes the keto form and enol form alone and mixtures thereof.


The term “acceptable salt” refers to a salt with known cations or aions, and may be applied to form use in the field.


Suitable salts with bases, for example, salts formed from compounds of formula (I) and formula (II) containing carboxyl groups, include salts of alkali metals (such as sodium and potassium), alkali earth metals (such as calcium and magnesium), ammonium and amines.


Suitable salts with acid radical additives, such as salts formed from compounds of formula (I) and formula (II) containing amino, include salts formed with inorganic acids such as hydrochloride, sulphate, sulphite, phosphate, hydrogen phosphate and nitrate, and salts formed with organic acids such as acetic acid, malic acid, tartaric acid, citric acid, lactic acid, salicylic acid, oxalic acid, etc.


Moreover, if the compound is obtained as an acid addition salt, free alkalis can be obtained by alkalizing a solution of the acid salt. In contrast, if a product is a free alkali, the addition salt can be prepared by dissolving the free alkali in a suitable organic solvent and treating the solution with an acid, which is consistent with a conventional process of preparing an acid addition salt from an alkaline compound. Those skilled in the art should understand various synthesis methods that can be used to prepare agromedically acceptable addition salts without undue experimentation.


The compound of the present invention can be used to control and kill various agroforestry pests, sanitary insect pests and pests harmful to animal health. In this specification, the “insecticide” is a general designation of substances that have the effect of preventing and controlling all the pests mentioned above. Examples of the pests include, but are not limited to: coleoptera insects such as Sitophilus zeamais, Tribolium castaneum, Henosepilachna vigintioctomacta, Henosepilachna sparsa, Agrarius fusillis, Anomala cupripes, Popillia quadriguttata, Monolepta hieroglyphica, Monochamus alternatus, Echinocnemus squameus, Basiprionota bisignata, Anoplophora chinensis, Apripona germari, Soclytus schevy, or Agriotes fuscicollis; lepidoptera insects such as Lymantria dispar, Malacosoma neustria testacea, Diaphania perspectalis, Clania variegata, Cnidocampa flauescens, Dendrolimus punctatus, Orgyia antiqua, Paranthrene tabaniformis, Spodoptera litura, Chilo suppressalis, Ostrinia nubilalis, Ephestia cautella, Adoxophyes orana, Laspyresia splendana, Agrotis fucosa, Galleria mellonella, Plutella xylostella, Phyllocnistis citrella, or Mythimna separata; hemiptera insects such as Stephanitis nashi; homoptera insects such as Nephotettix cincticeps, Unaspis yanonensis, Myzus persicae, Aphis gossydii, or Bemisia tabaci; orthoptera insects such as Gryllotalpa africana, or Locus migratoria; hymenoptera insects such as Solenopsis invicta, or Tremex fuscicornis; blattaria insects such as Blattella germanica, Periplaneta american, or Copotermes formosamus; diptera insects such as Musca domestica, Aedes aegypti, Delia platura, Culex sp., or Anopheles sinensis; and plant parasitic nematodes such as Meloidogyne, Pratylenchus spp., Aphelenchoides besseyi Christie, Bursaphelenchus xylophilus, etc. The pests harmful to animal health include Boophilus microplus, Haemaphysalis longicornis, Hyalomma anatolicum, Hypoderma spp., Fasciola hepatica, Moniezia blanchard, Ostertagia spp., Trypanosoma enansi, Babesia bigemina, etc.


The compound related to the present invention preferably has a high activity on agroforestry pests such as lepidoptera, hymenoptera, hemiptera, coleoptera, diptera and blattaria pests, as well as animal parasitic fleas and/or ticks and mites and sanitary insect pest, and more preferably has a high activity on piercing-sucking or chewing mouthpart pests.


Insecticide composition containing the active substances of the present invention


The active substances of the present invention may be prepared into an insecticide composition by a conventional method. These active compounds may be combined into conventional preparations, such as solutions, emulsions, suspensions, powders, foams, pastes, granules, aerosols, natural and synthetic materials impregnated with the active substances, microcapsules in polymers, coating compounds for seeds, and preparations for use with firing units (such as smoking cartridges, smoking cans, and smoking pans), as well as ultra-low volume (ULV) Cloud mist and Warm mist preparations.


These preparations may be produced by known methods, for example, the active compounds are mixed with extenders, which are liquid or liquefied gas or solid diluents or carriers, and optionally surfactants, i.e., emulsifiers and/or dispersants and/or foam formers. For example, when water is used as the extender, organic solvents may also be used as auxiliaries.


It is basically suitable to use liquid solvents as the diluents or carriers, such as aromatic hydrocarbons, for example, xylene, toluene or alkyl naphthalene; chlorinated aromatic or chlorinated aliphatic hydrocarbons such as chlorobenzene, vinyl chloride or methylene chloride; aliphatic hydrocarbons such as cyclohexane, paraffin or mineral oil fractions; alcohols such as ethanol or glycol as well as ethers and lipids thereof; ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone; or polar solvents that are not frequently used such as dimethylformamide, dimethyl sulphoxide, and water. The liquefied gas diluents or carriers refer to liquids that will become gas at normal temperature and pressure, such as aerosol propellants, for example, halogenated hydrocarbons and butane, propane, nitrogen and carbon dioxide.


The solid carriers may be ground natural minerals such as kaolin, clay, tale, quartz, activated clay, montmorillonite, or diatomite, and ground synthetic minerals such as highly dispersed silicic acid, alumina, and silicates. The solid carriers for granules are crushed and graded natural zircon, such as calcite, marble, pumice, sepiolite and dolomite, as well as granules synthesized from inorganic and organic coarse powders, and organic materials such as granules of sawdust, coconut shells, corn cobs and tobacco stems, etc.


Non-ionic and anionic emulsifiers may be used as emulsifiers and/or foam formers, for example, polyoxyethylene-fatty acid esters, polyoxyethylene-fatty alcohol ethers, such as alkaryl polyethylene glycol ethers, alkyl sulfonic acid esters, alkyl sulfates, aryl sulfonic esters, and albumin hydrolysates. The dispersants include, for example, lignin sulfite lye and methylcelluloses.


Adhesives such as carboxymethyl cellulose and natural and synthetic polymers in the form of powders, granules or emulsions, such as Arabic gum, polyvinyl alcohol and polyvinyl acetate, may be used in the preparations. Colorants such as inorganic dyes, for example, iron oxide, cobalt oxide and Prussian blue; organic dyes, such as dichloro dyes or metal cyanine dyes; and trace nutrients such as salts of iron, manganese, boron, cop, cobalt, aluminum and zinc may be used.


These active compounds of the present invention may be mixed with other active compounds to prepare a mixture that can be present in commercial preparations or in use preparation forms prepared from these preparations. The other active compounds include, but are not limited to: insecticides, baits, fungicides, acaricides, nematicides, fungicides, growth control agents, and the like. The insecticides include, for example, phosphates, carbamates, pyrethroids, chlorinated hydrocarbons, benzamides, nereistoxin and substances produced by microorganisms, such as abamectin.


Furthermore, these active compounds of the present invention may also be mixed with synergists to prepare a mixture that can be present in commercial preparations or in use preparation forms prepared from these preparations. The synergist is a compound that enhances the effect of the active compounds. Since the active compounds have activity, it is not necessary to add the synergist.


These preparations generally contain 0.001 to 99.99% by weight, preferably 0.01 to 99.9% by weight, more preferably 0.05 to 90% by weight of the active compound of the present invention in the insecticide composition. Concentration of the active compounds in the use preparation form prepared from the commercial preparations may vary within a wide range. The concentrations of the active compounds in the use preparation forms may range from 0.0000001 to 100% (g/v), and may preferably be between 0.0001 and 1%.


The present invention will be described in further detail below with reference to the specific embodiments, and the specific embodiments are only used to explain the present invention and are not used to limit the scope of the present invention. The experimental methods used in the following embodiments are conventional unless otherwise specified. The materials and reagents used are commercially available materials and reagents unless otherwise specified.


SYNTHESIS EMBODIMENTS
Embodiment 1: Synthesis of Compounds A1 to A47 by Using a Method A



embedded image


For instance, synthesis of a compound A1:


S1:5-amino-1H-pyrazole-3-cyano

Ethyl 2,3-dicyanopropionate (1.0 mmol) was added to 20.0 ml of ethanol and stirred vigorously, then hydrazine hydrate (2.0 mmol) was added to the reaction solution, heated and refluxed, then the heating was stopped after 3 hours, and the mixture was cooled to room temperature. The mixture was concentrated in vacuum and extracted with ethyl acetate and water, then the obtained ethyl acetate was concentrated and extracted in vacuum to obtain white solid 5-amino-1H-pyrazole-3-cyano, and the intermediate was directly used for next step without further purification.


S2:5,5-dimethyl-4,5-dihydropyrazole[1,5-α]quinazoline-2-cyano

Under the protection of nitrogen, a DMF mixture of 5-amino-H-pyrazole-3-cyano (1.0 mmol), 1-bromo-2-(1-bromo-1-methylethyl)benzene (1.0 mmol), cuprous iodide (0.2 mmol) and cesium carbonate (0.5 mmol) was stirred at 100° C. for 24 hours. The mixture was cooled to room temperature, and then filtered, and concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 5,5-dimethyl-4,5-dihydropyrazole[1,5-α]quinazoline-2-cyano (yield of the two steps: 45%).


The compounds A2 to A47 were synthesized with reference to the method of the compound A1 (wherein cyclization steps also included similar cyclization methods mentioned in documents such as Tetrahedron Letters (2015) 56: 1367; WO2016046404, and WO2013174822), with a difference that different raw materials were selected for reaction according to different target compounds, or the compounds were derived from the synthesized target products. Specific compounds were as shown in Table 1:
















TABLE 1





Com-









pound
Structural formula
R11
R12
R13
R14
R15
R16







A1


embedded image


—CN
—H
—H
—CH3
—CH3
—H





A2


embedded image


—CN
—Br
—H
—CH3
—CH3
—H





A3


embedded image


—CN
—Br
—CH3
—CH3
—CH3
—H





A4


embedded image


—CN
—Br
—Ac
—CH3
—CH3
—H





A5


embedded image


—Ac
—Br
—H
—CH3
—CH3
—H





A6


embedded image


—CONHCH3
—Br
—H
—CH3
—CH3
—H





A7


embedded image


—CONC5H10
—Br
—H
—CH3
—CH3
—H





A8


embedded image


—CN
—SOCF3
—H
—CH3
—CH3
—H





A9


embedded image


—CN
—SC2H5
—H
—CH3
—CH3
—H





A10


embedded image


—CF3
—H
—H
—CF3
—CF3
5′-NH2





A11


embedded image


—CF3
-Br
-H
—CF3
—CF3
5'-NH2





A12


embedded image


—CF3
-4 fluorophenyl
—H
—CF3
—CF3
5'-NH2





A13


embedded image


—CF3
—SCF3
—H
—CF3
—CF3
5′-NH2





A14


embedded image


—CF3
—SOC2H5
—H
—CF3
—CF3
5′-NH2





A15


embedded image


—CN
—NH2
—H
—CH3
—CH3
—H





A16


embedded image


—CN
—NHC4H9
—H
—CH3
—CH3
—H





A17


embedded image


—CN
—NHCOCH3
—H
—CH3
—CH3
—H





A18


embedded image


—CN
—NHCO2Ph
—H
—CH3
—CH3
—H





A19


embedded image


—CN
—NHCONHCH3
—H
—CH3
—CH3
—H





A20


embedded image


—CN
—NHSO2Ph-4CH3
—H
—CH3
—CH3
—H





A21


embedded image


—CN
—NO2
—H
—CH3
—CH3
—H





A22


embedded image


—H
—CN
—H
—CH2NH2
—F
5-Cl





A23


embedded image


—H
—CN
—H
—CH2NH2
—NH2
5-Cl





A24


embedded image


—H
—CN
—H
—CH2NHCH3
—NHCH3
5-Cl





A25


embedded image


—SCH3
—CN
—H
—CF3
—F
/





A26


embedded image


—SOCH3
—CN
—H
—CF3
—F
/





A27


embedded image


—SCH3
—COOEt
—H
—CF3
—F
/





A28


embedded image


—SCH3
—CONH2
—H
—CF3
—F
/





A29


embedded image


—SCH3
—CON(CH3)2
—H
—CF3
—F
/





A30


embedded image


—SCH3
—CON2C4CH3
—H
—CF3
—F
/





A31


embedded image


—SCH3
—CN
—COOPh
—CF3
—F
/





A32


embedded image


—SCH3
—CN
—CONHCH3
—CF3
—F
/





A33


embedded image


—SCH3
—CN
—SO2CH3
—CF3
—F
/





A34


embedded image


—SCH3
—CN
—CH2C2H3
—CF3
—F
/





A35


embedded image


—SCH3
—CN
—C2H4Br
—CF3
—F
/





A36


embedded image


—NH2
—H
—H
CH2CF3
—F
Z2═N





A37


embedded image


—NHC2H5
—H
—H
—CH2CF3
—F
Z2═N





A38


embedded image


—N(C2H5)CH2C2H3
—H
—H
—CH2CF3
—F
Z2═N





A39


embedded image


—NHCOCH3
—H
—H
—CH2CF3
—F
Z2═N





A40


embedded image


—NHCOOCH3
—H
—H
—CH2CF3
—F
Z2═N





A41


embedded image


—NHCONHCH3
—H
—H
—CH2CF3
—F
Z2═N





A42


embedded image


—NHSO2CH3
—H
—H
—CH2CF3
—F
Z2═N





A43


embedded image


—NO2
—H
—H
—CH2CF3
—F
Z2═N





A44


embedded image


—SCH3
—COOEt
—H
—CH3
—CH3
4-F, Z2═Z4═N





A45


embedded image


—SCH3
—SO2Ph
—H
—CH3
—CH3
4-F, Z2═Z4═N





A46


embedded image


—SCH2Ph
—CN
—H
—CH3
—CH3
4-F, Z2═Z4═N





A47


embedded image


—SO2CH2Ph
—CN
—H
—CH3
—CH3
4-F, Z2═Z4═N









Embodiment 2: Synthesis of Compounds B1 to B12 by Using a Method B



embedded image


For instance, synthesis of a compound B1:


S1:2-amino-4-(4-methoxybenzene)-1H-pyrrole-3-cyano

2-bromo-1-(4-methoxyphenyl)-acetyl (1.0 mmol) was added to 15 ml of DMF, and then sodium azide (10.0 mmol) was added to the reaction solution. After the reaction mixture was stirred for 48 hours, the reaction mixture was filtered, and an obtained filtrate was extracted with ethyl ether for multiple times. Concentration in vacuum was performed, the residues were dissolved with methanol, and then 10% palladium carbon (0.2 mmol) was added thereto in a hydrogen atmosphere. The reaction mixture was stirred for 24 hours, and then filtered. An obtained filtrate was concentrated in vacuum, the residues were dissolved with tetrahydrofuran, and then acetic anhydride (2.0 mmol) and triethylamine (2.0 mmol) were added thereto. The reaction mixture was stirred for 5 hours, and then concentrated in vacuum, and the residues were purified by column chromatography to obtain N-(2-(4-methoxyphenyl)-2-ethoxy)-acetamide (yield: 78%).


N-(2-(4-methoxyphenyl)-2-ethoxy)-acetamide (1.0 mmol) was added to 15 ml of ethanol, and then malononitrile (2.0 mmol) and sodium ethoxide (1.5 mmol) were added thereto. The mixture was heated and refluxed for 12 hours, and then concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound (yield: 89%).


S2:2-bromo-2-(2-chloro-4-nitrophenyl)malononitrile

Under nitrogen protection, 2-chloro-4-nitro-benzoyl chloride (1.0 mmol) was dissolved in 10 ml of dry pyridine, cooled to 0° C., then trimethylsilylnitrile (1.1 mmol) was slowly added dropwise to the reaction solution, and the reaction solution was naturally heated to room temperature. After stirring for 10 hours, the reaction mixture was cooled to 0° C. again, and 2 ml of phosphorous oxybromide was added to the reaction mixture. After stirring for 12 hours, the solution was removed in vacuum, and the residues were extracted with water and ethyl acetate. Then the ethyl acetate was obtained by concentration and extraction in vacuum, and the residues were purified by column chromatography to obtain the 2-bromo-2-(2-chloro-4-nitrophenyl)malononitrile (yield: 56%).


S3:2-(4-methoxybenzene)-8-nitropyrrole[1,2-α]quinazoline-3,5,5(4H)-tricyano

Under the protection of nitrogen, a DMF mixture of 2-amino-4-(4-methoxybenzene)-1H-pyrrole-3-cyano (1.0 mmol), 2-bromo-2-(2-chloro-4-nitrophenyl)malononitrile (1.1 mmol), cuprous iodide (0.2 mmol) and sodium ethoxide (0.5 mmol) was stirred at 120° C. for 24 hours. The mixture was cooled to room temperature, and then filtered, and concentrated in vacuum, and the residues were purified by column chromatography to obtain the 2-(4-methoxybenzene)-8-nitropyrrole[1,2-α]quinazoline-3,5,5(4H)-tricyano (yield: 53%).


The compounds B2 to B12 were synthesized with reference to the method of the compound B1 (similar cyclization methods mentioned in documents such as Synthetic Communications (2015) 45: 2426; Tetrahedron (2014) 55: 4997; and WO2007149907), with a difference that different raw materials were selected for reaction according to different target compounds, and some compounds, such as compounds B9, B10, B11, B12, etc., could be obtained by modifying B7. Specific compounds were as shown in Table 2:
















TABLE 2





Compound
Structural formula
R11
R12
R13
R14
R15
R16







B1


embedded image


4-methoxy phenyl
—CN
—H
—CN
—CN
5′-NO2





B2


embedded image


4- methoxy phenyl
—CN
—CH3
—CN
—CN
5′-NO2





B3


embedded image


4- methoxy phenyl
—COCH3
—H
—CN
—CN
5′-NO2





B4


embedded image


4- methoxy phenyl
—COCH3
—H
—CONH2
—CONH2
5′-NO2





B5


embedded image


Phenyl
—SO2Ph
—H
—F
—F
5′-Cl





B6


embedded image


—CN
—CN
—H
—CN
—CN
5′-NO2





B7


embedded image


—CN
—CN
—H
—CN
—CN
5′-NH2





B8


embedded image


—CN
—CN
—H
—CN
—CN
5′- NHCOC2 H3





B9


embedded image


—CN
—CN
—H
—CN
—CN
5′-Br





B10


embedded image


—CN
—CN
—H
—CN
—CN
5′- NHSO2C H3





B11


embedded image


—CN
—CN
—H
—CN
—CN
5′- NHCOOC H3





B12


embedded image


—CN
—CN
—H
—CN
—CN
5′- NHCONH CH3









Embodiment 3: Synthesis of Compounds C1 to C64 by Using a Method C



embedded image


For instance, synthesis of a compound C1:


S1: (2-amino-3-chloro-5-(trifluoromethyl)phenyl)boric acid

Under the protection of nitrogen, 2-bromo-6-chloro-4-trifluoromethylaniline (1.0 mmol) was dissolved in 20 ml of dry tetrahydrofuran, and cooled to 0° C., then n-butyl lithium (2.5 mmol, 1.6 M n-hexane solution) was slowly added dropwise to the reaction mixture, and stirred for 2 hours. Trimethylchlorosilane (2.5 mmol) was slowly added dropwise to the reaction mixture for reaction, and then the reaction mixture was naturally heated and stirred for 12 hours, the solvent was removed by vacuum concentration, and the target compound (2-amino-3-chloro-5-(trifluoromethyl)phenyl)boric acid (yield: 87%) was obtained by reduced pressure distillation.


S2:2-chloro-6-(1,2-dichloro-3-butene-2-yl)-4-(trifluoromethyl)phenylamine

Under the protection of nitrogen, a DMF mixture (3.0 ml) of 3-bromo-3,4-dichloro-1-butene (1.0 mmol), Pd(dppf)Cl2 (0.15 mmol), sodium carbonate (0.15 mmol) and (2-amino-3-chloro-5-(trifluoromethyl)phenyl)boric acid (1.5 mmol) and water (0.5 ml) were stirred at 100° C. for 10 hours. After the solution was removed in vacuum, the residues were diluted with water (10 ml). Then a water layer was extracted with ethyl acetate, and the ethyl acetate was obtained by concentration and extraction in vacuum, and the residues were purified by column chromatography to obtain the target compound 2-chloro-6-(1,2-dichloro-3-butene-2-yl)-4-(trifluoromethyl)phenylamine (yield: 85%).


S3: 2-bromo-1-chloro-3-(1,2-dichloro-3-butene-2-yl)-5-(trifluoromethyl)phenyl

Under the protection of nitrogen, 2-bromo-1-chloro-3-(1,2-dichloro-3-butene-2-yl)-5-(trifluoromethyl)phenyl (1.0 mmol) and cupric bromide (1.5 mmol) were dissolved in 10 ml of acetonitrile, cooled to −5° C., and then isoamyl nitrite (1.3 mmol) was slowly added thereto, and the reaction mixture was heated to 50° C. After three hours, the mixture was filtered, and the filtrate was concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 2-bromo-1-chloro-3-(1,2-dichloro-3-butene-2-yl)-5-(trifluoromethyl)phenyl (yield: 91%).


S4: 9-chloro-7-trifluoromethylphenyl-5-chloromethyl-5-vinyl-4,5-dihydropyrrole[1,5-α]quinazoline-2-cyano

Under the protection of nitrogen, a DMF mixture of 5-amino-1H-pyrazole-3-cyano (1.0 mmol), 2-bromo-1-chloro-3-(1,2-dichloro-3-butene-2-yl)-5-(trifluoromethyl)phenyl (1.1 mmol), cuprous iodide (0.2 mmol) and sodium ethoxide (0.5 mmol) was stirred at 120° C. for 24 hours. The mixture was cooled to room temperature, and then filtered. The filtrate was concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 9-chloro-7-trifluoromethylphenyl-5-chloromethyl-5-vinyl-4,5-dihydropyrrole[1,5-α]quinazoline-2-cyano (yield: 52%).


The compounds C2 to C64 were synthesized with reference to the method of the compound C1 (similar cyclization methods were mentioned in documents such as WO2007144669), with a difference that different raw materials were selected for reaction according to different target compounds. Specific compounds were as shown in Table 3.
















TABLE 3





Compound
Structural formula
R11
R12
R13
R14
R15
R16







C1


embedded image


—CN
—H
—H
—C2H3
—CH2Cl
4′-CF3, 6′-Cl





C2


embedded image


—CN
—H
—H
—C2H3
—CH2CF3
4′-CF3, 6′-Cl





C3


embedded image


—CN
—H
—H
—C2H3
—CF3
4′-CF3, 6′-Cl





C4


embedded image


—CN
—H
—H
—C2H3
—H
4′-CF3, 6′-Cl





C5


embedded image


—CN
—Br
—H
—C2H3
—CH2Cl
4′-CF3, 6′-Cl





C6


embedded image


—CN
—Br
—H
—C2H3
—CH2CF3
4′-CF3, 6′-Cl





C7


embedded image


—CN
—Br
—H
—C2H3
—CF3
4′-CF3, 6′-Cl





C8


embedded image


—CN
—Br
—H
—C2H3
—H
4′-CF3, 6′-Cl





C9


embedded image


—CN
-6 trifluoro methylphenyl
[*]—H
—C2H3
—CH2Cl
4′-CF3, 6′-Cl





C10


embedded image


—CN
-3-2,5- dimethyl furanyl
—H
—C2H3
—CH2Cl
4′-CF3, 6′-Cl





C11


embedded image


—CN
-6 trifluoro methylphenyl
—H
—C2H3
—CF3
4′-CF3, 6′-Cl





C12


embedded image


—CN
-3-2,5- dimethyl furanyl
—H
—C2H3
—CF3
4′-CF3, 6′-Cl





C13


embedded image


—CN
—SOCF3
—H
—C2H3
—CH2Cl
4′-CF3, 6′-Cl





C14


embedded image


—CN
—SOCF3
—H
—C2H3
—CH2CF3
4′-CF3, 6′-Cl





C15


embedded image


—CN
—SOCF3
—H
—C2H3
—CF3
4′-CF3, 6′-Cl





C16


embedded image


—CN
—SOCF3
—H
—C2H3
—CH
4′-CF3, 6′-Cl





C17


embedded image


—CN
—SOC2H5
—H
—C2H3
—CH2Cl
4′-CF3, 6′-Cl





C18


embedded image


—CN
—SOCH3
—H
—C2H3
—CH2Cl
4′-CF3, 6′-Cl





C19


embedded image


—COCH3
—SOCH3
—H
—C2H3
—CH2Cl
4′-CF3, 6′-Cl





C20


embedded image


—CN
—SOCF3
—H
—C2H3
—CH2CN
4′-CF3, 6′-Cl





C21


embedded image


—CN
—SOC2H5
—H
—C2H3
—CH2CN
4′-CF3, 6′-Cl





C22


embedded image


—CN
—SOCH3
—H
—C2H3
—CH2CN
4′-CF3, 6′-Cl





C23


embedded image


—COCH3
—SOC2H5
—H
—C2H3
—CH2CN
4′-CF3, 6′-Cl





C24


embedded image


—CN
—SOCF3
—H
—CH2CN
—CH2OH
4′-CF3, 6′-Cl





C25


embedded image


—CN
—SOC2H5
—H
—CH2CN
—CH2OH
4′-CF3, 6′-Cl





C26


embedded image


—CN
—SOCH3
—H
—CH2CN
—CH2OH
4′-CF3, 6′-Cl





C27


embedded image


—COCH3
—SOCH3
—H
—CH2CN
—CH2OH
4′-CF3, 6′-Cl





C28


embedded image


—CN
—SOCF3
—H
—CH2CN
—CH2Br
4′-CF3, 6′-Cl





C29


embedded image


—CN
—SOCF3
—H
—CH2CN
—CH2N(CH3)2
4′-CF3, 6′-Cl





C30


embedded image


—CN
—SOCF3
—H
—CH2CN
—COOH
4′-CF3, 6′-Cl





C31


embedded image


—CN
—SOCF3
—H
—CH2CN
—COOMe
4′-CF3, 6′-Cl





C32


embedded image


—CN
—SOCF3
—H
—CH2CN
—CONH2
4′-CF3, 6′-Cl





C33


embedded image


—CN
—SOCF3
—H
—CH2CN
—CONHCH3
4′-CF3, 6′-Cl





C34


embedded image


—CN
—SOCF3
—H
—CH2CN
—CON2C4CH3
4′-CF3, 6′-Cl





C35


embedded image


—CN
—SOCF3
—H
—CH2COMe
—CONHCH3
4′-CF3, 6′-Cl





C36


embedded image


—CN
—SOCF3
—H
—CH2COOH
—COOH
4′-CF3, 6′-Cl





C37


embedded image


—CN
—SOCF3
—H
—CH2COOH
—COOMe
4′-CF3, 6′-Cl





C38


embedded image


—CN
—SOCF3
—H
—CH2COONH2
—COONH2
4′-CF3, 6′-Cl





C39


embedded image


—CN
—SOCF3
—H
—CH2COMe
—COOMe
4′-CF3, 6′-Cl





C40


embedded image


—CN
—SOCF3
—COCH3
—CH2COOMe
—COOMe
4′-CF3, 6′-Cl





C41


embedded image


—COCH3
—SOCH3
—H
—CH2CN
—CH2Br
4′-CF3, 6′-Cl





C42


embedded image


—COCH3
—SOCH3
 H
—CH2NHCH3
—CH2CN
4′-CF3, 6′-Cl





C43


embedded image


—COCH3
—SOCH3
 H
—COOH
—CH2CN
4′-CF3, 6′-Cl





C44


embedded image


—COCH3
—SOCH3
—H
—COOMe
—CH2CN
4′-CF3, 6′-Cl





C45


embedded image


—COCH3
—SOCH3
 H
—CONHCH3
—CH2CN
4′-CF3, 6′-Cl





C46


embedded image


—COCH3
—SOCH3
—H
—CONHCH3
—CH2COOMe
4′-CF3, 6′-Cl





C47


embedded image


—COCH3
—SOCH3
—H
—COOH
—CH2COOH
4′-CF3, 6′-Cl





C48


embedded image


—COCH3
—SOCH3
—H
—COOME
—CH2COOMe
4′-CF3, 6′-Cl





C49


embedded image


—COCH3
—SOCH3
—H
—CONH2
—CH2CONH2
4′-CF3, 6′-Cl





C50


embedded image


—CN
-3-2,5- dimethyl furanyl
—H
—C2H3
—H
4′-CF3, 6′-Cl





C51


embedded image


—CN
—SOCF3
—H
—C2H3(OH)2
—H
4′-CF3, 6′-Cl





C52


embedded image


—CN
-3-2,5- dimethyl furanyl
—H
—C2H3(OH)2
—H
4′-CF3, 6′-Cl





C53


embedded image


—CN
6- trifluoro methylphenyl
—H
—C2H3(OH)2
—CH2Cl
4′-CF3, 6′-Cl





C54


embedded image


—CN
-3-2,5- dimethyl furanyl
—H
—C2H3(OH)2
—CF3
4′-CF3, 6′-Cl





C55


embedded image


—CN
—SOCF3
—H
—C2H3(OH)2
—CH2Cl
4′-CF3, 6′-Cl





C56


embedded image


—CN
—SOCF3
 H
—C2H3(OH)2
—CH2CF3
4′-CF3, 6′-Cl





C57


embedded image


—CN
—SOCF3
 H
—C2H3(OH)2
—CF3
4′-CF3, 6′-Cl





C58


embedded image


—CN
—SOCF3
—H
—CH2CN
—C2H2COOMe
4′-CF3, 6′-Cl





C59


embedded image


—CN
—SOC2H5
—H
—CH2CN
—C2H2COOMe
4′-CF3, 6′-Cl





C60


embedded image


—COCH3
—SOCH3
—H
—CH2CN
—C2H2COOMe
4′-CF3, 6′-Cl





C61


embedded image


—C2H5
—Br
—H
—C2H3
—C2H3
4′-CF3, 6′-Cl





C62


embedded image


—C2H5
-3-2,5- dimethyl thienyl
—H
—C2H3
—C2H3
4′-CF3, 6′-Cl





C63


embedded image


—C2H5
—Br
—H
—C2H2COOMe
—C2H2COOMe
4′-CF3, 6′-Cl





C64


embedded image


—C2H5
-3-2,5- dimethyl thienyl
—H
—C2H2COOMe
—C2H2COOMe
4′-CF3, 6′-Cl
















TABLE 4







Hydrogen Spectrum and Mass Spectrum Data of Nuclear Magnetic


Resonance of Some Compounds shown in Formula (I) of Table 1









Com-




pound

1H-NMR(600 MHz)

MS (ESI)





A1

1H-NMR (600 MHz, CDCl3) δ 7.73

[M + H]+ 225.1



(dd, J = 8.0, 1.4 Hz, 1H), 7.50-7.46




(m, 1H), 7.44-7.37 (m, 2H), 5.93




(s, 1H), 5.78 (Brs, 1H), 1.27(s, 3H),




1.25(s, 3H).



A2

1H-NMR (600 MHz, CDCl3) δ 7.75

[M + H]+ 302.9



(dd, J = 8.0, 1.3 Hz, 1H), 7.56-7.51




(m, 1H), 7.48-7.45 (m, 2H), 5.86




(Brs, 1H), 1.28(s, 3H), 1.27(s, 3H).



A4

1H-NMR (600 MHz, CDCl3) δ 7.75

[M + H]+ 345.1



(dd, J = 8.0, 1.3 Hz, 1H), 7.56-7.51




(m, 1H), 7.48-7.45 (m, 2H), 2.06




(s, 3H), 1.30(s, 3H), 1.29(s, 3H).



A5

1H-NMR (600 MHz, CDCl3) δ 7.77

[M + H]+ 319.8



(dd, J = 8.0, 1.3 Hz, 1H), 7.57-7.53




(m, 1H), 7.49-7.47 (m, 2H), 2.16




(s, 3H), 1.28(s, 3H), 1.27(s, 3H).



A7

1H-NMR (600 MHz, CDCl3) δ 7.77

[M + H]+ 389.3



(dd, J = 8.0, 1.3 Hz, 1H), 7.57-7.53




(m, 1H), 7.49-7.47 (m, 2H), 2.01-1.93




(m, 2H), 1.83-1.74 (m, 2H),




1.67-1.59 (m, 1H), 1.40-1.27 (m, 4H),




1.28(s, 3H), 1.27(s, 3H) , 1.24-




1.13 (m, 1H).



A8

1H-NMR (600 MHz, CDCl3) δ 7.78 (dd,

[M + H]+ 341.0



J = 8.0, 1.3 Hz, 1H), 7.58-7.54




(m, 1H), 7.50-7.48 (m, 2H), 5.86




(Brs, 1H), 1.28(s, 3H), 1.27(s, 3H).



A12

1H-NMR (600 MHz, CDCl3) δ 7.40-7.38

[M + H]+ 485.4



(m, 2H), 7.35-7.33 (m, 2H), 7.12




(d, J = 8.0, 2H), 6.68-6.65 (m, 1H),




6.63-6.61 (m, 1H), 5.86 (Brs, 1H),




5.78 (s, 1H).



A15

1H-NMR (600 MHz, CDCl3) δ 7.73

[M + H]+ 240.5



(dd, J = 8.0, 1.4 Hz, 1H), 7.50-7.46




(m, 1H), 7.44-7.37 (m, 2H), 6.26




(Brs, 2H), 5.78 (Brs, 1H), 1.27(s, 3H),




1.25(s, 3H).



A18

1H-NMR (600 MHz, CDCl3) δ 9.25

[M + H]+ 359.9



(Brs, 1H), 7.73 (dd, J = 8.0, 1.4 Hz,




1H), 7.50-7.46 (m, 1H), 7.44-7.37




(m, 2H), 7.27-7.19 (m, 3H), 7.14-




7.10 (m, 2H), 5.58 (Brs, 1H),




1.27(s, 3H), 1.25(s, 3H).



A19

1H-NMR (600 MHz, CDCl3) δ 7.73

[M + H]+ 297.4



(dd, J = 8.0, 1.4 Hz, 1H), 7.50-7.46




(m, 1H), 7.44-7.37 (m, 2H), 6.06




(s, 1H), 5.78 (Brs, 1H), 2.78(s, 3H),




1.29(s, 3H), 1.28(s, 3H).



A21

1H-NMR (600 MHz, CDCl3) δ 7.76 (dd,

[M + H]+ 270.3



J = 8.0, 1.3 Hz, 1H), 7.56-7.51




(m, 1H), 7.49-7.47 (m, 2H), 5.93




(Brs, 1H), 1.29(s, 3H), 1.27(s, 3H).



A22

1H-NMR (600 MHz, CDCl3) δ 8.30

[M + H]+ 278.2



(s, 1H), 8.17 (d, J = 7.6 Hz, 1H), 8.10-




8.08 (m, 1H), 7.46 (d, J = 2.5 Hz, 1H),




5.21 (s, 1H), 4.78 (brs, 2H), 3.21-




3.45(m, 2H).



A26

1H-NMR (600 MHz, CDCl3) δ 7.78

[M + H]+ 345.1



(dd, J = 8.0, 1.3 Hz, 1H), 7.58-7.54




(m, 1H), 7.50-7.48 (m, 2H), 5.86




(Brs, 1H), 3.06 (s, 3H).



A27

1H-NMR (600 MHz, CDCl3) δ 7.79

[M + H]+ 376.0



(dd, J = 8.0, 1.3 Hz, 1H), 7.57-7.54




(m, 1H), 7.49-7.48 (m, 2H), 5.5




(Brs, 1H), 4.38 (d, J = 7.3 Hz, 2H), 2.54




(s, 3H), 1.29 (t, J = 7.3 Hz, 3H).



A29

1H-NMR (600 MHz, CDCl3) δ 7.79

[M + H]+ 375.1



(dd, J = 8.0, 1.3 Hz, 1H), 7.57-7.54




(m, 1H), 7.49-7.48 (m, 2H), 5.5




(Brs, 1H), 2.93 (s, 6H) 2.54 (s, 3H).



A33

1H-NMR (600 MHz, CDCl3) δ 7.79

[M + H]+ 407.1



(dd, J = 8.0, 1.3 Hz, 1H), 7.57-7.54




(m, 1H), 7.49-7.48 (m, 2H), 5.5




(Brs, 1H), 3.35 (s, 3H) 2.56 (s, 3H).



A37

1H-NMR (600 MHz, CDCl3) δ 8.40

[M + H]+ 316.1



(s, 1H), 7.50-7.46 (m, 1H), 7.44-




7.37 (m, 1H), 6.56 (s, 1H), 5.78




(Brs, 1H), 4.56 (s, 1H), 4.38 (d, J = 7.3




Hz, 2H), 2.56-2.58(m, 2H), 1.29




(t, J = 7.3 Hz, 3H).



A43

1H-NMR (600 MHz, CDCl3) δ 8.41

[M + H]+ 318.1



(s, 1H), 7.50-7.46 (m, 1H), 7.44-




7.37 (m, 1H), 6.76 (s, 1H), 5.78




(Brs, 1H), 2.56-2.58(m, 2H).



A44

1H NMR (600 MHz, CDCl3) δ 9.18

[M + H]+ 338.3



(s, 1H), 5.78 (Brs, 1H), 4.35 (d, J =




7.3 Hz, 2H), 2.54(s, 3H), 1.28 (t,




J = 7.3 Hz, 3H), 1.27 (s, 3H), 1.26 (s,




3H).



A45

1H-NMR (600 MHz, CDCl3) δ 9.18

[M + H]+ 405.1



(s, 1H), 7.44-7.37 (m, 2H), 7.27-




7.19 (m, 3H), 5.78 (Brs, 1H), 2.54(s, 3H),




1.27 (s, 3H), 1.26 (s, 3H).



A46

1H-NMR (600 MHz, CDCl3) δ 9.20

[M + H]+ 367.0



(s, 1H), 7.44-7.37 (m, 2H), 7.27-




7.19 (m, 3H), 5.78 (Brs, 1H), 4.46-4.44




(m, 2H), 1.27 (s, 3H), 1.26 (s, 3H).
















TABLE 5







Hydrogen Spectrum and Mass Spectrum Data of Nuclear Magnetic


Resonance of Some Compounds shown in Formula (I) of Table 2









Com-




pound

1H-NMR (600 MHz)

MS (ESI)












B1

1H NMR (600 MHz, CDCl3) δ 8.19

[M + H]+ 397.1



(d, J = 7.6 Hz, 1H), 8.11 (d, J = 8.0




Hz, 1H), 7.68 (d, J = 3.6 Hz, 2H),




7.48 (d, J = 2.6 Hz, 1H), 7.25 (s, 1H),




7.15 (d, J = 3.8 Hz, 2H), 5.40 (s, 1H),




3.86 (s, 3H).



B4

1H NMR (600 MHz, DMSO) δ 8.21

[M + H]+ 450.3



(d, J = 7.6 Hz, 1H), 8.15 (d, J = 8.0




Hz, 1H), 7.78 (d, J = 3.6 Hz, 2H),




7.53 (d, J = 2.6 Hz, 1H), 7.33 (s, 1H),




7.18 (d, J = 3.8 Hz, 2H), 6.67 (brs,




2H), 6.43 (brs, 2H), 5.44 (s, 1H), 3.89




(s, 3H), 2.59 (s, 3H).



B5

1H NMR (600 MHz, CDCl3) δ 7.87 (d,

[M + H]+ 469.9



J = 7.6 Hz, 2H), 7.69-7.68 (m, 1H),




7.68 (d, J = 3.6 Hz, 2H), 7.51-7.50




(m, 2H), 7.42-7.40 (m, 2H), 7.41-7.40




(m, 1H), 7.31-7.30 (m, 1H), 7.25 (s,




1H), 7.15-7.14 (m, 1H), 5.40 (s, 1H),




2.28 (s, 3H).



B6

1H NMR (600 MHz, CDCl3) δ 8.18 (d,

[M + H]+ 316.2



J = 7.6 Hz, 1H), 8.11 (d, J = 8.0




Hz, 1H), 7.48 (d, J = 2.6 Hz, 1H),




7.24 (s, 1H), 5.38 (s, 1H).



B7

1H NMR (600 MHz, CDCl3) δ 8.18

[M + H]+ 286.2



(d, J = 7.6 Hz, 1H), 8.11 (d, J = 8.0




Hz, 1H), 7.48 (d, J = 2.6 Hz, 1H),




7.24 (s, 1H), 5.38 (s, 1H), 4.67 (brs,




2H).



B8

1H NMR (600 MHz, CDCl3) δ 9.76(s,

[M + H]+ 340.0



1H), 8.17 (d, J = 7.6 Hz, 1H), 8.09




(d, J = 8.0 Hz, 1H), 7.49 (d, J = 2.6




Hz, 1H), 7.25 (s, 1H), 6.53-6.55 (m,




1H), 6.02 (dd, J = 8.0, 2.0 Hz, 1H),




5.86 (dd, J = 6.0, 2.0 Hz, 1H), 5.38 (s,




1H),.



B9

1H NMR (600 MHz, CDCl3) δ 8.17

[M + H]+ 349.1



(d, J = 7.6 Hz, 1H), 8.10 (d, J = 7.9




Hz, 1H), 7.46 (d, J = 2.5 Hz, 1H),




7.24 (s, 1H), 5.21 (s, 1H).
















TABLE 6







Hydrogen Spectrum and Mass Spectrum Data of Nuclear


Magnetic Resonance









Com-




pound

1H-NMR(600 MHz)

MS (ESI)





C5

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 450.9



(s, 1H), 7.58 (s, 1H), 7.28 (s, 1H),




6.30-6.29 (m, 1H), 5.02-4.99




(m, 2H), 3.55-3.23 (m, 2H).



C6

1H NMR (600 MHz, CDCl3) δ 8.14

[M + H]+ 485.1



(s, 1H), 7.56 (s, 1H), 7.17 (s, 1H),




6.30-6.29 (m, 1H), 5.02-4.99




(m, 2H), 2.81-2.79 (m, 2H).



C7

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 470.9



(s, 1H), 7.58 (s, 1H), 7.28 (s, 1H),




6.30-6.29 (m, 1H), 5.02-4.99 (m, 2H).



C8

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 402.9



(s, 1H), 7.58 (s, 1H), 7.28 (s, 1H),




6.30-6.29 (m, 1H), 5.02-4.99 (m, 2H),




4.65 (t, J = 3.6 Hz, 1H).



C9

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 517.1



(s, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.68




(d, J = 6.8 Hz, 1H), 7.51-7.49 (m,




2H), 7.58 (s, 1H), 7.28 (s, 1H), 6.30-




6.29 (m, 1H), 5.02-4.99 (m, 2H),




3.55-3.23 (m, 2H).



C12

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 487.0



(s, 1H), 7.58 (s, 1H), 7.28 (s, 1H),




6.30-6.29 (m, 1H), 6.01 (s, 1H),




5.02-4.99 (m, 2H), 2.28 (s, 3H), 2.25 (s,




3H).



C15

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 508.9



(s, 1H), 7.58 (s, 1H), 7.16 (s, 1H),




6.30-6.29 (m, 1H), 5.02-4.99 (m, 2H).



C20

1H NMR (600 MHz, CDCl3) δ 8.14

[M + H]+ 480.0



(s, 1H), 7.56 (s, 1H), 7.17 (s, 1H),




6.30-6.29 (m, 1H), 5.02-4.99 (m, 2H),




2.86-2.73 (m, 2H).



C24

1H NMR (600 MHz, CDCl3) δ 8.14 (s,

[M + H]+ 484.1



1H), 7.56 (s, 1H), 7.11 (s, 1H), 4.56




(s, 1H), 2.86-2.73 (m, 2H),




2.64-2.53 (m, 2H).



C28

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 545.9



(s, 1H), 7.57 (s, 1H), 7.08 (s, 1H),




2.86-2.73 (m, 2H), 2.64-2.53 (m, 2H).



C30

1H NMR (600 MHz, CDCl3) δ 10.20

[M + H]+ 497.9



(brs, 1H), 8.14 (s, 1H), 7.56 (s, 1H),




7.11 (s, 1H), 2.86-2.73 (m, 2H).



C31

1H NMR (600 MHz, CDCl3) δ 8.14

[M + H]+ 511.9



(s, 1H), 7.56 (s, 1H), 7.11 (s, 1H), 3.68




(s, 3H), 2.86-2.73 (m, 2H).



C36

1H NMR (600 MHz, CDCl3) δ 10.20

[M + H]+ 516.9



(brs, 1H), 9.86 (brs, 1H), 8.13 (s,




1H), 7.58 (s, 1H), 7.28 (s, 1H),




3.55-3.23 (m, 2H).



C37

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 545.0



(s, 1H), 7.58 (s, 1H), 7.28 (s, 1H), 3.82




(s, 3H), 3.66 (s, 3H), 3.55-3.23 (m, 2H).



C40

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 587.0



(s, 1H), 7.58 (s, 1H), 3.82 (s, 3H), 3.66




(s, 3H), 3.55-3.23 (m, 2H), 2.04 (s, 3H).



C54

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 521.0



(s, 1H), 7.58 (s, 1H), 7.18 (s, 1H), 6.03




(s, 1H), 4.06-4.04 (m, 1H) 3.81-3.56




(m, 2H), 3.78 (s, 1H), 3.44 (s,




1H), 2.82 (s, 3H), 2.66 (s, 3H),.



C59

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 498.0



(s, 1H), 7.58 (s, 1H), 7.48 (d, J = 6.4




Hz, 1H), 7.08 (s, 1H), 5.46 (dd,




J = 6.4, 2.0 Hz, 1H), 3.77 (s, 3H), 3.55-




3.23 (m, 2H), 3.30 (d, J = 7.0 Hz, 1H),




3.28-3.26 (m, 1H), 1.40 (t, J = 7.6




Hz, 3H).



C61

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 432.0



(s, 1H), 7.67 (s, 1H), 7.08 (s, 1H),




6.32-6.30 (m, 2H), 5.01-5.00 (m, 1H),




4.98-4.96 (m, 1H), 4.82-4.70 (m,




2H), 4.08 (dd, J = 8.6, 2.4 Hz, 2H), 1.25




(t, J = 8.6 Hz, 3H).



C62

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 464.1



(s, 1H), 7.67 (s, 1H), 7.08 (s, 1H), 6.68




(s, 1H), 6.32-6.30 (m, 2H), 5.01-5.00




(m, 1H), 4.98-4.96 (m, 1H), 4.82-




4.70 (m, 2H), 4.08 (dd, J = 8.6, 2.4




Hz, 2H), 2.36 (s, 3H), 2.30 (s, 3H),




1.25 (t, J-8.6 Hz, 3H).



C63

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 548.0



(s, 1H), 7.67 (s, 1H), 7.08 (s, 1H),




6.32-6.30 (m, 2H), 5.01-5.00 (m, 1H),




4.98-4.96 (m, 1H), 4.08 (dd, J =




8.7, 2.4 Hz, 2H), 3.78 (s, 3H), 3.57




(s, 3H), 1.25 (t, J = 8.7 Hz, 3H).









Embodiment 4: Synthesis of Compounds a-1 to a-138 by Using a Method D

Method D:




embedded image


Taking a compound a-44 for example, a specific preparation process was as follows:


S1:5-amino-1H-pyrazole-3-cyano

Ethyl 2,3-dicyanopropionate (1.0 mmol) was added to 20.0 mL of ethanol and stirred vigorously, then hydrazine hydrate (2.0 mmol) was added to the reaction solution, heated and refluxed, then the heating was stopped after 3 hours, and the mixture was cooled to room temperature. The mixture was concentrated in vacuum and extracted with ethyl acetate and water, then the obtained ethyl acetate was concentrated and extracted in vacuum to obtain white solid 5-amino-1H-pyrazole-3-cyano, and the intermediate was directly used for next step without further purification.


S2: 5,5-dichloro-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline[3,2-e]pyridine-2-cyano

Under the protection of nitrogen, a DMF mixture of 5-amino-1H-pyrazole-3-cyano (1.0 mmol), 2-bromo-3-(trichloromethyl)-5-trifluoromethylpyridine (1.0 mmol), cuprous iodide (0.2 mmol) and cesium carbonate (0.5 mmol) was stirred at 120° C. for 24 hours. The mixture was cooled to room temperature, and then filtered, and concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 5,5-dichloro-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline[3,2-e]pyridine-2-cyano (yield of the two steps: 25%).


S3: 5,5-dichloro-7-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-α]quinazoline[3,2-e]pyridine-2-cyano

Under the protection of nitrogen, an anhydrous toluene mixture of 5,5-dichloro-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline[3,2-e]pyridine-2-cyano (0.2 mmol), trifluoromethylsulfinyl chloride (0.5 mmol) and dimethylamine p-toluenesulfonate was stirred and heated at 100° C. for 24 hours. The mixture was cooled to room temperature, and then filtered, and concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 5,5-dichloro-7-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-α]quinazoline[3,2-e]pyridine-2-cyano (yield: 77%).


The compounds a-1 to a-138 were synthesized with reference to the method of the compound a-44 (wherein cyclization steps also included similar cyclization methods mentioned in documents such as Tetrahedron Letters (2015) 56: 1367; WO2016046404, and WO2013174822), with a difference that different raw materials were selected for reaction according to different target compounds, or the compounds were derived from the synthesized target products through hydrolysis, simple esterification or amidation or reduction-oxidation. Specific compounds were as shown in Table 7.









TABLE 7







Compound Structure with a General Formula Shown in Formula (a)














Structural









formula
Compound
R1
R2
R3
R4
R5
R6





Formula
a-1
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
5-CF3


(a)
a-2




—CH2CN




a-3




—CH2CONH2




a-4




—CH2CONHCH3




a-5




—CH2CH2OH




a-6




—CH(CO2Me)CH3




a-7


—CH3

—CH2CO2Me




a-8


—CH2CH2Cl

—CH2CO2Me




a-9


H

—CH2CO2Et




a-10




—CH2CO2CH2CF3




a-11




—CH2CO2CH2CHF2




a-12




—CH2CO2CH(CF3)2




a-13




—CH2CO2C(CH3)2CF3




a-14




—CH2CO2C(CF3)2CH3




a-15




—CH2CO2CH(CF3)OCH3




a-16




—CH2Ph




a-17




—CH2COCH3




a-18




—CH2Br




a-19




—CH2CF3




a-20




—CH2COCF3




a-21

—SOCH2CH3


—CH2CO2Me




a-22

—SOCF3
H
—CO2Et
—CH2CO2Et




a-23




—CH2CO2Me




a-24




—CH2CO2CH2CF3




a-25



—COCF3
—CH2COCF3




a-26




—CH2COCH3




a-27




—CH2Ph




a-28




—CH2CO2Me




a-29




—CH2Br




a-30




—CH2CN




a-31




—CH2CF3




a-32



—COCH3
—CH2COCH3




a-33




—CH2CO2Me




a-34




—CH2Br




a-35




—CH2CN




a-36




—CH2CF3




a-37




—CH2COCF3




a-38



—CONHMe
—CH2COCH3




a-39




—CH2CO2Me




a-40




—CH2Br




a-41




—CH2CF3




a-42




—CH2COCF3




a-43



—NHMe
—CH2CN




a-44



—Cl
—Cl




a-45




—CH2Br




a-46




—CH2Cl




a-47




—CH2CN




a-48




—CH2CF3




a-49



—Br
—CH2Cl




a-50




—CH2COCF3




a-51



—CH3
—CH3




a-52



—CN
—CN




a-53




—CH2CN




a-54




—CH2CF3




a-55




—CH2Cl




a-56




—CH2CO2Me




a-57




—CH2COCF3




a-58



CF3
—CF3




a-59




—CH2CN




a-60




—CH2CF3




a-61




—CH2Cl




a-62




—CH2CO2Me




a-63




—CH2COCF3




a-64
—CN
—SOCF3
H
H
—CO2Me




a-65




—CH2CO2Me




a-66




—CH(CO2Me)CH3




a-67




—CH2CO2CH2CF3




a-68




—CO2CH2CF3




a-69




—CH2CO2CH(CF3)2




a-70




—CH2COCF3




a-71




—COCF3




a-72




—CN




a-73




—CH2CN




a-74




—CF3




a-75




—CH2CF3




a-76




—CONHMe




a-77




—CH2CONHCH3




a-78




—CH2COCH3




a-79




—COCH3




a-80




—Cl




a-81




—Br




a-82




—CH2Cl




a-83




—CH2CH2Cl




a-84




—CHCHCl




a-85




—CH(CH3)2




a-86




—CH═CHCH3




a-87
—CF3
—SOCF3
H
H
—CO2Me




a-88




—CH2CO2Me




a-89




—CH(CO2Me)CH3




a-90




—CH2CO2CH2CF3




a-91




—CO2CH2CF3




a-92




—CH2CO2CH(CF3)2




a-93




—CH2COCF3




a-94




—COCF3




a-95




—CN




a-96




—CH2CN




a-97




—CF3




a-98




—CH2CF3




a-99




—CONHMe




a-100




—CH2CONHCH3




a-101




—CH2COCH3




a-102




—COCH3




a-103




—Cl




a-104




—Br




a-105




—CH2Cl




a-106




—CH2CH2Cl




a-107




—CHCHCl




a-108




—CH(CH3)2




a-109




—CH═CHCH3




a-110
—CN
—CCF3
H
H
—CO2Me




a-111




—CH2CO2Me




a-112




—CH(CO2Me)CH3




a-113




—CH2CO2CH2CF3




a-114




—CO2CH2CF3




a-115




—CH2CO2CH(CF3)2




a-116




—CH2COCF3




a-117




—COCF3




a-118




—CN




a-119




—CH2CN




a-120




—CF3




a-121




—CH2CF3




a-122




—CONHMe




a-123




—CH2CONHCH3




a-124




—CH2COCH3




a-125




—COCH3




a-126




—Cl




a-127




—Br




a-128




—CH2Cl




a-129




—CH2CH2Cl




a-130




—CHCHCl




a-131




—CH(CH3)2




a-132




—CH═CHCH3




a-133
—CN
—Cl
H
—CO2Me
—CH2CO2Me




a-134

—CF3







a-135

—OCF3







a-136
—CF3
—CN







a-137

—OCF3







a-138

—SOCF3









Embodiment 5: Synthesis of Compounds b-1 to b-138 by Using a Method E

Method E:




embedded image


Taking a compound b-87 for example, a specific synthesis process was as follows:


S1: 5-amino-1H-pyrazole-3-trifluoromethyl (Referring to Document Journal of Medical Chemistry (2017) 60: 5099)

Under the protection of nitrogen, sodium hydride (2.5 mmol) was added to 20 ml of anhydrous tetrahydrofuran at 0° C., then anhydrous acetonitrile (2.0 mmol) and ethyl trifluoroacetate (1.0 mmol) were added to the reaction solution, heated and refluxed, and then the heating was stopped after 20 hours. The mixture was cooled to room temperature, and concentrated in vacuum. The mixture was extracted with ethyl ether and water, and diluted hydrochloric acid was added to adjust a pH to 2, then the mixture was extracted with ethyl ether, and concentrated in vacuum to obtain brown oily matter 4,4,4-trifluoro-3-carbonyl butyronitrile. The intermediate was directly used in next step without further purification.


Methanesulfonic acid (2.0 ml) was added to a mixture of 4,4,4-trifluoro-3-carbonyl butyronitrile (1.0 mmol) and hydrazine hydrate (1.0 ml), and the mixture was heated to 80° C. and reacted for 10 hours. Then, water and ethyl acetate were added for extraction, and concentrated in vacuum. The residues obtained were purified by column chromatography to obtain the target compound 5-amino-1H-pyrazole-3-trifluoromethyl which was as a yellow liquid (yield of the two steps: 15%), 1H NMR (400 MHz, DMSO-d6): δ 12.15 (s, 1H), 5.53 (s, 1H), 5.35 (s, 2H).


S2:6-chloro-2-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline[4,3-e]pyridine-5-methyl formate

Under the protection of nitrogen, a DMF mixture of 5-amino-1H-pyrazole-3-trifluoromethyl (1.0 mmol), 2-bromo-2-(3-bromo-5-chloropyridine-4-yl)-methyl acetate (1.0 mmol), cuprous iodide (0.2 mmol) and sodium ethoxide (0.5 mmol) was stirred at 100° C. for 24 hours. The mixture was cooled to room temperature, and then concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 6-chloro-2-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline[4,3-e]pyridine-5-methyl formate (yield: 35%).


S3: 6-chloro-2-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-α]quinazoline[4,3-e]pyridine-5-methyl formate

Under the protection of nitrogen, an anhydrous toluene mixture of 6-chloro-2-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline[4,3-e]pyridine-5-methyl formate (0.2 mmol), trifluoromethylsulfinyl chloride (0.5 mmol) and dimethylamine p-toluenesulfonate was stirred and heated at 100° C. for 24 hours. The mixture was cooled to room temperature, and then concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 6-chloro-2-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-α]quinazoline[4,3-e]pyridine-5-methyl formate, wherein the yield was 85%.


The compounds b-1 to b-138 were synthesized with reference to the method of the compound b-87 (wherein cyclization steps also included similar cyclization methods mentioned in documents such as Synthetic Communications (2015) 45: 2426; Tetrahedron Letters (2014) 55: 4997; and WO2007149907) with a difference that different raw materials were selected for reaction according to different target compounds, or the compounds were derived from the synthesized target products through hydrolysis, simple esterification or amidation or reduction-oxidation. Specific compounds were as shown in Table 8.









TABLE 8







Compound Structure with a General Formula Shown in Formula (b)














Structural









formula
Compound
R1
R2
R3
R4
R5
R6





Formula
b-1
—CN
 SOCF3
H
—CO2Me
—CH2CO2Me
5-Cl


(b)
b-2




—CH2CN




b-3




—CH2CONH2




b-4




—CH2CONHCH3




b-5




—CH2CH2OH




b-6




—CH(CO2Me)CH3




b-7


—CH3

—CH2CO2Me




b-8


—CH2CH2Cl

—CH2CO2Me




b-9


H

—CH2CO2Et




b-10




—CH2CO2CH2CF3




b-11




—CH2CO2CH2CHF2




b-12




—CH2CO2CH(CF3)2




b-13




—CH2CO2C(CH3)2CF3




b-14




—CH2CO2C(CF3)2CH3




b-15




—CH2CO2CH(CF3)OCH3




b-16




—CH2Ph




b-17




—CH2COCH3




b-18




—CH2Br




b-19




—CH2CF3




b-20




—CH2COCF3




b-21

—SOCH2CH3


—CH2CO2Me




b-22

—SOCF3
H
—CO2Et
—CH2CO2Et




b-23




—CH2CO2Me




b-24




—CH2CO2CH2CF3




b-25



—COCF3
—CH2COCF3




b-26




—CH2COCH3




b-27




—CH2Ph




b-28




—CH2CO2Me




b-29




—CH2Br




b-30




—CH2CN




b-31




—CH2CF3




b-32



—COCH3
—CH2COCH3




b-33




—CH2CO2Me




b-34




—CH2Br




b-35




—CH2CN




b-36




—CH2CF3




b-37




—CH2COCF3




b-38



—CONHMe
—CH2COCH3




b-39




—CH2CO2Me




b-40




—CH2Br




b-41




—CH2CF3




b-42




—CH2COCF3




b-43



—NHMe
—CH2CN




b-44



—Cl
—Cl




b-45




—CH2Br




b-46




—CH2Cl




b-47




—CH2CN




b-48




—CH2CF3




b-49



—Br
—CH2Cl




b-50




—CH2COCF3




b-51



—CH3
—CH3




b-52



—CN
—CN




b-53




—CH2CN




b-54




—CH2CF3




b-55




—CH2Cl




b-56




—CH2CO2Me




b-57




—CH2COCF3




b-58



CF3
—CF3




b-59




—CH2CN




b-60




—CH2CF3




b-61




—CH2Cl




b-62




—CH2CO2Me




b-63




—CH2COCF3




b-64
—CN
—SOCF3
H
H
—CO2Me




b-65




—CH2CO2Me




b-66




—CH(CO2Me)CH3




b-67




—CH2CO2CH2CF3




b-68




—CO2CH2CF3




b-69




—CH2CO2CH(CF3)2




b-70




—CH2COCF3




b-71




—COCF3




b-72




—CN




b-73




—CH2CN




b-74




—CF3




b-75




—CH2CF3




b-76




—CONHMe




b-77




—CH2CONHCH3




b-78




—CH2COCH3




b-79




—COCH3




b-80




—Cl




b-81




—Br




b-82




—CH2Cl




b-83




—CH2CH2Cl




b-84




—CHCHCl




b-85




—CH(CH3)2




b-86




—CH═CHCH3




b-87
—CF3
—SOCF3
H
H
—CO2Me




b-88




—CH2CO2Me




b-89




—CH(CO2Me)CH3




b-90




—CH2CO2CH2CF3




b-91




—CO2CH2CF3




b-92




—CH2CO2CH(CF3)2




b-93




—CH2COCF3




b-94




—COCF3




b-95




—CN




b-96




—CH2CN




b-97




—CF3




b-98




—CH2CF3




b-99




—CONHMe




b-100




—CH2CONHCH3




b-101




—CH2COCH3




b-102




—COCH3




b-103




—Cl




b-104




—Br




b-105




—CH2Cl




b-106




—CH2CH2Cl




b-107




—CHCHCl




b-108




—CH(CH3)2




b-109




—CH═CHCH3




b-110
—CN
—OCF3
H
H
—CO2Me




b-111




—CH2CO2Me




b-112




—CH(CO2Me)CH3




b-113




—CH2CO2CH2CF3




b-114




—CO2CH2CF3




b-115




—CH2CO2CH(CF3)2




b-116




—CH2COCF3




b-117




—COCF3




b-118




—CN




b-119




—CH2CN




b-120




—CF3




b-121




—CH2CF3




b-122




—CONHMe




b-123




—CH2CONHCH3




b-124




—CH2COCH3




b-125




—COCH3




b-126




—Cl




b-127




—Br




b-128




—CH2Cl




b-129




—CH2CH2Cl




b-130




—CHCHCl




b-131




—CH(CH3)2




b-132




—CH═CHCH3




b-133
—CN
—Cl
H
—CO2Me
—CH2CO2Me




b-134

—CF3







b-135

—OCF3







b-136
—CF3
—CN







b-137

—OCF3







b-138

—SOCF3









Embodiment 6: Synthesis of Compounds c-1 To c-349 by Using a Method F

Method F:




embedded image


Taking a compound c-27 for example, a specific synthesis process was as follows:


S1: 6-chloro-2-cyano-5-(2′2-diethoxy)-8-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-ethyl formate

Under the protection of nitrogen, a DMF mixture of 5-amino-1H-pyrazole-3-cyano (1.0 mmol), 2-bromo-2-(2-bromo-6-chloro-4-trifluoromethylphenyl)diethyl malate (1.0 mmol), cuprous iodide (0.2 mmol) and caesium carbonate (0.5 mmol) was stirred at 100° C. for 24 hours. The mixture was cooled to room temperature, and then filtered. The filtrate was concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 6-chloro-2-cyano-5-(2′2-diethoxy)-8-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-ethyl formate (yield: 30%).


S2: 6-chloro-2-cyano-5-(2′2-diethoxy)-8-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-ethyl formate

Under the protection of nitrogen, an anhydrous toluene mixture of 6-chloro-2-cyano-5-(2′2-diethoxy)-8-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-ethyl formate (0.2 mmol), trifluoromethylsulfinyl chloride (0.5 mmol) and dimethylamine p-toluenesulfonate was stirred and heated at 100° C. for 24 hours. The mixture was cooled to room temperature, and then concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 6-chloro-2-cyano-5-(2′2-diethoxy)-8-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-ethyl formate, wherein the yield was 82%.


S3: 2-(6-chloro-2-cyano-5-(2′2-diethoxy)-8-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-yl)-acetic acid

6-chloro-2-cyano-5-(2′2-diethoxy)-8-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-ethyl formate (1.0 mmol) was dissolved in 5 ml of dioxane, and then 10 ml of 1N HCl was added thereto. The mixture was heated and refluxed for 5 hours, and then ethyl acetate was added for extraction. Then the mixture was concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 2-(6-chloro-2-cyano-5-(2′2-diethoxy)-8-trifluoromethyl-3-trifluoromethylsulfinyl-4,5-dihydropyrazole[1,5-]quinazoline-5-yl)-acetic acid, wherein the yield was 78.


The compounds c-1 to c-349 were synthesized with reference to the method of the compound c-27 (wherein cyclization steps also included similar cyclization methods mentioned in documents such as WO2007144669) with a difference that different raw materials were selected for reaction according to different target compounds, or the compounds were derived from the synthesized target products through hydrolysis, simple esterification or amidation or reduction-oxidation. Specific compounds were as shown in Table 9.









TABLE 9







Compound Structure with a General Formula Shown in Formula (c)













Structural




















formula
Compound
R1
R2
R3
R4
R5
R6





General
c-1
—CN
—CN
H
—CO2Me
—CH2CO2Me
3-Cl, and


formula
c-2

—CF3



5-CF3


(c)
c-3

—OCF3







c 4
—CF3
—CN







c-5

—CF3







c-6

—OCF3







c-7

—SOCF3







c-8
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me




c-9




—CH2CN




c-10




—CH2CONH2




c-11




—CH2CONHCH3




c-12




—CH2CH2OH




c-13




—CH(CO2Me)CH3




c-14


—CH3

—CO2Me




c-15


—Ac






c-16


—CH2CH2Cl






c-17


H

—CH2CO2Et




c-18




—COOH




c-19




—CH2CO2CH2CF3




c-20




—CH2CO2CH2CHF2




c-21




—CH2CO2CH(CF3)2




c-22




—CH2CO2C(CH3)2CF3




c-23




—CH2CO2C(CF3)2CH3




c-24




—CH2CO2C(CF3)OCH3




c-25



—CO2Et
—CH2CO2Me




c-26




—CH2CO2Et




c-27




—CH2CO2H




c-28




—CH2CO2CH2CF3




c-29




—CH2CO2CH2CHF2




c-30




—CH2CO2CH(CF3)2




c-31




—CH2CO2C(CH3)2CF3




c-32




—CH2CO2C(CF3)2CH3




c-33




—CH2CO2C(CF3)OCH3




c-34



—COCF3
—CH2COCF3




c-35




—CH2COCH3




c-36




—CH2Ph




c-37




—CH(CH3)2




c-38




—CH2CO2Me




c-39




—COCH3




c-40




—CO2Me




c-41




—CH2Br




c-42




—CH2CH2Cl




c-43




—CN




c-44




—CH2CN




c-45




—CF3




c-46




—CH2CF3




c-47



—COCH3
—CH2COCF3




c-48




—CH2COCH3




c-49




—CH2Ph




c-50




—CH(CH3)2




c-51




—CH2CO2Me




c-52




—COCH3




c-53




—CO2Me




c-54




—CH2Br




c-55




—CH2CH2Cl




c-56




—CN




c-57




—CH2CN




c-58




—CF3




c-59




—CH2CF3




c-60



—CO2Me
—CO2Me




c-61




—CH2Ph




c-62




—CH3




c-63




—CH2COCH3




c-64




—CH2Br




c-65




—CH2CH2Cl




c-66




—Br




c-67




—CN




c-68




—CF3




c-69




—CH2CF3




c-70




—CH2COCF3




c-71



—CONHMe
—CH2COCH3




c-72




—COCH3




c-73




—CO2Me




c-74




—CH2CO2Me




c-75




—CH2Ph




c-76




—CH3




c-77




—Br




c-78




—CH2Br




c-79




—CH2CH2Cl




c-80




—CN




c-81




—CH2CN




c-82




—CF3




c-83




—CH2CF3




c-84




—CH2COCF3




c-85




—COCF3




c-86



—F
—F




c-87



—Cl
—Cl




c-88




—CH2Br




c-89




—CH2Cl




c-90




—CN




c-91




—CH2CN




c-92




—CF3




c-93




—CH2CF3




c-94



—Br
—Br




c-95




—CH2Cl




c-96




—CH2COCF3




c-97




—COCF3




c-98



—CH3
—CH3




c-99




—CH2CH3




c-100



—CN
—CN




c-101




—CH2CN




c-102




—CF3




c-103




—CH2CF3




c-104




—CH2Cl




c-105




—CH2CO2Me




c-106




—COCH3




c-107




—COCF3




c-108




—CH2COCF3




c-109



—CF3
—CF3




c-110




—CH2CF3




c-111




—CH2CN




c-112




—CH2Cl




c-113




—CH2CO2Me




c-114




—COCH3




c-115




—COCF3




c-116




—CH2COCF3




c-117



—CO2nBu
—CH2CO2nBu




c-118
—SOCH2CH3


—CO2Me
—CH2CO2Me




c-119
—CN
—SOCF3
H
H
—CO2Me




c-120




—CH2CO2Me




c-121




—C(CO2Me)CH3




c-122




—CH2CO2CH2CF3




c-123




—CO2CH2CF3




c-124




—CH2CO2CH(CF3)2




c-125




—CH2COCF3




c-126




—COCF3




c-127




—CN




c-128




—CH2CN




c-129




—CF3




c-130




—CH2CF3




c-131




—CONHMe




c-132




—CH2CONHCH3




c-133




—CH2COCH3




c-134




—COCH3




c-135




—Cl




c-136




—Br




c-137




—CH2Cl




c-138




—CH2CH2Cl




c-139




—CH═CHCl




c-140




—CH(CH3)2




c-141




—CH═CHCH3




c-142
—CF3
—SOCF3
H
H
—CO2Me




c-143




—CH2CO2Me




c-144




—C(CO2Me)CH3




c-145




—CH2CO2CH2CF3




c-146




—CO2CH2CF3




c-147




—CH2CO2CH(CF3)2




c-148




—CH2COCF3




c-149




—COCF3




c-150




—CN




c-151




—CH2CN




c-152




—CF3




c-153




—CH2CF3




c-154




—CONHMe




c-155




—CH2CONHCH3




c-156




—CH2COCH3




c-157




—COCH3




c-158




—Cl




c-159




—Br




c-160




—CH2Cl




c-161




—CH2CH2Cl




c-162




—CH═CHCl




c-163




—CH(CH3)2




c-164




—CH═CHCH3




c-165
—CN
—OCF3
H
H
—CO2Me




c-166




—CH2CO2Me




c-167




—C(CO2Me)CH3




c-168




—CH2CO2CH2CF3




c-169




—CO2CH2CF3




c-170




—CH2CO2CH(CF3)2




c-171




—CH2COCF3




c-172




—COCF3




c-173




—CN




c-174




—CH2CN




c-175




—CF3




c-176




—CH2CF3




c-177




—CONHMe




c-178




—CH2CONHCH3




c-179




—CH2COCH3




c-180




—COCH3




c-181




—Cl




c-182




—Br




c-183




—CH2Cl




c-184




—CH2CH2Cl




c-185




—CH═CHCl




c-186




—CH(CH3)2




c-187




—CH═CHCH3




c-188
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
3-Br, and



c-189




—CH2CO2Et
5-CF3



c-190




—CH2CO2CH2CF3




c-191




—CH2CO2CH2CHF2




c-192



—CO2Et
—CH2CO2Me




c-193




—CH2CO2Et




c-194



—CO2Me
—CH2CO2Me
3-CF3, and



c-195




—CH2CO2Et
5-CF3



c-196




—CH2CO2CH2CF3




c-197




—CH2CO2CH2CHF2




c-198



—CO2Et
—CH2CO2Me




c-199




—CH2CO2Et




c-200



—CO2Me
—CH2CO2Me
3-Me, and



c-201




—CH2CO2Et
5-CF3



c-202




—CH2CO2CH2CF3




c-203




—CH2CO2CH2CHF2




c-204



—CO2Et
—CH2CO2Me




c-205




—CH2CO2Et




c-206



—CO2Me
—CH2CO2Me
3-CN,



c-207




—CH2CO2Et
and 5-



c-208




—CH2CO2CH2CF3
CF3



c-209




—CH2CO2CH2CHF2




c-210



—CO2Et
—CH2CO2Me




c-211




—CH2CO2Et




c-212



—CO2Me
—CH2CO2Me
3-CO2Me,



c-213




—CH2CO2Et
and 5-CF3



c-214




—CH2CO2CH2CF3




c-215




—CH2CO2CH2CHF2




c-216



—CO2Et
—CH2CO2Me




c-217




—CH2CO2Et




c-218



—CO2Me
—CH2CO2Me
3-NO2,



c-219




—CH2CO2Et
and



c-220




—CH2CO2CH2CF3
5-CF3



c-221




—CH2CO2CH2CHF2




c-222



—CO2Et
—CH2CO2Me




c-223




—CH2CO2Et




c-224
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
3-Cl,



c-225




—CH2CO2Et
and 5-



c-226




—CH2CO2CH2CF3
OCF3



c-227




—CH2CO2CH2CHF2




c-228



—CO2Et
—CH2CO2Me




c-229




—CH2CO2Et




c-230



—CO2Me
—CH2CO2Me
3-Br,



c-231




—CH2CO2Et
and 5-



c-232




—CH2CO2CH2CF3
OCF3



c-233




—CH2CO2CH2CHF2




c-234



—CO2Et
—CH2CO2Me




c-235




—CH2CO2Et




c-236



—CO2Me
—CH2CO2Me
3-Me,



c-237




—CH2CO2Et
and 5-



c-238




—CH2CO2CH2CF3
OCF3



c-239




—CH2CO2CH2CHF2




c-240



—CO2Et
—CH2CO2Me




c-241




—CH2CO2Et




c-242



—CO2Me
—CH2CO2Me
3-CN,



c-243




—CH2CO2Et
and 5-



c-244




—CH2CO2CH2CF3
OCF3



c-245




—CH2CO2CH2CHF2




c-246



—CO2Et
—CH2CO2Me




c-247




—CH2CO2Et




c-248



—CO2Me
—CH2CO2Me
3-CH3,



c-249




—CH2CO2Et
and



c-250




—CH2CO2CH2CF3
5-OCF3



c-251




—CH2CO2CH2CHF2




c-252



—CO2Et
—CH2CO2Me




c-253




—CH2CO2Et




c-254



—CO2Me
—CH2CO2Me
3-CO2Me,



c-255




—CH2CO2Et
and



c-256




—CH2CO2CH2CF3
5-OCF3



c-257




—CH2CO2CH2CHF2




c-258



—CO2Et
—CH2CO2Me




c-259




—CH2CO2Et




c-260



—CO2Me
—CH2CO2Me
3-NO2,



c-261




—CH2CO2Et
and



c-262




—CH2CO2CH2CF3
5-OCF3



c-263




—CH2CO2CH2CHF2




c-264



—CO2Et
—CH2CO2Me




c-265




—CH2CO2Et




c-266
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
3-Cl,



c-267




—CH2CO2Et
and 5-NO2



c-268




—CH2CO2CH2CF3




c-269




—CH2CO2CH2CHF2




c-270



—CO2Et
—CH2CO2Me




c-271




—CH2CO2Et




c-272



—CO2Me
—CH2CO2Me
3-Br,



c-273




—CH2CO2Et
and 5-



c-274




—CH2CO2CH2CF3
NO2



c-275




—CH2CO2CH2CHF2




c-276



—CO2Et
—CH2CO2Me




c-277




—CH2CO2Et




c-278



—CO2Me
—CH2CO2Me
3-Me,



c-279




—CH2CO2Et
and 5-



c-280




—CH2CO2CH2CF3
NO2



c-281




—CH2CO2CH2CHF2




c-282



—CO2Et
—CH2CO2Me




c-283




—CH2CO2Et




c-284



—CO2Me
—CH2CO2Me
3-CN,



c-285




—CH2CO2Et
and 5-



c-286




—CH2CO2CH2CF3
NO2



c-287




—CH2CO2CH2CHF2




c-288



—CO2Et
—CH2CO2Me




c-289




—CH2CO2Et




c-290



—CO2Me
—CH2CO2Me
3-CF3,



c-291




—CH2CO2Et
and 5-



c-292




—CH2CO2CH2CF3
NO2



c-293




—CH2CO2CH2CHF2




c-294



—CO2Et
—CH2CO2Me




c-295




—CH2CO2Et




c-296



—CO2Me
—CH2CO2Me
3-CO2Me,



c-297




—CH2CO2Et
and 5-NO2



c-298




—CH2CO2CH2CF3




c-299




—CH2CO2CH2CHF2




c-300



—CO2Et
—CH2CO2Me




c-301




—CH2CO2Et




c-302



—CO2Me
—CH2CO2Me
3-NO2,



c-303




—CH2CO2Et
and



c-304




—CH2CO2CH2CF3
5-NO2



c-305




—CH2CO2CH2CHF2




c-306



—CO2Et
—CH2CO2Me




c-307




—CH2CO2Et




c-308
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
3-Cl, and



c-309




—CH2CO2Et
5-Cl



c-310




—CH2CO2CH2CF3




c-311




—CH2CO2CH2CHF2




c-312



—CO2Et
—CH2CO2Me




c-313




—CH2CO2Et




c-314



—CO2Me
—CH2CO2Me
3-Br, and



c-315




—CH2CO2Et
5-Cl



c-316




—CH2CO2CH2CF3




c-317




—CH2CO2CH2CHF2




c-318



—CO2Et
—CH2CO2Me




c-319




—CH2CO2Et




c-320



—CO2Me
—CH2CO2Me




c-321




—CH2CO2Et
3-Me,



c-322




—CH2CO2CH2CF3
and 5-Cl



c-323




—CH2CO2CH2CHF2




c-324



—CO2Et
—CH2CO2Me




c-325




—CH2CO2Et




c-326



—CO2Me
—CH2CO2Me
3-CN,



c-327




—CH2CO2Et
and 5-



c-328




—CH2CO2CH2CF3
Cl



c-329




—CH2CO2CH2CHF2




c-330



—CO2Et
—CH2CO2Me




c-331




—CH2CO2Et




c-332



—CO2Me
—CH2CO2Me
3-CF3,



c-333




—CH2CO2Et
and 5-Cl



c-334




—CH2CO2CH2CF3




c-335




—CH2CO2CH2CHF2




c-336



—CO2Et
—CH2CO2Me




c-337




—CH2CO2Et




c-338



—CO2Me
—CH2CO2Me
3-CO2Me,



c-339




—CH2CO2Et
and 5-Cl



c-340




—CH2CO2CH2CF3




c-341




—CH2CO2CH2CHF2




c-342



—CO2Et
—CH2CO2Me




c-343




—CH2CO2Et




c-344



—CO2Me
—CH2CO2Me
3-NO2, and



c-345




—CH2CO2Et
5-Cl



c-346




—CH2CO2CH2CF3




c-347




—CH2CO2CH2CHF2




c-348



—CO2Et
—CH2CO2Me




c-349




—CH2CO2Et









Embodiment 7: Synthesis of Compounds d-1 to d-142 by Using a Method G

Method G:




embedded image


Taking a compound d-12 for example, a specific synthesis process was as follows:


S1: 9-chloro-2-cyano-3-cyclohexanethiol-5-(2′2-dimethoxy)-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-methyl formate (Referring to Document Synthetic Communications (2012) 42: 3472)

Under the protection of nitrogen, an anhydrous acetonitrile mixture of 9-chloro-2-cyano-5-(2′2-dimethoxy)-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-methyl formate (2.0 mmol, synthesized with a method similar to S of the compound c-27, with a yield of 26%), dicyclohexyl disulfide (1.0 mmol), ferric tribromide (0.5 mmol) and elemental iodine (0.5 mmol) was stirred at 85° C. for 24 hours. The mixture was cooled to room temperature, and then concentrated in vacuum, and the residues were purified by column chromatography to obtain the target compound 9-chloro-2-cyano-3-cyclohexanethiol-5-(2′2-dimethoxy)-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-methyl formate (yield: 90%).


S2: 9-chloro-2-cyano-3-cyclohexanesulfinyl-5-(2′2-dimethoxy)-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-methyl formate

9-chloro-2-cyano-3-cyclohexanethiol-5-(2′2-dimethoxy)-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-methyl formate (1.0 mmol) was dissolved in anhydrous methylene chloride, and cooled to −15° C. Then, m-chloroperoxybenzoic acid (85%, 1.1 mmol) was added thereto, and the mixture was reacted at low temperature for 1 hour under stirring. The mixture was cooled to room temperature, added with an aqueous solution of sodium hydrogen carbonate, extracted with methylene chloride, and concentrated in vacuum. The residues were purified by column chromatography to obtain the target compound 9-chloro-2-cyano-3-cyclohexanesulfinyl-5-(2′2-dimethoxy)-7-trifluoromethyl-4,5-dihydropyrazole[1,5-α]quinazoline-5-methyl formate, wherein the yield was 97%.


The compounds d-1 to d-142 were synthesized with reference to the method of the compound d-12 (wherein cyclization steps also included similar cyclization methods mentioned in documents such as Tetrahedron Letters (2015) 56: 1367; WO2016046404; Synthetic Communications (2015) 45: 2426; Tetrahedron Letters (2014) 55: 4997; and WO2007149907), with a difference that different raw materials were selected for reaction according to different target compounds, or the compounds were derived from the synthesized target products through hydrolysis, simple esterification or amidation or reduction-oxidation. Specific compounds were as shown in Table 10.









TABLE 10







CompoundStructure with a General FormulaShown in Formula (d)














Structural









formula
Compound
R1
R2
R3
R4
R5
R6





General
d-1
—CN
—CF3
H
—CO2Me
—CH2CO2Me
4-CF3,


formula
d-2

—Br



and 6-Cl


(d)
d-3

—OCF3







d-4

—Cl







d-5
—CF3
—CF3







d-6

—OCF3







d-7

—CN







d-8
—COCH3
—SOCF3
H
—CO2Me
—CH2CO2Me




d-9
—CH2NH2








d-10
—CN
—SOPh







d-11

—SOCH2Ph







d-12

—SOC6H13







d-13

—SOCH3







d-14

—SOCH2CH3










d-15



embedded image












d-16



embedded image












d-17



embedded image












d-18



embedded image












d-19
—CF3
—SOCF3
H
—CO2Me
—CH2CO2Me




d-20
—CN
—SOCF3
H
—CO2Me
—CH2CONH2




d-21




—CH2CONHCH3




d-22




—CH2CON(CH3)2




d-23




—CH2CH2OH




d-24




—CH(CO2Me)CH3




d-25




—CH2CO2H




d-26




—CH2CO2Et




d-27




—CH2CO2CH2CF3




d-28




—CH2CO2CH2CHF2




d-29




—CH2CO2CH(CF3)2




d-30




—CH2CO2C(CH3)2CF3




d-31




—CH2CO2C(CF3)2CH3




d-32




—CH2CO2CH(CF3)OCH3




d-33




—CH2COCH3




d-34




—CH2Br




d-35




—CH2CF3




d-36




—CH2COCF3




d-37



—CO2Et
—CH2CO2Et




d-38




—CH2CO2H




d-39




—CH2CO2Me




d-40




—CH2CO2CH2CF3




d-41




—CH2CO2CH2CHF2




d-42




—CH2CO2CH(CF3)2




d-43




—CH2CO2C(CH3)2CF3




d-44




—CH2CO2C(CF3)2CH3




d-45




—CH2CO2CH(CF3)OCH3




d-46



—COCH3
—CH2COCH3




d-47




—CH2CO2Me




d-48




—CH2CF3




d-49




—CH2COCF3




d-50



—COCF3
—CH2COCF3




d-51




—CH2COCH3




d-52




—CH2Ph




d-53




—CH(CH3)2




d-54




—CH2CO2Me




d-55




—CH2CF3




d-56



—CONHMe
—CH2COCF3




d-57




—CH2Br




d-58



—NHMe
—CH2CN




d-59




—Cl




d-60



—Cl
—CH2CN




d-61




—CH2CF3




d-62



—Br
—CH2Cl




d-63




—CH2COCF3




d-64




—CH2COCF3




d-65



—CN
—CH2CF3




d-66




—CH2Cl




d-67




—CH2CO2Me




d-68



—CF3
—CH2COCF3




d-69




—CH2CF3




d-70




—CH2CN




d-71




—CH2CO2Me




d-72



—CO2nBu
—CH2CO2nBu




d-73



—COOCH(CH3)2
—COOCH(CH3)2




d-74
—CN
—SOCF3
H
H
—CO2Me




d-75




—CH2CO2Me




d-76




—C(CO2Me)CH3




d-77




—CH2CO2CH2CF3




d-78




—CO2CH2CF3




d-79




—CH2CO2CH(CF3)2




d-80




—CH2COCF3




d-81




—COCF3




d-82




—CN




d-83




—CH2CN




d-84




—CF3




d-85




—CH2CF3




d-86




—CONHMe




d-87




—CH2CONHCH3




d-88




—CH2COCH3




d-89




—COCH3




d-90




—Cl




d-91




—Br




d-92




—CH2Cl




d-93




—CH2CH2Cl




d-94




—CH═CHCl




d-95




—CH(CH3)2




d-96




—CH═CHCH3




d-97
—CF3
—SOCF3
H
H
—CO2Me




d-98




—CH2CO2Me




d-99




—C(CO2Me)CH3




d-100




—CH2CO2CH2CF3




d-101




—CO2CH2CF3




d-102




—CH2CO2CH(CF3)2




d-103




—CH2COCF3




d-104




—COCF3




d-105




—CN




d-106




—CH2CN




d-107




—CF3




d-108




—CH2CF3




d-109




—CONHMe




d-110




—CH2CONHCH3




d-111




—CH2COCH3




d-112




—COCH3




d-113




—Cl




d-114




—Br




d-115




—CH2Cl




d-116




—CH2CH2Cl




d-117




—CH═CHCl




d-118




—CH(CH3)2




d-119




—CH═CHCH3




d-120
—CN
—OCF3
H
H
—CO2Me




d-121




—CH2CO2Me




d-122




—C(CO2Me)CH3




d-123




—CH2CO2CH2CF3




d-124




—CO2CH2CF3




d-125




—CH2CO2CH(CF3)2




d-126




—CH2COCF3




d-127




—COCF3




d-128




—CN




d-129




—CH2CN




d-130




—CF3




d-131




—CH2CF3




d-132




—CONHMe




d-133




—CH2CONHCH3




d-134




—CH2COCH3




d-135-




—COCH3




d-136




—Cl




d-137




—Br




d-138




—CH2Cl




d-139




—CH2CH2Cl




d-140




—CH═CHCl




d-141




—CH(CH3)2




d-142




—CH═CHCH3









Embodiment 8: Synthesis of Compounds e-1 to e-24 by Using a Method H

Method H:




embedded image


The compounds e-1 to e-24 were synthesized with the methods of the compound series c and (wherein cyclization steps also included similar cyclization methods mentioned in documents such as WO2016046404; WO2013174822; Synthetic Communications (2015) 45: 2426; Tetrahedron Letters (2014) 55: 4997; and WO2007149907), with a difference that different raw materials were selected for reaction according to different target compounds, or the compounds were derived from the synthesized target products through hydrolysis, simple esterification or amidation or reduction-oxidation. Specific compounds were as shown in Table 11.









TABLE 11







Compound Structure with a General Formula Shown in Formula (e)














Structural









formula
Compound
R1
R2
R3
R4
R5
R6





General
e-1
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
3-Cl, and 6-CF3


formula
e-2




—CH2CO2Et



(e)
e-3




—CH2CO2CH2CF3




e-4




—CH2CO2CH2CHF2




e-5



—CO2Et
—CH2CO2Et




e-6




—CH2CO2Me




e-7
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
3-Cl, and 4-CF3



e-8




—CH2CO2Et




e-9




—CH2CO2CH2CF3




e-10




—CH2CO2CH2CHF2




e-11



—CO2Et
—CH2CO2Et




e-12




—CH2CO2Me




e-13
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
5-Cl, and 6-CF3



e-14




—CH2CO2Et




e-15




—CH2CO2CH2CF3




e-16




—CH2CO2CH2CHF2




e-17



—CO2Et
—CH2CO2Et




e-18




—CH2CO2Me




e-19
—CN
—SOCF3
H
—CO2Me
—CH2CO2Me
4-Cl, and 5-CF3



e-20




—CH2CO2Et




e-21




—CH2CO2CH2CF3




e-22




—CH2CO2CH2CHF2




e-23



—CO2Et
—CH2CO2Et




e-24




—CH2CO2Me









Hydrogen spectrum and mass spectrum data of nuclear magnetic resonance of some compounds shown in the general formula (a) of Table 7 were shown in Table 12.









TABLE 12







Hydrogen Spectrum and Mass Spectrum Data of Nuclear Magnetic


Resonance of Some Compounds Shown in General Formula (a)









Com-




pound

1H-NMR(600 MHz)

MS (ESI)












a-1

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 512.1



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.74 (s, 3H), 3.60(s, 3H),




3.33-3.25(m, 2H).



a-2

1H NMR (600 MHz, CDCl3) δ 8.43

[M + H]+ 479.0



(s, 1H), 7.60 (s, 1H), 7.20 (brs, 1H),




3.61(s, 3H), 3.31-3.26(m, 2H).



a-3

1H NMR (600 MHz, CDCl3) δ 8.36

[M + H]+ 497.1



(s, 1H), 7.50 (s, 1H), 7.49 (brs, 1H),




6.98 (brs, 2H), 3.74(s, 3H),




3.33-3.25(m, 2H).



a-4

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 510.9



(s, 1H), 7.55 (s, 1H), 7.49 (brs, 1H),




7.24 (brs, 1H), 3.74(s, 3H),




3.33-3.25(m, 2H), 2.80(s, 3H).



a-5

1H NMR (600 MHz, CDCl3) δ 8.37

[M + H]+ 484.2



(s, 1H), 7.45 (s, 1H), 7.39 (brs, 1H),




4.34 (brs, 1H), 3.80(dd, J = 6.4, 2.0




Hz, 2H), 3.74(s, 3H), 3.34-3.25(dd, J =




6.4, 2.0 Hz, 2H).



a-6

1H NMR (600 MHz, CDCl3) δ 8.37

[M + H]+ 526.0



(s, 1H), 7.45 (s, 1H), 7.39 (brs, 1H),




3.84 (s, 3H), 3.74(s, 3H), 3.25(dd,




J = 5.4, 1.80 Hz, 1H), 1.14(d, J = 8.0,




3H).



a-7

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 526.1



(s, 1H), 7.56 (s, 1H), 3.74 (s, 3H),




3.60(s, 3H), 3.33-3.25(m, 2H),




3.04 (s, 3H).



a-8

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 574.1



(s, 1H), 7.56 (s, 1H), 3.74 (s, 3H),




3.60(s, 3H), 3.63-3.55(m, 2H),




3.53-3.48(m, 2H), 3.33-3.25(m, 2H).



a-9

1H NMR (600 MHz, CDCl3) δ 8.37

[M + H]+ 526.0



(s, 1H), 7.45 (s, 1H), 7.39 (brs, 1H),




3.84 (dd, J = 5.4, 1.80 Hz, 2H),




3.74(s, 3H), 3.34-3.25(m, 2H), 1.14(t, J =




8.0, 3H).



a-10

1H NMR (600 MHz, CDCl3) δ 8.36

[M + H]+ 580.0



(s, 1H), 8.15 (s, 1H), 7.54 (t, J = 2.3




Hz, 1H), 4.78-4.63 (m, 2H), 4.49-4.29




(m, 2H), 3.82 (d, J = 4.8 Hz, 3H),




3.71-3.46 (m, 2H).



a-11

1H NMR (600 MHz, CDCl3) δ 8.34

[M + H]+ 562.1



(s, 1H), 7.59 (s, 1H), 6.92 (s, 1H), 5.87




(tdt, J = 54.7, 24.2, 3.9 Hz, 1H),




4.35-4.12 (m, 2H), 3.83 (d, J = 6.8 Hz,




3H), 3.63-3.35 (m, 2H).



a-12

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 648.2



(s, 1H), 7.61 (s, 1H), 6.95 (s, 1H), 5.69-




5.59 (m, 1H), 3.85 (d, J = 21.5 Hz, 3H),




3.81-3.62 (m, 2H).



a-14

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 662.2



(d, J = 1.8 Hz, 1H), 7.60 (d, J = 1.3 Hz,




1H), 6.87 (s, 1H), 3.83 (s, 3H),




3.71-3.50 (m, 2H), 1.87 (s, 1H).



a-16

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 530.1



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




7.23-7.19(m, 5H), 3.74 (s, 3H),




3.33-3.25(m, 2H).



a-17

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 496.0



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.74 (s, 3H), 3.33-3.25(m, 2H),




2.10 (s, 3H).



a-18

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 531.9



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.72 (s, 3H), 3.13-3.05(m, 2H).



a-19
H NMR (600 MHz, CDCl3) δ 8.35
[M + H]+ 521.9



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.68 (s, 3H), 3.03-2.95(m, 2H).



a-20

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 549.9



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.72 (s, 3H), 3.10-3.04(m, 2H).



a-21

1H NMR (600 MHz, CDCl3) δ 8.07

[M + H]+ 472.0



(S, 1H), 7.57 (S, 1H), 7.40 (s, 1H), 3.80




(d, J = 16.4 Hz, 3H), 3.61 (d, J = 31.8




Hz, 3H), 3.51-3.40 (m, 1H), 3.46-




3.29 (m, 1H), 3.20-2.98 (m, 2H),




1.38-1.29 (m, 3H).



a-22

1H NMR (600 MHz, CDCl3) δ 8.10

[M + H]+ 540.0



(m, 1H), 7.57 (s, 1H), 7.27 (s, 1H), 4.38-




4.21 (m, 2H), 4.15-4.00 (m, 2H),




3.69-3.30 (m, 2H), 1.25 (td, J = 7.1,




1.4 Hz, 3H), 1.17 (dt, J = 16.7, 7.1 Hz, 3H).



a-26

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 534.0



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.33-3.25(m, 2H), 2.10 (s, 3H).



a-27

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 568.1



(s, 1H), 7.55 (s, 1H), 7.44 (brs, 1H),




7.23-7.19(m, 5H), 3.33-3.25(m, 2H).



a-28

1H NMR (600 MHz, CDCl3) δ 8.38

[M + H]+ 550.1



(s, 1H), 7.53 (s, 1H), 7.45 (brs, 1H),




3.74 (s, 3H), 3.33-3.25(m, 2H).



a-29

1H NMR (600 MHz, CDCl3) δ 8.36

[M + H]+ 569.9



(s, 1H), 7.49 (s, 1H), 7.46 (brs, 1H),




3.13-3.06(m, 2H).



a-30

1H NMR (600 MHz, CDCl3) δ 8.39

[M + H]+ 516.9



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.13-3.05(m, 2H).



a-36

1H NMR (600 MHz, CDCl3) δ 8.39

[M + H]+ 506.0



(s, 1H), 7.53 (s, 1H), 7.40 (brs, 1H),




3.13-3.05(m, 2H), 2.40 (s, 3H).



a-37

1H NMR (600 MHz, CDCl3) δ 8.37

[M + H]+ 534.0



(s, 1H), 7.46 (s, 1H), 7.39 (brs, 1H),




3.11-3.06(m, 2H), 2.38 (s, 3H).



a-44

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 449.9



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H).



a-45

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 507.8



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.13-3.05(m, 2H).



a-47

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 544.8



(s, 1H), 7.55 (s, 1H), 7.45 (brs, 1H),




3.10-3.02(m, 2H).



a-51

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 409.9



(s, 1H), 7.56 (s, 1H), 7.45 (brs,




1H),1.37 (s, 6H).



a-52

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 432.0



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H).



a-53

1H NMR (600 MHz, CDCl3) δ 8.33

[M + H]+ 544.8



(s, 1H), 7.50 (s, 1H), 7.40 (brs, 1H),




3.10-3.02(m, 2H).



a-56

1H NMR (600 MHz, CDCl3) δ

[M + H]+ 479.1



8.35 (s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.60(s, 3H), 3.33-3.25(m, 2H).



a-57

1H NMR (600 MHz, CDCl3) δ 8.36

[M + H]+ 517.1



(s, 1H), 7.58 (s, 1H), 7.47 (brs, 1H),




3.13-3.05(m, 2H).



a-59

1H NMR (600 MHz, CDCl3) δ 8.23

[M + H]+ 488.8



(s, 1H), 7.47 (s, 1H), 7.20 (brs, 1H),




3.00-2.92(m, 2H).



a-62

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 522.1



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.60(s, 3H), 3.31-3.23(m, 2H).



a-63

1H NMR (600 MHz, CDCl3) δ 8.33

[M + H]+ 559.9



(s, 1H), 7.55 (s, 1H), 7.40 (brs, 1H),




3.14-3.05(m, 2H).



a-64

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 440.1



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




4.74 (s, 1H), 3.60(s, 3H).



a-65

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 454.1



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




4.74 (s, 1H), 3.60(s, 3H),




3.33-3.25(m, 2H).



a-71

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 477.9



(s, 1H), 7.58 (s, 1H), 7.43 (brs, 1H),




4.75 (s, 1H).



a-72

1H NMR (600 MHz, CDCl3) δ 8.30

[M + H]+ 407.0



(s, 1H), 7.50 (s, 1H), 7.41 (brs, 1H),




4.65 (s, 1H).



a-80

1H NMR (600 MHz, CDCl3) δ 8.38

[M + H]+ 415.9



(s, 1H), 7.61 (s, 1H), 7.38 (brs, 1H),




4.81 (s, 1H).



a-83

1H NMR (600 MHz, CDCl3) δ 8.38

[M + H]+ 444.1



(s, 1H), 7.61 (s, 1H), 7.38 (brs, 1H),




4.81 (s, 1H), 3.63-3.55(m, 2H),




3.53-3.48(m, 2H).



a-86

1H NMR (600 MHz, CDCl3) δ 8.39

[M + H]+ 441.9



(s, 1H), 7.58 (s, 1H), 7.48 (brs, 1H),




6.23(d, J = 8.3 Hz, 1H), 6.02(dd,




J = 1.3, 8.3 Hz, 1H), 4.81 (s, 1H).



a-87

1H NMR (600 MHz, CDCl3) δ 8.25

[M + H]+ 483.1



(s, 1H), 7.55 (s, 1H), 7.35 (brs, 1H),




4.74 (s, 1H), 3.60(s, 3H).



a-88

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 497.1



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




4.74 (s, 1H), 3.60(s, 3H), 3.33-3.25(m, 2H).



a-95

1H NMR (600 MHz, CDCl3) δ 8.30

[M + H]+ 449.9



(s, 1H), 7.50 (s, 1H), 7.41 (brs, 1H),




4.65 (s, 1H).



a-109

1H NMR (600 MHz, CDCl3) δ 8.39

[M + H]+ 464.9



(s, 1H), 7.58 (s, 1H), 7.48 (brs, 1H),




6.23(d, J = 8.3 Hz, 1H), 6.02(dd, J = 1.3,




8.3 Hz, 1H), 4.81 (s, 1H), 1.63(d,




J = 9.3 Hz, 3H).



a-111

1H NMR (600 MHz, CDCl3) δ 8.36

[M + H]+ 422.1



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




4.74 (s, 1H), 3.60(s, 3H), 3.32-3.25(m, 2H).



a-118

1H NMR (600 MHz, CDCl3) δ 8.30

[M + H]+ 375.1



(s, 1H), 7.50 (s, 1H), 7.41 (brs, 1H),




4.65 (s, 1H).



a-122

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 407.1



(s, 1H), 7.65 (s, 1H), 7.50 (brs, 1H),




7.42 (brs, 1H), 4.65 (s, 1H), 2.82 (s, 3H).



a-132

1H NMR (600 MHz, CDCl3) δ 8.40

[M + H]+ 389.9



(s, 1H), 7.58 (s, 1H), 7.48 (brs, 1H),




6.23(d, J = 8.3 Hz, 1H), 6.02(dd, J = 1.3,




8.3 Hz, 1H), 4.81 (s, 1H), 1.63(d,




J = 9.3 Hz, 3H).



a-133

1H NMR (600 MHz, CDCl3) δ 8.45

[M + H]+ 430.1



(s, 1H), 7.51 (s, 1H), 7.43 (brs, 1H),




3.76 (s, 3H), 3.61(s, 3H), 3.31-3.25(m, 2H).



a-134

1H NMR (600 MHz, CDCl3) δ 8.35

[M + H]+ 464.1



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.71 (s, 3H), 3.64(s, 3H), 3.32-3.26(m, 2H).



a-136

1H NMR (600 MHz, CDCl3) δ 8.30

[M + H]+ 464.1



(s, 1H), 7.55 (s, 1H), 7.47 (brs, 1H),




3.74 (s, 3H), 3.66(s, 3H), 3.35-3.29(m, 2H).









Hydrogen spectrum and mass spectrum data of nuclear magnetic resonance of some compounds shown in the general formula (b) of Table 8 were shown in Table 13.









TABLE 13







Hydrogen Spectrum and Mass Spectrum Data of Nuclear Magnetic


Resonance of Some Compounds Shown in General Formula (b)









Com-




pound

1H-NMR(600 MHz)

MS (ESI)





b-1

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 478.0



(s, 1H), 7.96 (s, 1H), 7.45 (brs, 1H),




3.74 (s, 3H), 3.60(s, 3H), 3.32-3.25(m, 2H).



b-2

1H NMR (600 MHz, CDCl3) δ 8.86

[M + H]+ 445.0



(s, 1H), 7.97 (s, 1H), 7.21 (brs, 1H),




3.62(s, 3H), 3.31-3.27(m, 2H).



b-3

1H NMR (600 MHz, CDCl3) δ 8.86

[M + H]+ 463.1



(s, 1H), 7.95 (s, 1H), 7.49 (brs, 1H),




6.28 (brs, 2H), 3.73(s, 3H), 3.33-3.26(m, 2H).



b-4

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 476.9



(s, 1H), 7.95 (s, 1H), 7.50 (brs, 1H),




7.25 (brs, 1H), 3.73(s, 3H),




3.35-3.26(m, 2H), 2.81(s, 3H).



b-5

1H NMR (600 MHz, CDCl3) δ 8.87

[M + H]+ 450.1



(s, 1H), 7.85 (s, 1H), 7.49 (brs, 1H),




4.44 (brs, 1H), 3.81(dd, J = 6.4, 2.0 Hz,




2H), 3.77(s, 3H), 3.34-3.27(dd, J =




6.3, 2.1 Hz, 2H).



b-6

1H NMR (600 MHz, CDCl3) δ 8.87

[M + H]+ 492.0



(s, 1H), 7.95 (s, 1H), 7.37 (brs, 1H),




3.85 (s, 3H), 3.75(s, 3H), 3.25(dd, J =




5.5, 1.8 Hz, 1H), 1.15(d, J = 8.1,




3H).



b-7

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 492.0



(s, 1H), 7.96 (s, 1H), 3.76 (s, 3H),




3.61(s, 3H), 3.35-3.28(m, 2H), 3.06 (s, 3H).



b-8

1H NMR (600 MHz, CDCl3) δ 8.86

[M + H]+ 540.0



(s, 1H), 7.98 (s, 1H), 3.75 (s, 3H),




3.59(s, 3H), 3.69-3.59(m, 2H),




3.54-3.48(m, 2H), 3.35-3.2(m, 2H).



b-9

1H NMR (600 MHz, CDCl3) δ 8.89

[M + H]+ 492.0



(s, 1H), 7.47 (s, 1H), 7.34 (brs, 1H),




3.83 (dd, J = 5.4, 1.8 Hz, 2H),




3.76(s, 3H), 3.35-3.26(m, 2H), 1.13(t, J =




8.0, 3H).



b-10

1H NMR (600 MHz, CDCl3) δ 8.86

[M + H]+ 545.9



(s, 1H), 8.15 (s, 1H), 7.54 (t, J = 2.5




Hz, 1H), 4.79-4.63 (m, 2H), 4.49-4.26




(m, 2H), 3.82 (d, J = 4.6 Hz,




3H), 3.72-3.46 (m, 2H).



b-11

1H NMR (600 MHz, CDCl3) δ 8.84

[M + H]+ 528.0



(s, 1H), 7.99 (s, 1H), 6.95 (s, 1H),




5.89 (tdt, J = 54.7, 24.2, 3.9 Hz, 1H),




4.36-4.13 (m, 2H), 3.83 (d, J = 6.9




Hz, 3H), 3.64-3.35 (m, 2H).



b-12

1H NMR (600 MHz, CDCl3) δ 8.96

[M + H]+ 613.9



(s, 1H), 7.67 (s, 1H), 6.96 (s, 1H),




5.68-5.57 (m, 1H), 3.85 (d, J = 22.5




Hz, 3H), 3.81-3.62 (m, 2H).



b-14

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 628.0



(d, J = 1.8 Hz, 1H), 7.90 (d, J = 1.3




Hz, 1H), 6.97 (s, 1H), 3.85 (s, 3H),




3.72-3.54 (m, 2H), 1.86 (s, 1H).



b-16

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 496.1



(s, 1H), 7.86 (s, 1H), 7.49 (brs, 1H),




7.22-7.18(m, 5H), 3.75 (s, 3H),




3.32-3.25(m, 2H).



b-17

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 462.0



(s, 1H), 7.58 (s, 1H), 7.46 (brs, 1H),




3.75 (s, 3H), 3.31-3.23(m, 2H),




2.13 (s, 3H).



b-18

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 497.9



(s, 1H), 7.86 (s, 1H), 7.44 (brs, 1H),




3.72 (s, 3H), 3.13-3.05(m, 2H).



b-19
H NMR (600 MHz, CDCl3) δ 8.86
[M + H]+ 487.9



(s, 1H), 7.77 (s, 1H), 7.51 (brs, 1H),




3.68 (s, 3H), 3.06-2.98(m, 2H).



b-20

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 515.9



(s, 1H), 7.86 (s, 1H), 7.45 (brs, 1H),




3.73 (s, 3H), 3.17-3.11(m, 2H).



b-21

1H NMR (600 MHz, CDCl3) δ 8.97

[M + H]+ 438.0



(S, 1H), 7.97 (S, 1H), 7.48 (s, 1H),




3.81 (d, J = 16.5 Hz, 3H), 3.62 (d, J =




31.2 Hz, 3H), 3.50-3.40 (m, 1H),




3.45-3.29 (m, 1H), 3.31-3.08 (m, 2H),




1.39-1.30 (m, 3H).



b-23

1H NMR (600 MHz, CDCl3) δ 8.93

[M + H]+ 491.1



(s, 1H), 7.97 (d, J = 1.9 Hz, 1H), 6.86




(brs, 1H), 4.40-4.20 (m, 2H), 3.63




(s, 3H), 3.53-3.31 (m, 2H), 1.25 (td, J =




7.2, 3.0 Hz, 3H).



b-25

1H NMR (600 MHz, CDCl3) δ 8.93

[M + H]+ 553.9



(s, 1H), 7.97 (d, J = 1.9 Hz, 1H), 6.86




(brs, 1H), 4.30-4.10 (m, 2H).



b-27

1H NMR (600 MHz, CDCl3) δ 8.99

[M + H]+ 534.0



(s, 1H), 7.95 (s, 1H), 7.44 (brs, 1H),




7.23-7.19(m, 5H), 3.35-3.25(m, 2H).



b-28

1H NMR (600 MHz, CDCl3) δ 8.98

[M + H]+ 515.9



(s, 1H), 7.93 (s, 1H), 7.45 (brs, 1H),




3.75 (s, 3H), 3.33-3.25(m, 2H).



b-30

1H NMR (600 MHz, CDCl3) δ 8.99

[M + H]+ 482.9



(s, 1H), 7.86 (s, 1H), 7.46 (brs, 1H),




3.13-3.05(m, 2H).



b-34

1H NMR (600 MHz, CDCl3) δ 8.99

[M + H]+ 481.9



(s, 1H), 7.83 (s, 1H), 7.41 (brs, 1H),




3.14-3.06(m, 2H), 2.44 (s, 3H).



b-37

1H NMR (600 MHz, CDCl3) δ 8.97

[M + H]+ 499.9



(s, 1H), 7.86 (s, 1H), 7.39 (brs, 1H),




3.11-3.06(m, 2H), 2.9 (s, 3H).



b-43

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 416.0



(s, 1H), 7.76 (s, 1H), 7.45 (brs, 1H),




5.45 (brs, 1H), 3.37 (s, 3H),




3.01-2.96(m, 2H).



b-47

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 420.9



(s, 1H), 7.85 (s, 1H), 7.40 (brs, 1H),




3.18-3.09(m, 2H).



b-48

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 463.9



(s, 1H), 7.85 (s, 1H), 7.40 (brs, 1H),




3.01-2.89(m, 2H).



b-50

1H NMR (600 MHz, CDCl3) δ 8.89

[M + H]+ 535.8



(s, 1H), 7.75 (s, 1H), 7.32 (brs, 1H),




2.91-2.79(m, 2H).



b-54

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 454.9



(s, 1H), 7.70 (s, 1H), 7.30 (brs, 1H),




2.81-2.68(m, 2H).



b-56

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 445.0



(s, 1H), 7.86 (s, 1H), 7.45 (brs, 1H),




3.61(s, 3H), 3.35-3.25(m, 2H).



b-57

1H NMR (600 MHz, CDCl3) δ 8.96

[M + H]+ 482.9



(s, 1H), 7.78 (s, 1H), 7.49 (brs, 1H),




3.14-3.05(m, 2H).



b-59

1H NMR (600 MHz, CDCl3) δ 8.93

[M + H]+ 454.9



(s, 1H), 7.77 (s, 1H), 7.21 (brs, 1H),




3.01-2.95(m, 2H).



b-62

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 487.9



(s, 1H), 7.76 (s, 1H), 7.47 (brs, 1H),




3.61(s, 3H), 3.31-3.23(m, 2H).



b-63

1H NMR (600 MHz, CDCl3) δ 8.93

[M + H]+ 525.9



(s, 1H), 7.75 (s, 1H), 7.42 (brs, 1H),




3.15-3.07(m, 2H).



b-66

1H NMR (600 MHz, CDCl3) δ 8.87

[M + H]+ 434.0



(s, 1H), 7.95 (s, 1H), 7.37 (brs, 1H),




4.74 (s, 1H), 3.75(s, 3H), 3.25(dd,




J = 5.5, 1.9 Hz, 1H), 1.15(d, J = 8.1,




3H).



b-68

1H NMR (600 MHz, CDCl3) δ 8.80

[M + H]+ 487.9



(s, 1H), 7.90 (s, 1H), 7.41 (brs, 1H),




4.65 (m, 1H), 4.47 (s, 2H),




2.95-2.77(m, 2H).



b-70

1H NMR (600 MHz, CDCl3) δ 8.81

[M + H]+ 457.9



(s, 1H), 7.91 (s, 1H), 7.42 (brs, 1H),




4.65 (m, 1H), 2.95-2.77(m, 2H).



b-73

1H NMR (600 MHz, CDCl3) δ 8.82

[M + H]+ 386.9



(s, 1H), 7.92 (s, 1H), 7.41 (brs, 1H),




4.65 (m, 1H), 2.93-2.73(m, 2H).



b-80

1H NMR (600 MHz, CDCl3) δ 8.89

[M + H]+ 381.9



(s, 1H), 7.95 (s, 1H), 7.42 (brs, 1H),




4.66 (m, 1H).



b-86

1H NMR (600 MHz, CDCl3) δ 8.89

[M + H]+ 388.0



(s, 1H), 7.98 (s, 1H), 7.49 (brs, 1H),




6.24(d, J = 8.4 Hz, 1H), 6.03(dd,




J = 1.4, 8.4 Hz, 1H), 4.82 (s, 1H).



b-87

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 448.9



(s, 1H), 7.95 (s, 1H), 7.41 (brs, 1H),




4.75 (s, 1H), 3.60(s, 3H).



b-88

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 462.9



(s, 1H), 7.96 (s, 1H), 7.45 (brs, 1H),




4.76 (s, 1H), 3.61(s, 3H), 3.34-3.26(m, 2H).



b-94

1H NMR (600 MHz, CDCl3) δ 8.80

[M + H]+ 486.9



(s, 1H), 7.80 (s, 1H), 7.47 (brs, 1H),




4.66 (s, 1H).



b-99

1H NMR (600 MHz, CDCl3) δ 8.81

[M + H]+ 447.9



(s, 1H), 7.82 (s, 1H), 7.27 (brs, 1H),




5.27 (brs, 1H), 4.66 (s, 1H), 2.86 (s, 3H).



b-104

1H NMR (600 MHz, CDCl3) δ 8.80

[M + H]+ 468.8



(s, 1H), 7.78 (s, 1H), 7.38 (brs, 1H),




4.89 (s, 1H).



b-111

1H NMR (600 MHz, CDCl3) δ 8.86

[M + H]+ 388.0



(s, 1H), 7.86 (s, 1H), 7.41 (brs, 1H),




4.68 (s, 1H), 3.61(s, 3H), 3.33-3.28(m, 2H).



b-116

1H NMR (600 MHz, CDCl3) δ 8.83

[M + H]+ 426.0



(s, 1H), 8.01 (s, 1H), 7.39 (brs, 1H),




4.66 (m, 1H), 2.96-2.77(m, 2H).



b-118

1H NMR (600 MHz, CDCl3) δ 8.90

[M + H]+ 341.0



(s, 1H), 7.80 (s, 1H), 7.37 (brs, 1H),




4.65 (s, 1H).



b-123

1H NMR (600 MHz, CDCl3) δ 8.95

[M + H]+ 387.0



(s, 1H), 7.95 (s, 1H), 7.42 (brs, 1H),




7.36 (brs, 1H), 4.75 (s, 1H),




3.11-3.06(m, 2H), 2.82 (s, 3H).



b-131

1H NMR (600 MHz, CDCl3) δ 8.87

[M + H]+ 358.0



(s, 1H), 7.91 (s, 1H), 7.42 (brs, 1H),




4.75 (d, J = 8.1, 1H), 2.11-2.06(m, 1H),




0.92 (d, J = 10.1, 6H).



b-134

1H NMR (600 MHz, CDCl3) δ 8.85

[M + H]+ 430.1



(s, 1H), 7.96 (s, 1H), 7.45 (brs, 1H),




3.71 (s, 3H), 3.64(s, 3H), 3.32-3.26(m, 2H).



b-135

1H NMR (600 MHz, CDCl3) δ 8.89

[M + H]+ 446.0



(s, 1H), 7.96 (s, 1H), 7.43 (brs, 1H),




3.73 (s, 3H), 3.63(s, 3H), 3.31-3.27(m, 2H).



b-136

1H NMR (600 MHz, CDCl3) δ 8.90

[M + H]+ 430.0



(s, 1H), 7.95 (s, 1H), 7.47 (brs, 1H),




3.74 (s, 3H), 3.66(s, 3H), 3.35-3.29(m, 2H).



b-138

1H NMR (600 MHz, CDCl3) δ 8.87(s, 1H),

[M + H]+ 521.1



7.96 (s, 1H), 7.43 (brs, 1H),




3.72 (s, 3H), 3.66(s, 3H), 3.32-3.26(m, 2H).









Hydrogen spectrum and mass spectrum data of nuclear magnetic resonance of some compounds shown in the general formula (c) of Table 9 were shown in Table 14.









TABLE 14







Hydrogen Spectrum and Mass Spectrum Data of Nuclear Magnetic


Resonance of Some Compounds Shown in General Formula (c)









Com-




pound

1H-NMR(600 MHz)

MS (ESI)





c-2

1H NMR (600 MHz, CDCl3) δ 8.14 (s, 1H),

[M + H]+ 497.1



7.57 (s, 1H), 7.05 (brs, 1H), 3.82




(s, 3H), 3.64 (s, 3H), 3.57-3.25 (m, 2H).



c-4

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 497.2



(s, 1H), 7.60 (s, 1H), 7.05 (brs, 1H), 3.82




(s, 3H), 3.64 (s, 3H), 3.57-3.25 (m, 2H).



c-7

1H NMR (600 MHz, CDCl3) δ 8.20 (s, 1H),

[M + H]+ 587.9



7.60 (s, 1H), 7.05 (brs, 1H), 3.82




(s, 3H), 3.64 (s, 3H), 3.57-3.25 (m, 2H).



c-8

1H NMR (600 MHz, CDCl3) δ 8.13 (s, 1H),

[M + H]+ 544.9



7.58 (s, 1H), 7.28 (s, 1H), 3.82




(s, 3H), 3.66 (s, 3H), 3.55-3.23 (m, 2H).





1H NMR (600 MHz, CDCl3) δ 8.14 (s, 1H),





7.57 (s, 1H), 6.82 (s, 1H), 3.82




(s, 3H), 3.62 (s, 3H), 3.49 (d, J = 1.5 Hz, 2H).



c-14

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 559.1



(s, 1H), 7.56 (s, 1H), 3.84 (s, 3H),




3.60(s, 3H), 3.33-3.25(m, 2H), 3.04 (s, 3H).



c-15

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 587.1



(s, 1H), 7.56 (s, 1H), 3.84 (s, 3H),




3.60(s, 3H), 3.33-3.25(m, 2H), 2.12 (s, 3H).



c-17

1H NMR (600 MHz, CDCl3) δ 8.13 (d,

[M + H]+ 559.0



J = 1.3 Hz, 1H), 7.57 (d, J = 1.2 Hz,




1H), 6.84 (s, 1H), 4.11-3.99 (m, 2H),




3.81 (s, 3H), 3.48 (d, J = 2.2 Hz, 2H),




1.16 (t, J = 7.1 Hz, 3H).



c-18

1H NMR (600 MHz, CDCl3) δ 8.12 (d,

[M + H]+ 530.9



J = 1.8 Hz, 1H), 7.57 (d, J = 1.8 Hz,




1H), 7.03 (s, 1H), 3.81 (s, 3H), 3.59-3.33




(m, 2H), 2.27 (s, 1H).



c-19

1H NMR (600 MHz, CDCl3) δ 8.18-8.13

[M + H]+ 612.9



(m, 1H), 7.66-7.56 (m, 1H), 6.87




(s, 1H), 4.48-4.31 (m, 2H), 3.83 (d,




J = 6.7 Hz, 3H), 3.70-3.48 (m, 2H).



c-20

1H NMR (600 MHz, CDCl3) δ 8.14 (dd,

[M + H]+ 595.0



J = 4.8, 1.7 Hz, 1H), 7.59 (d, J = 0.3




Hz, 1H), 5.87 (tdt, J = 54.7, 23.8, 3.9 Hz,




1H), 4.33-4.14 (m, 2H), 3.83 (d, J =




7.3 Hz, 3H), 3.60-3.37 (m, 2H).



c-21

1H NMR (600 MHz, CDCl3) δ 8.16 (s, 1H),

[M + H]+ 680.9



7.61 (s, 1H), 6.95 (s, 1H), 5.69-




5.59 (m, 1H), 3.85 (d, J = 21.5 Hz, 3H),




3.81-3.62 (m, 2H).



c-25

1H NMR (600 MHz, CDCl3) δ 8.13 (dd,

[M + H]+ 559.0



J = 4.9, 1.8 Hz, 1H), 7.57 (d, J = 1.8




Hz, 1H), 6.86 (s, 1H), 4.40-4.20 (m, 2H),




3.63 (d, J = 23.3 Hz, 3H), 3.53-




3.31 (m, 2H), 1.25 (td, J = 7.1, 3.0 Hz, 3H).



c-26

1H NMR (600 MHz, CDCl3) δ 8.15-8.10

[M + H]+ 572.9



(m, 1H), 7.57 (s, 1H), 7.27 (s, 1H),




4.38-4.21 (m, 2H), 4.15-4.00 (m, 2H),




3.69-3.30 (m, 2H), 1.25 (td, J =




7.1, 1.4 Hz, 3H), 1.17 (dt, J = 16.7,




7.1 Hz, 3H).



c-28

1H NMR (600 MHz, CDCl3) δ 8.15 (dd,

[M + H]+ 627.0



J = 4.5, 1.8 Hz, 1H), 7.65-7.57 (m,




1H), 6.84 (s, 1H), 4.48-4.22 (m, 4H),




3.71-3.46 (m, 2H), 1.25 (td, J = 7.1,




1.1 Hz, 3H).



c-29

1H NMR (600 MHz, CDCl3) δ 8.14 (dd,

[M + H]+ 609.0



J = 4.1, 1.8 Hz, 1H), 7.59 (t, J = 2.4




Hz, 1H), 5.88 (tdt, J = 54.7, 26.4, 3.9 Hz,




1H), 4.43-4.16 (m, 4H), 3.60-




3.35 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H).



c-34

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 620.9



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




3.33-3.25(m, 2H).



c-36

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 601.0



(s, 1H), 7.55 (s, 1H), 7.44 (brs, 1H),




7.23-7.19(m, 5H), 3.33-3.25(m, 2H).



c-39

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 552.9



(s, 1H), 7.55 (s, 1H), 7.44 (brs, 1H),




2.43(s, 3H).



c-42

1H NMR (600 MHz, CDCl3) δ 8.18

[M + H]+ 572.9



(s, 1H), 7.61 (s, 1H), 7.38 (brs, 1H),




3.63-3.55(m, 2H), 3.53-3.48(m, 2H).



c-47

1H NMR (600 MHz, CDCl3) δ 8.18

[M + H]+ 566.9



(s, 1H), 7.61 (s, 1H), 7.38 (brs, 1H),




3.53-3.48(m, 2H), 2.49 (s, 3H).



c-53

1H NMR (600 MHz, CDCl3) δ 8.20

[M + H]+ 514.9



(s, 1H), 7.61 (s, 1H), 7.38 (brs, 1H),




3.59 (s, 3H), 2.49 (s, 3H).



c-54

1H NMR (600 MHz, CDCl3) δ 8.18

[M + H]+ 549.0



(s, 1H), 7.61 (s, 1H), 7.38 (brs, 1H),




3.23-3.19(m, 2H), 2.49 (s, 3H).



c-57

1H NMR (600 MHz, CDCl3) δ 8.18

[M + H]+ 495.9



(s, 1H), 7.61 (s, 1H), 7.38 (brs, 1H),




3.13-3.08(m, 2H), 2.49 (s, 3H).



c-61

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 563.1



(d, J = 1.3 Hz, 1H), 7.57 (d, J = 1.2 Hz,




1H), 7.35-7.19 (m, 5H), 6.84 (s, 1H),




3.81 (s, 3H), 3.53-3.38(m, 2H).



c-64

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 564.9



(d, J = 1.5 Hz, 1H), 7.57 (d, J = 1.2 Hz,




1H), 6.84 (s, 1H), 3.81 (s, 3H),




3.33-3.20(m, 2H).



c-67

1H NMR (600 MHz, CDCl3) δ 8.16 (d,

[M + H]+ 497.9



J = 1.8 Hz, 1H), 7.57 (d, J = 1.2 Hz,




1H), 6.84 (s, 1H).



c-72

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 512.9



J = 2.0 Hz, 1H), 7.67 (d, J = 1.2 Hz,




1H), 7.54 (s, 1H), 6.84 (s, 1H), 2.94




(s, 3H), 2.46 (s, 3H).



c-73

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 530.0



J = 2.0 Hz, 1H), 7.67 (d, J = 1.2 Hz,




1H), 7.54 (s, 1H), 6.84 (s, 1H), 3.74




(s, 3H), 2.86 (s, 3H).



c-77

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 550.0



J = 2.0 Hz, 1H), 7.67 (d, J = 1.2 Hz,




1H), 7.54 (s, 1H), 6.84 (s, 1H), 2.86 (s, 3H).



c-80

1H NMR (600 MHz, CDCl3) δ 8.07 (d,

[M + H]+ 496.9



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 7.54 (s, 1H), 6.84 (s, 1H), 2.87 (s, 3H).



c-84

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 581.9



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 7.54 (s, 1H), 6.84 (s, 1H),




3.13-3.08(m, 2H), 2.87 (s, 3H).



c-86

1H NMR (600 MHz, CDCl3) δ 8.07 (d,

[M + H]+ 451.0



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.84 (s, 1H).



c-91

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 487.9



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.88 (s, 1H), 3.10-3.05(m, 2H).



c-93

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 530.9



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.88 (s, 1H), 2.50-2.35(m, 2H).



c-97

1H NMR (600 MHz, CDCl3) δ 8.09 (d,

[M + H]+ 588.8



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.88 (s, 1H).



c-98

1H NMR (600 MHz, CDCl3) δ 8.19 (d,

[M + H]+ 443.1



J = 2.0 Hz, 1H), 7.70 (d, J = 1.2 Hz,




1H), 6.88 (s, 1H), 1.38 (s, 6H).



c-101

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 478.8



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.89 (s, 1H), 3.11-3.05(m, 2H).



c-105

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 512.1



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.89 (s, 1H), 3.87 (s, 3H),




3.11-3.05(m, 2H).



c-107

1H NMR (600 MHz, CDCl3) δ 8.11 (d,

[M + H]+ 535.9



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.58 (s, 1H).



c-110

1H NMR (600 MHz, CDCl3) δ 8.07 (d,

[M + H]+ 565.1



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.89 (s, 1H), 2.91-2.75(m, 2H).



c-111

1H NMR (600 MHz, CDCl3) δ 8.08 (d,

[M + H]+ 520.9



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.95 (s, 1H), 3.11-2.95(m, 2H).



c-114

1H NMR (600 MHz, CDCl3) δ 8.10 (d,

[M + H]+ 524.9



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.95 (s, 1H), 2.45(s, 3H).



c-117

1H NMR (600 MHz, CDCl3) δ 8.15 (s, 1H),

[M + H]+ 629.0



7.59(s, 1H), 6.88 (s, 0H), 4.24-




4.19 (m, 2H), 4.08-3.93 (m, 2H),




3.57-3.45 (m, 1H), 3.48-3.32 (m, 1H),




1.62-1.53 (m, 2H), 1.50 (dddd, J = 13.7,




6.9, 3.5, 2.3 Hz, 2H), 1.31-1.19




(m, 4H), 1.01-0.81 (m, 6H).



c-118

1H NMR (600 MHz, CDCl3) δ 8.18 (s, 1H),

[M + H]+ 505.0



7.57 (s, 1H), 7.45 (s, 1H), 3.80




(d, J = 16.4 Hz, 3H), 3.61 (d, J = 31.8




Hz, 3H), 3.51-3.40 (m, 1H), 3.46-




3.29 (m, 1H), 3.20-2.98 (m, 2H),




1.38-1.29 (m, 3H).



c-123

1H NMR (600 MHz, CDCl3) δ 8.10 (d,

[M + H]+ 540.9



J = 2.0 Hz, 1H), 7.68 (d, J = 1.2 Hz,




1H), 6.95 (s, 1H), 4.89 (s, 1H), 4.45(dd,




J = 4.8, 1.7 Hz, 2H).



c-126

1H NMR (600 MHz, CDCl3) δ 8.11 (d,

[M + H]+ 510.9



J = 2.0 Hz, 1H), 7.69 (d, J = 1.2 Hz,




1H), 6.95 (s, 1H), 4.89 (s, 1H).



c-128

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 453.9



(s, 1H), 7.69 (s, 1H), 6.95 (brs, 1H),




3.74 (d, J = 6.9 Hz, 1H), 2.33-2.25(m, 2H).



c-135

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 448.9



(s, 1H), 7.61 (s, 1H), 6.39 (brs, 1H),




4.71 (s, 1H).



c-139

1H NMR (600 MHz, CDCl3) δ 8.16(s,

[M + H]+ 474.9



1H), 7.61 (s, 1H), 6.79 (brs, 1H),




6.59 (dd, J = 12.8, 8.9 Hz, 1H), 6.09 (d,




J = 8.9 Hz, 1H), 4.71 (d, J = 6.9




Hz, 1H).



c-149

1H NMR (600 MHz, CDCl3) δ 8.15 (d,

[M + H]+ 553.9



J = 2.0 Hz, 1H), 7.69 (d, J = 1.2 Hz,




1H), 6.95 (s, 1H), 4.90 (s, 1H).



c-150

1H NMR (600 MHz, CDCl3) δ 8.20 (d,

[M + H]+ 483.0



J = 2.0 Hz, 1H), 7.69 (d, J = 1.2 Hz,




1H), 6.35 (s, 1H), 4.91 (s, 1H).



c-152

1H NMR (600 MHz, CDCl3) δ 8.10 (d,

[M + H]+ 525.9



J = 2.0 Hz, 1H), 7.65 (d, J = 1.2 Hz,




1H), 6.25 (s, 1H), 4.71 (s, 1H).



c-154

1H NMR (600 MHz, CDCl3) δ 8.10 (d,

[M + H]+ 514.9



J = 2.0 Hz, 1H), 7.65 (d, J = 1.2 Hz,




1H), 6.75 (brs, 1H), 6.25 (brs, 1H),




4.70 (s, 1H), 2.93 (s, 3H).



c-166

1H NMR (600 MHz, CDCl3) δ 8.16 (d,

[M + H]+ 455.0



J = 2.0 Hz, 1H), 7.68 (d, J = 1.4 Hz,




1H), 6.89 (s, 1H), 3.87 (s, 3H),




3.11-3.05(m, 2H).



c-169

1H NMR (600 MHz, CDCl3) δ 8.06 (d,

[M + H]+ 523.0



J = 2.0 Hz, 1H), 7.68 (d, J = 1.4 Hz,




1H), 6.89 (s, 1H), 4.87 (d, J = 12.0 Hz,




1H), 4.67-4.60 (m, 2H), 3.11-3.05(m,




2H).



c-173

1H NMR (600 MHz, CDCl3) δ 8.05 (d,

[M + H]+ 408.0



J = 2.0 Hz, 1H), 7.69 (d, J = 1.2 Hz,




1H), 6.95 (s, 1H), 4.91 (s, 1H).



c-180

1H NMR (600 MHz, CDCl3) δ 8.09 (d,

[M + H]+ 439.0



J = 2.0 Hz, 1H), 7.68 (d, J = 1.4 Hz,




1H), 6.89 (s, 1H), 4.87 (d, J = 12.0 Hz,




1H), 3.11-3.05(m, 2H), 2.05(s, 2H).



c-188

1H NMR (600 MHz, CDCl3) δ 8.03 (s, 1H),

[M + H]+ 589.0



7.88 (s, 1H), 7.28 (s, 1H), 3.82




(s, 3H), 3.66 (s, 3H), 3.55-3.23 (m, 2H).



c-196

1H NMR (600 MHz, CDCl3) δ 8.08-8.13

[M + H]+ 647.0



(m, 1H), 7.86-7.84 (m, 1H), 6.87




(s, 1H), 4.48-4.31 (m, 2H), 3.83 (d,




J = 6.7 Hz, 3H), 3.70-3.48 (m, 2H).



c-203

1H NMR (600 MHz, CDCl3) δ 8.04

[M + H]+ 575.0



(s, 1H), 7.89 (s, 1H), 5.87 (tdt, J = 54.7,




23.8, 3.9 Hz, 1H), 4.33-4.14 (m, 2H),




3.85 (d, J = 7.3 Hz, 3H), 3.60-3.37




(m, 2H).



c-210

1H NMR (600 MHz, CDCl3) δ 8.03 (dd,

[M + H]+ 550.0



J = 4.9, 1.8 Hz, 1H), 7.87 (d, J = 1.8




Hz, 1H), 6.86 (s, 1H), 4.40-4.20 (m, 2H),




3.63 (d, J = 23.3 Hz, 3H), 3.53-




3.31 (m, 2H), 1.25 (td, J = 7.1, 3.0 Hz, 3H).



c-217

1H NMR (600 MHz, CDCl3) δ 8.05 (m, 1H),

[M + H]+ 597.0



7.87 (s, 1H), 7.27 (s, 1H), 4.38-




4.21 (m, 2H), 4.15-4.00 (m, 2H), 3.69-3.30




(m, 2H), 1.25 (td, J = 7.1, 1.4




Hz, 3H), 1.17 (dt, J = 16.7, 7.1 Hz, 3H).



c-221

1H NMR (600 MHz, CDCl3) δ 8.04 (dd,

[M + H]+ 606.0



J = 4.8, 1.7 Hz, 1H), 7.59 (d, J = 0.3




Hz, 1H), 5.87 (tdt, J = 54.7, 23.8, 3.9 Hz,




1H), 4.33-4.14 (m, 2H), 3.83 (d, J =




7.3 Hz, 3H), 3.60-3.37 (m, 2H).



c-224

1H NMR (600 MHz, CDCl3) δ 7.33 (s, 1H),

[M + H]+ 560.9



6.86 (s, 1H), 5.28 (s, 1H), 3.82




(s, 3H), 3.66 (s, 3H), 3.55-3.23 (m, 2H).



c-231

1H NMR (600 MHz, CDCl3) δ 7.43 (d,

[M + H]+ 618.9



J = 1.3 Hz, 1H), 6.92 (d, J = 1.2 Hz,




1H), 6.84 (s, 1H), 4.11-3.99 (m, 2H),




3.81 (s, 3H), 3.48 (d, J = 2.2 Hz, 2H),




1.16 (t, J = 7.1 Hz, 3H).



c-238

1H NMR (600 MHz, CDCl3) δ 6.88 (m, 1H),

[M + H]+ 609.0



6.76 (m, 1H), 6.57 (s, 1H), 4.48-




4.31 (m, 2H), 3.83 (d, J = 6.7 Hz, 3H),




3.70-3.48 (m, 2H).



c-245

1H NMR (600 MHz, CDCl3) δ 7.75 (dd,

[M + H]+ 602.0



J = 4.8, 1.7 Hz, 1H), 7.28 (d, J = 0.3




Hz, 1H), 5.87 (tdt, J = 54.7, 23.8, 3.9 Hz,




1H), 4.33-4.14 (m, 2H), 3.83 (d, J =




7.3 Hz, 3H), 3.60-3.37 (m, 2H).



c-253

1H NMR (600 MHz, CDCl3) δ 6.88 (m, 1H),

[M + H]+ 569.0



6.74 (s, 1H), 5.27 (s, 1H), 4.38-




4.21 (m, 2H), 4.15-4.00 (m, 2H), 3.69-3.30




(m, 2H), 1.25 (td, J = 7.1, 1.4




Hz, 3H), 1.17 (dt, J = 16.7, 7.1 Hz, 3H).



c-258

1H NMR (600 MHz, CDCl3) δ 7.53

[M + H]+ 599.0



(s, 1H), 7.37 (s, 1H), 6.86 (s, 1H), 4.40-




4.20 (m, 2H), 4.34 (dd, J = 23.3,7.8 Hz,




2H), 3.63 (s, 3H), 3.55 (s, 3H), 3.53-




3.31 (m, 2H), 1.25 (td, J = 7.1, 3.0 Hz, 3H).



c-262

1H NMR (600 MHz, CDCl3) δ 7.77 (m, 1H),

[M + H]+ 640.0



7.36 (m, 1H), 6.87 (s, 1H), 4.48-




4.31 (m, 2H), 3.83 (d, J = 6.7 Hz, 3H),




3.70-3.48 (m, 2H).



c-266

1H NMR (600 MHz, CDCl3) δ 8.23 (s, 1H),

[M + H]+ 522.0



7.88 (s, 1H), 7.58 (s, 1H), 3.82




(s, 3H), 3.66 (s, 3H), 3.55-3.23 (m, 2H).



c-273

1H NMR (600 MHz, CDCl3) δ 8.43 (s, 1H),

[M + H]+ 579.9



7.87 (s, 1H), 7.54 (s, 1H), 4.11-




3.99 (m, 2H), 3.81 (s, 3H), 3.48 (d,




J = 2.2 Hz, 2H), 1.16 (t, J = 7.1 Hz, 3H).



c-286

1H NMR (600 MHz, CDCl3) δ 8.55 (m, 1H),

[M + H]+ 581.0



8.26 (m, 1H), 6.87 (s, 1H), 4.48-




4.31 (m, 2H), 3.83 (d, J = 6.7 Hz, 3H),




3.70-3.48 (m, 2H).



c-306

1H NMR (600 MHz, CDCl3) δ 8.49 (s, 1H),

[M + H]+ 549.0



8.27 (s, 1H), 6.86 (s, 1H), 4.40-




4.20 (m, 2H), 3.63 (d, J = 23.3 Hz, 3H),




3.53-3.31 (m, 2H), 1.25 (td, J =




7.1, 3.0 Hz, 3H).



c-317

1H NMR (600 MHz, CDCl3) δ 7.59-7.46

[M + H]+ 604.9



(m, 2H), 5.87 (tdt, J = 54.7, 23.8,




3.9 Hz, 1H), 4.33-4.14 (m, 2H), 3.83




(d, J = 7.3 Hz, 3H), 3.60-3.37 (m,




2H).



c-327

1H NMR (600 MHz, CDCl3) δ 8.16 (d,

[M + H]+ 516.0



J = 1.3 Hz, 1H), 7.50 (d, J = 1.2 Hz,




1H), 6.84 (s, 1H), 4.11-3.99 (m, 2H),




3.81 (s, 3H), 3.48 (d, J = 2.2 Hz, 2H),




1.16 (t, J = 7.1 Hz, 3H).



c-346

1H NMR (600 MHz, CDCl3) δ 8.58-8.43

[M + H]+ 589.9



(m, 2H), 6.87 (s, 1H), 4.48-4.31




(m, 2H), 3.83 (d, J = 6.7 Hz, 3H),




3.70-3.48 (m, 2H).









Hydrogen spectrum and mass spectrum data of nuclear magnetic resonance of some compounds shown in the general formula (d) of Table 10 were shown in Table 15.









TABLE 15







Hydrogen Spectrum and Mass Spectrum Data of Nuclear Magnetic


Resonance of Some Compounds Shown in General Formula (d)









Com-




pound

1H-NMR(600 MHz)

MS (ESI)





d-3

1H NMR (600 MHz, CDCl3) δ 8.12

[M + H]+ 513.1



(s, 1H), 7.69 (s, 1H), 7.57 (brs, 1H),




3.75 (s, 3H), 3.67(s, 3H), 3.36-3.29(m, 2H).



d-7

1H NMR (600 MHz, CDCl3) δ 8.01

[M + H]+ 497.1



(s, 1H), 7.75 (s, 1H), 7.58 (brs, 1H),




3.71 (s, 3H), 3.70(s, 3H), 3.35-3.29(m, 2H).



d-8

1H NMR (600 MHz, CDCl3) δ 7.91

[M + H]+ 562.0



(s, 1H), 7.65 (s, 1H), 7.58 (brs, 1H),




3.74 (s, 3H), 3.60(s, 3H), 3.24-3.06(m, 2H),




2.11(s, 3H).



d-9

1H NMR (600 MHz, CDCl3) δ 8.61

[M + H]+ 548.9



(brs, 2H), 7.61 (s, 1H), 7.55 (s, 1H),




7.54 (brs, 1H), 4.34 (s, 2H), 3.73




(s, 3H), 3.61(s, 3H), 3.25-3.06(m, 2H).



d-12

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 559.1



(s, 1H), 7.57-7.49 (m, 1H), 7.35 (t, J =




2.2 Hz, 1H), 3.80 (d, J = 18.3 Hz, 3H),




3.61 (d, J = 35.5 Hz, 3H), 3.56-3.37




(m, 2H), 2.92 (II, J = 11.8, 3.4 Hz, 1H),




2.07-1.98 (m, 2H), 1.97-1.86 (m,




2H), 1.77-1.69 (m, 1H), 1.52-1.43 (m, 2H),




1.44-1.34 (m, 3H).



d-13

1H NMR (600 MHz, CDCl3) δ 8.12 (s, 1H),

[M + H]+ 491.1



7.55 (s, 1H), 7.24 (d, J = 153.3




Hz, 1H), 3.82 (d, J = 16.2 Hz, 3H), 3.62




(d, J = 15.5 Hz, 3H), 3.48-3.36 (m,




1H), 3.45-3.29 (m, 1H), 2.99 (d,




J = 13.9 Hz, 3H).



d-14

1H NMR (600 MHz, CDCl3) δ 8.14 (s, 1H),

[M + H]+ 505.0



7.57 (s, 1H), 7.40 (s, 1H), 3.80




(d, J = 16.4 Hz, 3H), 3.61 (d, J = 31.8




Hz, 3H), 3.51-3.40 (m, 1H), 3.46-




3.29 (m, 1H), 3.20-2.98 (m, 2H),




1.38-1.29 (m, 3H).



d-15

1H NMR (600 MHz, CDCl3) δ 8.71-8.63

[M + H]+ 638.0



(m, 1H), 8.11 (s, 1H), 8.01 (dd, J =




18.1, 7.8 Hz, 1H), 7.95 (qd, J = 7.5,




1.7 Hz, 1H), 7.60 (s, 1H), 7.52-7.48




(m, 1H), 7.43 (dddd, J = 20.7, 7.5, 4.7,




1.1 Hz, 1H), 4.26-4.07 (m, 2H), 4.07-




4.01 (m, 1H), 3.69 (t, J = 6.8 Hz, 1H),




3.56-3.29 (m, 2H), 1.59 (dq, J =




14.0, 7.2 Hz, 1H), 1.54-1.44 (m, 2H),




1.31-1.21 (m, 3H), 1.14 (ddd, J =




25.1, 15.4, 8.0 Hz, 2H), 0.93-0.79 (m, 6H).



d-17

1H NMR (600 MHz, CDCl3) δ 8.07

[M + H]+ 671.0



(s, 1H), 7.78 (s, 2H), 7.52 (dt, J = 6.6, 2.3




Hz, 3H), 6.99 (s, 1H), 4.14 (ddt, J = 45.1,




10.8, 6.8 Hz, 2H), 3.85 (t, J = 6.8




Hz, 2H), 3.36 (s, 2H), 1.60-1.51 (m, 2H),




1.45-1.37 (m, 2H), 1.25-1.18




(m, 4H), 0.86 (td, J = 7.4, 1.9 Hz, 6H).



d-18

1H NMR (600 MHz, CDCl3) δ 8.07 (s, 1H),

[M + H]+ 651.2



7.66 (s, 2H), 7.55-7.48 (m, 1H),




7.38-7.30 (m, 3H), 4.22-4.10 (m, 2H),




4.09-3.99 (m, 1H), 3.84 (td, J =




6.8, 2.7 Hz, 1H), 3.44 (d, J = 17.2 Hz, 1H),




3.32 (dd, J = 17.3, 8.4 Hz, 1H),




2.41 (d, J = 7.6 Hz, 3H), 1.62-1.49 (m, 3H),




1.41-1.34 (m, 1H), 1.24-




1.15 (m, 4H), 0.87-0.82 (m, 6H).



d-20

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 529.9



(s, 1H), 7.46 (s, 1H), 7.45 (brs, 1H),




5.45 (brs, 2H), 3.62 (s, 3H),




3.13-3.05(m, 2H).



d-24

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 559.0



(s, 1H), 7.47 (s, 1H), 7.45 (brs, 1H),




3.64 (s, 3H), 3.62 (s, 3H), 3.395 (dd,




J = 3.4, 1.8 Hz, 1H), 1.12 (d, J = 2.8




Hz, 3H).



d-27

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 612.9



(s, 1H), 7.42 (s, 1H), 7.54 (t, J = 2.3




Hz, 1H), 4.78-4.63 (m, 2H), 4.49-4.29




(m, 2H), 3.82 (d, J = 4.8 Hz,




3H), 3.71-3.46 (m, 2H).



d-33

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 529.0



(s, 1H), 7.46 (s, 1H), 7.45 (brs, 1H),




3.74 (s, 3H), 3.33-3.25(m, 2H),




2.10 (s, 3H).



d-34

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 564.9



(s, 1H), 7.44 (s, 1H), 7.46 (brs, 1H),




3.72 (s, 3H), 3.13-3.05(m, 2H).



d-35
H NMR (600 MHz, CDCl3) δ 8.18
[M + H]+ 554.9



(s, 1H), 7.43 (s, 1H), 7.45 (brs, 1H),




3.68 (s, 3H), 3.03-2.95(m, 2H).



d-38

1H NMR (600 MHz, DMSO) δ 9.57 (d,

[M + H]+ 545.0



J = 57.9 Hz, 1H), 8.18 (m, 2H), 4.29-




4.16 (m, 2H), 3.55-3.46 (m, 2H),




1.15 (dt, J = 15.9, 7.1 Hz, 3H).



d-42

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 694.9



(s, 1H), 7.41 (s, 1H), 6.95 (brs, 1H),




5.69-5.59 (m, 1H), 3.85 (d, J = 21.5 Hz,




3H), 3.81-3.62 (m, 2H).



d-46

1H NMR (600 MHz, CDCl3) δ 8.10

[M + H]+ 513.0



(s, 1H), 7.44 (s, 1H), 7.46 (brs, 1H),




3.13-3.06(m, 2H), 2.43 (s, 3H),




2.10 (s, 3H)..



d-48

1H NMR (600 MHz, CDCl3) δ 8.09

[M + H]+ 538.9



(s, 1H), 7.43 (s, 1H), 7.40 (brs, 1H),




3.13-3.05(m, 2H), 2.40 (s, 3H).



d-49

1H NMR (600 MHz, CDCl3) δ 8.07

[M + H]+ 566.9



(s, 1H), 7.46 (s, 1H), 7.39 (brs, 1H),




3.11-3.06(m, 2H), 2.39 (s, 3H).



d-50

1H NMR (600 MHz, CDCl3) δ 8.05

[M + H]+ 620.9



(s, 1H), 7.46 (s, 1H), 7.45 (brs, 1H),




3.13-3.05(m, 2H).



d-52

1H NMR (600 MHz, CDCl3) δ 8.05

[M + H]+ 601.8



(s, 1H), 7.51 (s, 1H), 7.44 (brs, 1H),




7.23-7.19(m, 5H), 3.33-3.25(m, 2H).



d-54

1H NMR (600 MHz, CDCl3) δ 8.08

[M + H]+ 582.8



(s, 1H), 7.50 (s, 1H), 7.45 (brs, 1H),




3.74 (s, 3H), 3.33-3.25(m, 2H).



d-60

1H NMR (600 MHz, CDCl3) δ 8.05

[M + H]+ 487.9



(s, 1H), 7.55 (s, 1H), 7.41 (brs, 1H),




3.11-3.02(m, 2H).



d-63

1H NMR (600 MHz, CDCl3) δ 8.07

[M + H]+ 602.8



(s, 1H), 7.56 (s, 1H), 7.42 (brs, 1H),




3.31-3.22(m, 2H).



d-64

1H NMR (600 MHz, CDCl3) δ 8.06

[M + H]+ 549.9



(s, 1H), 7.58 (s, 1H), 7.43 (brs, 1H),




3.15-3.07(m, 2H).



d-65

1H NMR (600 MHz, CDCl3) δ 8.03

[M + H]+ 521.9



(s, 1H), 7.50 (s, 1H), 7.41 (brs, 1H),




3.12-3.07(m, 2H).



d-67

1H NMR (600 MHz, CDCl3) δ 8.05

[M + H]+ 511.9



(s, 1H), 7.56 (s, 1H), 7.44 (brs, 1H),




3.61(s, 3H), 3.33-3.25(m, 2H).



d-69

1H NMR (600 MHz, CDCl3) δ 8.03

[M + H]+ 565.1



(s, 1H), 7.47 (s, 1H), 7.20 (brs, 1H),




3.00-2.92(m, 2H).



d-70

1H NMR (600 MHz, CDCl3) δ 8.07

[M + H]+ 521.9



(s, 1H), 7.47 (s, 1H), 7.21 (brs, 1H),




3.01-2.93(m, 2H).



d-72

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 629.0



(s, 1H), 7.57 (s, 1H), 6.88 (s, 0H), 4.24-




4.19 (m, 2H), 4.08-3.93 (m, 2H),




3.57-3.45 (m, 1H), 3.48-3.32 (m, 1H),




1.62-1.53 (m, 2H), 1.50 (dddd, J = 13.7,




6.9, 3.5, 2.3 Hz, 2H), 1.31-1.19




(m, 4H), 1.01-0.81 (m, 6H).



d-73

1H NMR (600 MHz, CDCl3) δ 8.12 (s, 1H),

[M + H]+ 601.0



7.57 (s, 1H), 6.85 (s, 1H), 5.11




(tt, J = 12.5, 6.2 Hz, 1H), 4.93 (dp,




J = 30.3, 6.3 Hz, 1H), 3.53-3.37 (m,




1H), 3.45-3.22 (m, 1H), 1.27-1.20




(m, 6H), 1.18-1.07 (m, 6H).



d-74

1H NMR (600 MHz, CDCl3) δ 8.15 (s,

[M + H]+ 486.9



1H), 7.56 (s, 1H), 7.45 (brs, 1H),




4.75 (s, 1H), 3.65(s, 3H).



d-81

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 510.9



(s, 1H), 7.58 (s, 1H), 7.47 (brs, 1H),




4.75 (s, 1H).



d-82

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 439.9



(s, 1H), 7.50 (s, 1H), 7.49 (brs, 1H),




4.76 (s, 1H).



d-85

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 497.1



(s, 1H), 7.66 (s, 1H), 7.45 (brs, 1H),




3.74 (d, J = 6.9 Hz, 1H), 2.33-2.25(m, 2H).



d-90

1H NMR (600 MHz, CDCl3) δ 8.18

[M + H]+ 448.9



(s, 1H), 7.61 (s, 1H), 7.39 (brs, 1H),




4.71 (s, 1H).



d-98

1H NMR (600 MHz, CDCl3) δ 8.15 (s, 1H),

[M + H]+ 530.1



7.56 (s, 1H), 7.35 (brs, 1H),




4.74 (s, 1H), 3.65(s, 3H), 3.31-3.25(m, 2H).



d-103

1H NMR (600 MHz, CDCl3) δ 8.18

[M + H]+ 567.9



(s, 1H), 7.56 (s, 1H), 7.35 (brs, 1H),




4.74 (s, 1H), 3.33-3.25(m, 2H).



d-107

1H NMR (600 MHz, CDCl3) δ 8.20

[M + H]+ 525.9



(s, 1H), 7.50 (s, 1H), 7.41 (brs, 1H),




4.65 (s, 1H).



d-109

1H NMR (600 MHz, CDCl3) δ 8.17

[M + H]+ 514.9



(s, 1H), 7.56 (s, 1H), 7.45 (brs, 1H),




7.35 (brs, 1H), 4.74 (s, 1H), 2.75(s, 3H).



d-112

1H NMR (600 MHz, CDCl3) δ 8.17

[M + H]+ 499.9



(s, 1H), 7.56 (s, 1H), 7.35 (brs, 1H),




4.74 (s, 1H), 2.45(s, 3H).



d-114

1H NMR (600 MHz, CDCl3) δ 8.20

[M + H]+ 535.8



(s, 1H), 7.56 (s, 1H), 7.35 (brs, 1H),




4.14 (s, 1H).



d-119

1H NMR (600 MHz, CDCl3) δ 8.19

[M + H]+ 497.8



(s, 1H), 7.58 (s, 1H), 7.44 (brs, 1H),




6.23(d, J = 8.3 Hz, 1H), 6.02(dd,




J = 1.3, 8.4 Hz, 1H), 4.81 (s, 1H),




1.63(d, J = 9.2 Hz, 3H).



d-122

1H NMR (600 MHz, CDCl3) δ 8.23

[M + H]+ 468.9



(s, 1H), 7.67 (s, 1H), 7.44 (brs, 1H),




4.81 (dd, J = 1.3, 8.4 Hz, 1H), 3.81




(s, 3H), 2.82 (m, 1H), 1.13(d, J = 10.2




Hz, 3H).



d-127

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 478.9



(s, 1H), 7.54 (s, 1H), 7.43 (brs, 1H),




4.74 (s, 1H).



d-129

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 421.9



(s, 1H), 7.49 (s, 1H), 7.43 (brs, 1H),




3.74 (s, 1H), 3.13-3.05(m, 2H).



d-133

1H NMR (600 MHz, CDCl3) δ 8.16

[M + H]+ 453.9



(s, 1H), 7.53 (brs, 1H), 7.49 (s, 1H),




7.43 (brs, 1H), 4.14 (s, 1H), 3.34 (s, 3H),




3.13-3.05(m, 2H).



d-141

1H NMR (600 MHz, CDCl3) δ 8.15

[M + H]+ 424.9



(s, 1H), 7.43 (s, 1H), 7.43 (brs, 1H),




3.74 (d, J = 8.4 Hz, 1H), 2.04-1.96




(m, 1H), 0.98 (d, J = 12.9 Hz, 6H).









Hydrogen spectrum and mass spectrum data of nuclear magnetic resonance of some compounds shown in the general formula (e) of Table 11 were shown in Table 16.









TABLE 16







Hydrogen Spectrum and Mass Spectrum Data of Nuclear Magnetic


Resonance of Some Compounds Shown in General Formula (e)









Com-




pound

1H-NMR(600 MHz)

MS (ESI)





e-1

1H NMR (600 MHz, CDCl3) δ 8.15 (dd,

[M + H]+ 545.1



J = 5.3, 1.8 Hz, 1H), 7.58 (d, J = 1.7




Hz, 1H), 7.15 (brs, 1H), 3.82 (s, 3H),




3.64 (s, 3H), 3.57-3.25 (m, 2H).



e-2

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 559.0



(d, J = 1.3 Hz, 1H), 7.57 (d, J = 1.2 Hz,




1H), 6.84 (brs, 1H), 4.11-3.99 (m, 2H),




3.81 (s, 3H), 3.48 (d, J = 2.2 Hz,




2H), 1.16 (t, J = 7.1 Hz, 3H).



e-3

1H NMR (600 MHz, CDCl3) δ 8.36

[M + H]+ 612.9



(s, 1H), 7.62 (s, 1H), 7.54 (t, J = 2.3




Hz, 1H), 4.78-4.63 (m, 2H), 4.49-4.29




(m, 2H), 3.82 (d, J = 4.8 Hz,




3H), 3.71-3.46 (m, 2H).



e-4

1H NMR (600 MHz, CDCl3) δ 8.34

[M + H]+ 594.9



(s, 1H), 7.64 (s, 1H), 6.92 (brs, 1H),




5.87 (tdt, J = 54.7, 24.2, 3.9 Hz, 1H),




4.35-4.12 (m, 2H), 3.83 (s, 3H),




3.63-3.35 (m, 2H).



e-5

1H NMR (600 MHz, CDCl3) δ 8.25

[M + H]+ 573.2



(m, 1H), 7.67 (s, 1H), 7.27 (brs, 1H),




4.38-4.21 (m, 2H), 4.15-4.00 (m, 2H),




3.69-3.30 (m, 2H), 1.25 (td, J =




7.1, 1.4 Hz, 3H), 1.17 (dt, J = 16.7,




7.1 Hz, 3H).



e-6

1H NMR (600 MHz, CDCl3) δ 8.23 (dd,

[M + H]+ 559.0



J = 4.9, 1.8 Hz, 1H), 7.67 (d, J = 1.8




Hz, 1H), 6.86 (brs, 1H), 4.40-4.20 (m, 2H),




3.63 (s, 3H), 3.53-3.31 (m,




2H), 1.25 (td, J = 7.1, 3.0 Hz, 3H).



e-7

1H NMR (600 MHz, CDCl3) δ 8.17 (dd,

[M + H]+ 545.1



J = 5.3, 1.8 Hz, 1H), 7.59 (d, J = 1.7




Hz, 1H), 7.16 (brs, 1H), 3.83 (s, 3H), 3.65




(s, 3H), 3.57-3.25 (m, 2H).



e-8

1H NMR (600 MHz, CDCl3) δ 8.13

[M + H]+ 559.0



(d, J = 1.3 Hz, 1H), 7.55 (d, J = 1.2 Hz,




1H), 6.82 (brs, 1H), 4.11-3.97 (m, 2H),




3.81 (s, 3H), 3.49 (d, J = 2.2 Hz,




2H), 1.16 (t, J = 7.2 Hz, 3H).



e-9

1H NMR (600 MHz, CDCl3) δ 8.35 (s, 1H),

[M + H]+ 612.9



7.63 (s, 1H), 7.44 (t, J = 2.3




Hz, 1H), 4.78-4.62 (m, 2H), 4.50-4.29




(m, 2H), 3.82 (d, J = 4.8 Hz,




3H), 3.71-3.46 (m, 2H).



e-10

1H NMR (600 MHz, CDCl3) δ 8.34

[M + H]+ 594.9



(s, 1H), 7.64 (s, 1H), 6.96 (brs, 1H),




5.87 (tdt, J = 54.7, 24.2, 3.9 Hz, 1H),




4.35-4.12 (m, 2H), 3.93 (s, 3H),




3.64-3.35 (m, 2H).



e-11

1H NMR (600 MHz, CDCl3) δ 8.25

[M + H]+ 573.2



(m, 1H), 7.67 (s, 1H), 7.27 (brs, 1H),




4.39-4.21 (m, 2H), 4.15-4.01 (m, 2H),




3.68-3.30 (m, 2H), 1.25 (td, J =




7.1, 1.5 Hz, 3H), 1.17 (dt, J = 16.7,




7.2 Hz, 3H).



e-12

1H NMR (600 MHz, CDCl3) δ 8.22

[M + H]+ 559.0



(dd, J = 4.9, 1.8 Hz, 1H), 7.68 (d, J = 1.8




Hz, 1H), 6.96 (brs, 1H), 4.40-4.20 (m, 2H),




3.63 (s, 3H), 3.53-3.31 (m,




2H), 1.25 (td, J = 7.1, 3.1 Hz, 3H).



e-13

1H NMR (600 MHz, CDCl3) δ 8.16 (dd,

[M + H]+ 545.1



J = 5.3, 1.9 Hz, 1H), 7.58 (d, J = 1.8




Hz, 1H), 7.13 (brs, 1H), 3.82 (s, 3H),




3.64 (s, 3H), 3.59-3.25 (m, 2H).



e-14

1H NMR (600 MHz, CDCl3) δ 8.11 (d,

[M + H]+ 559.0



J = 1.4 Hz, 1H), 7.47 (d, J = 1.2 Hz,




1H), 6.84 (brs, 1H), 4.11-3.99 (m, 2H),




3.83 (s, 3H), 3.48 (d, J = 2.2 Hz,




2H), 1.16 (t, J = 7.5 Hz, 3H).



e-15

1H NMR (600 MHz, CDCl3) δ 8.32

[M + H]+ 612.9



(s, 1H), 7.62 (s, 1H), 7.54 (t, J = 2.4




Hz, 1H), 4.78-4.63 (m, 2H), 4.49-4.29




(m, 2H), 3.81 (d, J = 4.8 Hz,




3H), 3.71-3.46 (m, 2H).



e-16

1H NMR (600 MHz, CDCl3) δ 8.33

[M + H]+ 594.9



(s, 1H), 7.64 (s, 1H), 6.92 (brs, 1H),




5.87 (tdt, J = 54.7, 24.2, 3.9 Hz, 1H),




4.34-4.12 (m, 2H), 3.83 (s, 3H),




3.64-3.35 (m, 2H).



e-17

1H NMR (600 MHz, CDCl3) δ 8.26

[M + H]+ 573.2



(m, 1H), 7.67 (s, 1H), 7.27 (brs, 1H),




4.40-4.21 (m, 2H), 4.15-4.01 (m, 2H),




3.69-3.30 (m, 2H), 1.25 (td, J =




7.3, 1.2Hz, 3H), 1.17 (dt, J = 16.7,




7.3 Hz, 3H).



e-18

1H NMR (600 MHz, CDCl3) δ 8.33 (dd,

[M + H]+ 559.0



J = 4.9, 1.9 Hz, 1H), 7.68 (d, J = 1.6




Hz, 1H), 6.86 (brs, 1H), 4.41-4.21




(m, 2H), 3.62 (s, 3H), 3.52-3.30 (m,




2H), 1.24 (td, J = 7.0, 3.0 Hz, 3H).



e-19

1H NMR (600 MHz, CDCl3) δ 8.20 (s, 1H),

[M + H]+ 545.1



7.77 (s, 1H), 7.05 (brs, 1H), 3.82




(s, 3H), 3.64 (s, 3H), 3.57-3.25 (m, 2H).



e-20

1H NMR (600 MHz, CDCl3) δ 8.23 (s, 1H),

[M + H]+ 545.1



7.77 (s, 1H), 6.84 (brs, 1H), 4.11-




3.99 (m, 2H), 3.81 (s, 3H), 3.48 (d,




J = 2.2 Hz, 2H), 1.16 (t, J = 7.1 Hz,




3H).



e-21

1H NMR (600 MHz, CDCl3) δ 8.26

[M + H]+ 559.0



(s, 1H), 7.87 (s, 1H), 7.54 (t, J = 2.3




Hz, 1H), 4.78-4.63 (m, 2H), 4.49-4.29




(m, 2H), 3.82 (s, 3H), 3.71-




3.46 (m, 2H).



e-22

1H NMR (600 MHz, CDCl3) δ 8.34 (s, 1H),

[M + H]+ 612.9



7.69 (s, 1H), 6.92 (brs, 1H),




5.87 (tdt, J = 54.7, 24.2, 3.9 Hz, 1H),




4.35-4.12 (m, 2H), 3.83 (s, 3H),




3.63-3.35 (m, 2H).



e-23

1H NMR (600 MHz, CDCl3) δ 8.25

[M + H]+ 594.9



(s, 1H), 7.57 (s, 1H), 7.27 (brs, 1H), 4.38-




4.21 (m, 2H), 4.15-4.00 (m, 2H),




3.69-3.30 (m, 2H), 1.25 (td, J = 7.1,




1.4 Hz, 3H), 1.17 (dt, J = 16.7, 7.1 Hz, 3H).



e-24

1H NMR (600 MHz, CDCl3) δ 8.23 (s, 1H),

[M + H]+ 573.2



7.88 (s, 1H), 6.86 (s, 1H), 4.40-




4.20 (m, 2H), 3.63 (s, 3H), 3.53-3.31




(m, 2H), 1.25 (td, J = 7.1, 3.0 Hz,




3H).









Embodiment 9: Insecticidal Activity Embodiment

(1) Insecticidal Activity on 2nd-Instar Larvae of Plutella xylostella.



Plutella xylostella (L.) is a lepidoptera pest with a chewing mouthpart and is a common vegetable pest. The 2nd-instar larvae of Plutella xylostella were used as test objects and tested by using a leaf immersion feeding method.


Operation process: Samples were weighed accurately, and respectively added with 200 μL of dimethyl sulfoxide to prepare 10 g/L mother liquor which was diluted into a concentration of 500 ppm with an aqueous solution containing 0.05% of Tween-80 during the test. A hole puncher with a diameter of 1.0 cm was used to make cleaned cabbage leaves into leaf discs. The leaf discs were immersed in a liquid medicine, taken out after 5 seconds, air-dried naturally, and transferred into a clean vessel. About 35 2nd-instar larvae of Plutella xylostella were put into the vessel and fed at a constant temperature of 28° C. Each concentration was repeated 3 times, and an aqueous solution containing 0.05% of Tween-80 was used as a control group. After being treated for 24 hours, a number of dead Plutella xylostella was counted, and a mortality (%) was calculated according to a formula that mortality (%)=(number of live larvae in the control group−number of treated live larvae)/number of live larvae in the control group*100%. The results were shown in Table 17 to Table 24.


(2) Insecticidal Activity on 2nd-Instar Larvae of Spodoptera exigua.



Spodoptera exigua is a lepidoptera pest with a chewing mouthpart and is a common vegetable pest. The 2nd-instar larvae of Spodoptera exigua were used as test objects and tested by using a leaf immersion feeding method.


Operation process: Samples were weighed accurately, and respectively added with 200 μL, of dimethyl sulfoxide to prepare 10 g/L mother liquor which was diluted into a concentration of 500 ppm with an aqueous solution containing 0.05% of Tween-80 during the test. A hole puncher with a diameter of 1.0 cm was used to make cleaned cabbage leaves into leaf discs. The leaf discs were immersed in a liquid medicine, taken out after 5 seconds, air-dried naturally, and transferred into a clean vessel. About 35 2nd -instar larvae of Spodoptera exigua were put into the vessel and fed at a constant temperature of 28° C. Each concentration was repeated 3 times, and an aqueous solution containing 0.05% of Tween-80 was used as a control group. After being treated for 24 hours, a number of dead Spodoptera exigua was counted, and a mortality (%) was calculated according to a formula that mortality (%)=(number of live larvae in the control group −number of treated live larvae)/number of live larvae in the control group * 100%. The results were shown in Table 17 to Table 24.


(3) Insecticidal Activity on Aphid Adults.


Aphid is a homoptera pest with a piercing-sucking mouthpart and is a common vegetable pest. Aphis craccivora were taken as test objects and tested by using an impregnation method.


Operation process: Samples were weighed accurately, and respectively added with 200 μL of dimethyl sulfoxide to prepare 10 g/L mother liquor which was diluted into a concentration of 500 ppm with an aqueous solution containing 0.05% of Tween-80 during the test. After the wingless Aphis craccivora adults stably sucked on bean sprouts, the wingless Aphis craccivora adults together with the bean sprouts were immersed into a liquid medicine with a concentration of 500 ppm, taken out after 5 seconds, air-dried naturally, transferred into a clean vessel, and fed at a constant temperature of 23° C. Each concentration was repeated 3 times, and an aqueous solution containing 0.05% of Tween-80 was used as a control group. After being treated for 24 hours, a number of dead Aphis craccivora was counted, and a mortality (%) was calculated according to a formula that mortality (%)=(number of live Aphis craccivora in the control group−number of treated live Aphis craccivora)/number of live Aphis craccivora in the control group*100%. The results were shown in Table 17 to Table 24.


(4) Insecticidal Activity on Solenopsis invicta.


As a hymenoptera pests and a social insect, Solenopsis invicta is one of the most destructive invasive organisms. Solenopsis invicta were used as test objects and tested by using a water test tube poison-feeding method.


Operation process: Samples were weighed accurately, and respectively added with 200 μL of dimethyl sulfoxide to prepare 10 g/L mother liquor which was diluted into a concentration of 100 ppm with a mixed aqueous solution containing 0.05% of Tween-80 and 5% of honey during the test. Solenopsis invicta were placed in a raising test tube, and a liquid medicine was injected into a silica gel plug of the raising test tube by a syringe as long as the liquid medicine did not seep out. The raising test tube was placed in a raising box horizontally, and a small amount of ham sausages were added to the raising test tube as food to raise the Solenopsis invicta at a constant temperature of 25° C. After being treated for 24 hours and 72 hours, a number of live Solenopsis invicta and a number of dead Solenopsis invicta were counted, and a mortality (%) was calculated according to a formula that mortality (%)=(number of live Solenopsis invicta in the control group−number of treated live Solenopsis invicta)/number of live Solenopsis invicta in the control group*100%. The results were shown in Table 17 to Table 24.









TABLE 17







Insecticidal Activity of Compounds of Formula (I) on Test Pests









Insecticidal activity














Plutella


Spodoptera


Aphis
















xylostella


exigua


craccivora


Solenopsis




Mortality
Mortality
Mortality

invicta



Com-
(%)
(%)
(%)
Mortality (%)


pound
500
500
500
100 ppm












No.
ppm
ppm
ppm
24 h
72 h















A1
95
90
100
20
87


A2
97
100
100
19
93


A3
90
100
100
25
100


A4
86
100
100
20
87


A5
100
100
100
34
100


A6
100
100
100
44
100


A7
100
100
100
20
100


A8
100
90
100
26
93


A9
100
100
100
24
100


A10
86
100
100
20
87


A11
100
100
100
34
100


A12
100
100
100
44
100


A13
100
100
100
20
100


A14
100
90
100
26
93


A15
100
100
100
24
100


A16
86
100
100
20
87


A17
100
100
100
34
100


A18
100
100
100
44
100


A19
100
100
100
20
100


A20
100
90
100
26
93


A21
100
100
100
24
100


A22
96
100
100
30
97


A23
100
100
100
34
100


A24
100
100
100
44
100


A25
100
100
100
38
100


A26
100
100
100
45
100


A27
100
100
100
30
100


A28
100
90
100
29
97


A29
100
100
100
26
95


A30
100
100
100
40
100


A31
100
100
100
20
100


A32
100
90
100
26
93


A33
100
100
100
24
100


A34
96
100
100
28
97


A35
100
100
100
31
99


A36
100
100
100
44
100


A37
100
100
100
20
100


A38
100
90
100
26
93


A39
100
100
100
24
100


A40
96
100
100
20
97


A41
100
100
100
24
100


A42
100
100
100
44
100


A43
100
100
100
20
100


A44
100
90
100
26
93


A45
100
100
100
24
100


A46
86
100
100
20
87


A47
100
100
100
34
100
















TABLE 18







Insecticidal Activity of Some Compounds of Formula (I) on Test Pests









Insecticidal activity














Plutella


Spodoptera


Aphis
















xylostella


exigua


craccivora


Solenopsis




Mortality
Mortality
Mortality

invicta



Com-
(%)
(%)
(%)
Mortality (%)


pound
500
500
500
100 ppm












No.
ppm
ppm
ppm
24 h
72 h















B1
100
100
100
20
100


B2
100
90
93
26
93


B3
100
100
100
24
100


B4
86
100
100
20
88


B5
100
100
100
34
100


B6
90
100
100
44
100


B7
100
100
100
38
100


B8
100
100
100
45
100


B9
100
100
100
38
100


B10
100
95
100
30
90


B11
100
100
100
33
95


B12
100
100
100
40
100
















TABLE 19







Insecticidal Activity of Compounds of


Formula (I) in Table 3 on Test Pests









Insecticidal activity














Plutella


Spodoptera


Aphis
















xylostella


exigua


craccivora


Solenopsis




Mortality
Mortality
Mortality

invicta



Com-
(%)
(%)
(%)
Mortality (%)


pound
500
500
500
100 ppm












No.
ppm
ppm
ppm
24 h
72 h















C1
89
100
100
20
100


C2
100
90
100
26
93


C3
100
100
100
24
100


C4
86
76
100
20
87


C5
100
100
100
34
100


C6
100
100
100
44
100


C7
100
100
100
38
100


C8
91
85
95
36
92


C9
100
100
100
39
100


C10
100
85
100
27
100


C11
100
100
100
46
100


C12
100
91
100
18
95


C13
100
100
100
32
100


C14
100
100
100
30
100


C15
89
100
100
29
90


C16
100
95
99
23
89


C17
88
89
100
15
68


C18
90
86
98
20
70


C19
90
90
100
18
70


C20
100
100
100
28
99


C21
90
95
100
19
99


C22
99
94
89
20
70


C23
86
88
95
18
80


C24
100
100
100
36
100


C25
92
97
86
25
71


C26
89
90
100
20
80


C27
76
86
100
27
86


C28
100
100
100
30
98


C29
100
93
100
30
100


C30
100
90
92
24
100


C31
100
100
100
34
100


C32
100
90
95
25
100


C33
100
100
100
36
100


C34
100
100
100
40
100


C35
100
100
100
38
100


C36
90
90
100
10
90


C37
100
100
100
20
100


C38
100
90
100
25
90


C39
90
100
98
24
87


C40
100
95
100
28
90


C41
89
94
100
19
90


C42
91
94
100
20
70


C43
86
89
95
18
80


C44
90
100
100
36
90


C45
93
97
86
25
71


C46
89
91
90
21
80


C47
77
86
80
27
87


C48
76
85
79
26
86


C49
87
89
90
20
81


C50
81
86
90
26
86


C51
87
85
79
19
86


C52
90
91
100
22
90


C53
78
89
90
28
97


C54
77
78
87
17
84


C55
88
80
91
19
83


C56
82
87
91
27
80


C57
78
76
80
20
89


C58
100
100
100
29
98


C59
100
90
100
29
100


C60
90
92
100
25
92


C61
88
100
90
28
100


C62
80
85
97
27
100


C63
98
90
96
29
98


C64
92
97
100
17
90
















TABLE 20







Insecticidal Activity of Some Compounds


of General Formula (a) on Test Pests









Insecticidal activity













Plutella


Spodoptera


Aphis






xylostella


exigua


craccivora


Solenopsis




Mortality
Mortality
Mortality

invicta




(%)
(%)
(%)
Mortality (%)


Com-
500
500
500
100 ppm












pound
ppm
ppm
ppm
24 h
72 h















a-1
100
100
100
20
100


a-2
97
97
100
19
98


a-3
90
90
100
25
100


a-4
86
95
100
20
97


a-5
90
89
100
24
96


a-6
100
100
100
34
100


a-7
95
91
100
20
90


a-8
95
90
95
10
90


a-9
100
100
100
14
100


a-10
100
100
100
20
97


a-11
100
100
100
24
100


a-12
100
100
100
19
100


a-13
100
100
100
20
100


a-14
100
100
100
26
100


a-15
100
100
100
21
100


a-16
96
86
100
20
87


a-17
96
89
100
24
90


a-18
96
86
100
20
87


a-19
95
91
100
20
90


a-20
100
90
100
26
93


a-21
91
79
100
24
90


a-22
100
100
100
30
100


a-26
100
100
100
34
100


a-27
100
100
100
25
100


a-28
100
95
100
23
99


a-29
100
91
100
14
96


a-30
96
90
100
20
97


a-36
100
96
100
14
91


a-37
100
96
100
15
99


a-38
90
90
100
26
100


a-39
90
89
100
25
93


a-40
90
89
100
19
90


a-41
86
81
99
20
94


a-42
96
96
100
21
96


a-43
86
81
99
20
94


a-44
100
95
100
15
95


a-45
100
91
100
20
90


a-47
100
90
100
19
97


a-51
91
89
100
16
95


a-52
100
89
91
20
89


a-53
100
96
100
20
100


a-56
100
90
100
16
93


a-57
100
100
100
24
100


a-59
96
91
100
28
97


a-62
100
100
100
21
99


a-63
100
100
100
24
100


a-64
100
99
100
20
99


a-65
100
100
100
26
100


a-71
100
99
100
24
100


a-72
96
89
100
20
91


a-76
95
85
91
24
80


a-77
90
86
96
44
90


a-80
91
85
100
10
100


a-83
100
90
100
26
93


a-86
100
89
100
24
89


a-87
96
100
100
20
97


a-88
100
100
100
34
100


a-95
96
89
100
21
92


a-100
91
90
100
20
90


a-109
95
89
100
20
90


a-111
100
100
100
19
97


a-112
100
96
100
16
99


a-118
96
95
100
25
100


a-122
91
89
100
20
90


a-132
90
90
100
26
94


a-133
100
100
100
24
100


a-134
100
100
100
27
100


a-136
100
100
100
11
100
















TABLE 21







Insecticidal Activity of Some Compounds


of General Formula (b) on Test Pests









Insecticidal activity













Plutella


Spodoptera


Aphis






xylostella


exigua


craccivora


Solenopsis




Mortality
Mortality
Mortality

invicta




(%)
(%)
(%)
Mortality (%)


Com-
500
500
500
100 ppm












pound
ppm
ppm
ppm
24 h
72 h















b-1
100
100
100
20
97


b-2
100
95
100
19
93


b-3
90
90
95
25
90


b-4
90
89
96
20
90


b-5
89
80
100
14
100


b-6
100
100
100
20
100


b-7
100
90
100
17
97


b-8
100
96
100
26
92


b-9
100
100
100
19
100


b-10
100
100
100
20
100


b-11
100
100
100
34
100


b-12
100
100
100
14
100


b-13
100
100
100
20
100


b-14
100
100
100
26
100


b-15
100
100
100
24
100


b-16
96
90
100
20
97


b-17
100
92
100
14
100


b-18
99
89
98
14
100


b-19
100
95
100
20
100


b-20
100
90
100
21
93


b-21
90
81
90
24
86


b-23
96
95
100
10
97


b-25
100
100
100
26
100


b-27
91
89
100
19
100


b-28
100
99
100
16
100


b-30
90
85
100
25
94


b-34
90
87
100
10
100


b-37
86
90
99
20
94


b-38
90
85
99
32
90


b-39
96
85
97
24
90


b-43
89
80
89
19
90


b-47
95
85
100
18
90


b-48
100
89
100
15
90


b-50
99
90
100
10
100


b-54
100
90
100
25
97


b-56
100
100
100
26
100


b-57
100
100
100
30
100


b-59
100
100
100
20
100


b-62
100
96
100
26
93


b-63
100
100
100
24
100


b-66
96
91
100
28
97


b-68
99
100
100
21
99


b-70
100
95
100
44
100


b-73
89
85
100
20
90


b-76
95
90
100
26
93


b-80
95
90
100
14
90


b-86
96
89
100
20
97


b-87
95
95
100
14
100


b-88
100
100
100
25
100


b-94
100
90
100
20
100


b-96
100
93
100
26
98


b-99
91
85
100
24
90


b-104
96
96
100
20
96


b-111
100
100
100
24
100


b-116
100
98
100
20
100


b-118
99
91
100
14
99


b-123
99
95
100
24
100


b-131
95
95
100
11
100


b-134
100
100
100
26
100


b-135
100
100
100
23
100


b-136
100
100
100
20
97


b-138
100
100
100
14
100
















TABLE 22







Insecticidal Activity of Some Compounds


of General Formula (c) on Test Pests









Insecticidal activity













Plutella


Spodoptera


Aphis






xylostella


exigua


craccivora


Solenopsis




Mortality
Mortality
Mortality

invicta




(%)
(%)
(%)
Mortality (%)


Com-
500
500
500
100 ppm












pound
ppm
ppm
ppm
24 h
72 h















c-2
95
90
100
20
97


c-4
97
100
100
29
93


c-7
100
100
100
20
100


c-8
100
100
100
20
100


c-9
99
100
100
14
100


c-10
99
95
100
24
100


c-13
100
95
100
21
100


c-14
100
96
100
26
100


c-15
95
90
100
24
100


c-19
100
100
100
20
100


c-20
100
100
100
14
100


c-34
100
100
100
34
100


c-36
92
90
95
21
100


c-37
96
90
100
21
93


c-39
95
89
100
24
90


c-42
86
80
100
20
97


c-47
90
89
100
35
99


c-49
100
95
100
44
100


c-53
100
96
100
20
100


c-54
100
90
100
26
96


c-57
95
89
100
24
95


c-61
96
100
100
26
97


c-64
96
90
100
14
100


c-67
100
100
100
25
100


c-72
100
90
100
23
99


c-73
100
100
100
14
90


c-77
96
90
100
20
97


c-80
100
100
100
13
90


c-84
99
96
100
25
95


c-86
100
99
100
16
100


c-91
90
82
100
25
94


c-93
90
89
100
30
100


c-96
86
90
99
20
84


c-97
100
100
100
32
100


c-98
96
90
100
24
90


c-101
89
80
100
19
99


c-105
96
100
100
25
100


c-106
99
95
100
27
100


c-107
99
90
100
26
99


c-110
100
100
100
14
100


c-111
98
99
100
17
99


c-113
98
91
99
14
98


c-114
96
89
100
18
100


c-117
100
100
100
25
100


c-118
95
85
100
20
90


c-121
100
90
100
19
97


c-123
100
96
100
26
99


c-126
100
100
100
35
100


c-128
91
89
100
20
90


c-131
90
84
92
26
94


c-135
90
79
96
24
89


c-139
96
91
100
28
87


c-145
100
95
100
11
99


c-149
100
100
100
31
100


c-150
95
87
91
20
90


c-152
100
89
100
16
93


c-154
89
71
91
24
80


c-159
96
100
100
20
97


c-164
100
80
100
24
90


c-166
100
100
100
25
100


c-169
100
100
100
20
99


c-173
95
90
100
25
93


c-180
95
82
100
21
91


c-186
89
81
99
20
87


c-188
100
100
100
14
100


c-196
100
90
100
20
97


c-203
97
100
100
29
100


c-210
100
100
100
20
100


c-217
100
100
100
20
100


c-221
99
100
100
14
100


c-224
99
95
100
25
100


c-231
100
100
100
21
100


c-238
100
96
100
26
100


c-245
95
94
100
14
100


c-253
96
100
100
20
97


c-258
100
100
100
14
100


c-262
100
100
100
34
100


c-266
92
90
95
21
100


c-273
96
90
100
21
93


c-286
95
89
100
24
90


c-306
96
80
100
20
97


c-317
90
89
100
20
100


c-327
100
95
100
34
100


c-346
100
96
100
20
100
















TABLE 23







Insecticidal Activity of Some Compounds


of General Formula (d) on Test Pests









Insecticidal activity













Plutella


Spodoptera


Aphis






xylostella


exigua


craccivora


Solenopsis




Mortality
Mortality
Mortality

invicta




(%)
(%)
(%)
Mortality (%)


Com-
500
500
500
100 ppm












pound
ppm
ppm
ppm
24 h
72 h















d-3
100
98
100
21
87


d-7
100
100
100
20
99


d-8
85
82
90
15
65


d-9
82
79
96
21
77


d-10
55
50
90
34
80


d-11
76
70
99
14
76


d-12
86
96
100
20
100


d-13
82
81
99
26
89


d-14
90
89
100
24
100


d-15
96
100
100
19
97


d-16
85
93
96
34
100


d-17
99
95
100
42
100


d-18
81
80
100
15
85


d-19
100
90
100
23
99


d-20
100
100
100
14
100


d-26
100
100
100
20
100


d-27
100
100
100
14
100


d-28
100
96
100
25
100


d-33
100
99
100
26
100


d-34
90
95
100
25
93


d-35
90
89
100
30
100


d-38
86
9
99
30
84


d-42
100
100
100
31
100


d-46
95
90
100
14
90


d-47
100
100
100
29
99


d-48
96
90
100
26
100


d-49
100
100
100
29
100


d-50
100
90
100
26
93


d-52
100
100
100
24
100


d-54
100
99
100
21
99


d-56
90
89
99
14
80


d-57
89
80
90
20
70


d-58
76
70
96
21
99


d-60
96
90
90
24
90


d-63
100
95
100
20
90


d-64
100
90
100
26
93


d-65
100
100
100
24
90


d-67
100
90
100
41
99


d-69
90
86
100
44
100


d-70
91
90
99
20
98


d-72
90
85
99
26
76


d-73
81
66
96
24
85


d-74
100
100
100
21
99


d-77
100
99
100
44
100


d-81
99
90
100
35
100


d-82
95
89
100
25
90


d-85
100
100
100
30
100


d-86
100
90
100
29
97


d-90
82
80
90
16
85


d-94
89
90
99
20
90


d-98
100
100
100
20
99


d-103
100
98
100
26
93


d-107
100
100
100
24
100


d-109
96
85
99
28
85


d-112
96
80
100
36
99


d-114
100
87
100
24
90


d-115
99
90
100
20
100


d-119
89
90
92
26
83


d-122
91
84
90
24
95


d-127
96
100
100
20
97


d-129
95
100
100
24
100


d-133
70
86
100
21
95


d-141
90
95
100
11
91
















TABLE 24







Insecticidal Activity of Some Compounds


of General Formula (e) on Test Pests









Insecticidal activity













Plutella


Spodoptera


Aphis






xylostella


exigua


craccivora


Solenopsis




Mortality
Mortality
Mortality

invicta




(%)
(%)
(%)
Mortality (%)


Com-
500
500
500
100 ppm












pound
ppm
ppm
ppm
24 h
72 h















e-1
100
100
100
33
100


e-2
100
100
100
25
100


e-3
100
95
100
20
98


e-4
100
100
100
32
100


e-5
100
100
100
34
100


e-6
100
100
100
34
100


e-7
100
100
100
29
99


e-8
100
100
100
35
100


e-9
96
90
100
40
96


e-10
100
100
100
37
100


e-11
100
100
100
33
100


e-12
100
100
100
34
100


e-13
100
100
100
20
100


e-14
100
100
100
34
100


e-15
90
89
100
32
100


e-16
100
100
100
32
99


e-17
100
100
100
30
100


e-18
100
100
100
29
100


e-19
100
100
100
31
90


e-20
100
100
100
31
100


e-21
100
100
100
30
100


e-22
100
100
100
35
100


e-23
100
100
100
34
93


e-24
100
100
100
34
100









It can be seen from the tables that the compounds illustrated in the present invention have a high killing activity on agroforestry pests, animal parasitic pests, sanitary insect pest and the like, have an good activity on lepidoptera, homoptera, hymenoptera pests and the like, have a delayed working effect on Solenopsis invicta, and have a better killing effect on a whole Solenopsis invicta nest and a queen Solenopsis invicta.


Embodiment 10: Environmental Safety Embodiment

Results of toxicity tests of some compounds of the present invention on environmental non-target organisms were shown in the table below:


(1) Toxicity Test on 2nd-Instar Larvae of Bombyx mori L.



Bombyx mori L. is an important economic insect sensitive to pesticides in an agricultural ecosystem, and is also one of the non-target organisms of environmental ecology listed in pesticide registration of China. The 2nd-instar larvae of Bombyx mori L. were used as test objects and tested by using a leaf immersion feeding method.


Operation process: Samples were weighed accurately, and respectively added with 200 μL of dimethyl sulfoxide to prepare 10 g/L mother liquor which was diluted into a concentration of 1000 ppm with an aqueous solution containing 0.05% of Tween-80 during the test. Young cotyledons of mulberries were collected, washed and air-dried, immersed in a liquid medicine, taken out after 5 seconds, naturally air-dryed, and then transferred into a clean vessel. About 35 2nd -instar larvae of Bombyx mori L. were put into the vessel and fed at a constant temperature of 25° C. Each concentration was repeated 3 times, and an aqueous solution containing 0.05% of Tween-80 was used as a control group. After being treated for 24 hours, a number of dead Bombyx mori L. was counted, and a mortality (%) was calculated according to a formula that mortality (%)=(number of live larvae in the control group −number of treated live larvae)/number of live larvae in the control group * 100%. The results were shown in Table 10.


(2) Toxicity Test on Adult Worker Bees of Apis cernan.


Adult worker bees of Apis cernan having the same size were selected for test. The worker bees were collected from beekeeping boxes in the daystart of the test day and tested by using a small beaker method.


Operation process: A small amount of absorbent cotton was put into a 5 mL small beaker, 5 mL of a test liquid medicine (a concentration of 500 ppm) was dropped into the absorbent cotton, and stirred gently to make the absorbent cotton completely wet but not leached obviously, then the small beaker was put into a 500 mL large beaker, then 15 worker bees were put into the large beaker, and finally the large beaker was sealed with gauze. After treatment, the large beaker was placed in a dark room of an artificial climate box. After taking the medicine for 48 hours, a number of live and dead worker bees were investigated. The results were shown in Table 25.









TABLE 25







Toxicity of Some Compounds of Formula (I) Shown in Table 1 to Table 3 on


Environmental Non-target Organisms













Toxicity
determination

Toxicity
determination



Bombyx mori L.
Apis cernan

Bombyx mori L.
Apis cernan


Compound
Mortality (%)
Mortality (%)

Mortality (%)
Mortality (%)


No.
1000 ppm
500 ppm
Compound No.
1000 ppm
500 ppm















A1
9
12
A22
0
3


A4
10
8
A23
0
5


A5
2
9
A26
7
10


A7
6
6
A27
10
15


A8
12
10
A30
8
8


A10
15
12
A32
10
4


A12
13
12
A36
3
0


A13
17
17
A43
3
8


A15
8
5
A44
8
8


A19
7
5
A45
10
11


A21
0
6
A46
7
2


B1
0
0
B7
6
6


B2
3
4
B8
5
4


B3
0
3
B9
0
5


B4
0
0
B10
3
3


B5
6
4
B11
7
3


B6
4
5
B12
5
6


C1
7
7
C32
6
9


C2
5
10
C35
4
4


C3
12
10
C36
2
3


C4
3
0
C37
6
8


C9
8
9
C38
4
0


C10
10
9
C40
4
4


C13
12
10
C43
0
4


C14
10
10
C45
6
3


C15
8
7
C46
5
3


C18
6
5
C50
5
2


C20
8
10
C51
9
5


C24
11
10
C52
10
7


C25
3
0
C56
6
8


C26
4
4
C58
4
4


C29
0
4
C61
9
10


C30
0
0
C62
10
11


C31
3
8
C64
7
9









Embodiment 11: Preparation of Insecticide Composition Containing the Compound of the Present Invention

(1) Oily Suspension.


The following components were prepared in proportion: 25% (weight percentage, same below) of any one of the above compounds; 5% of polyoxyethylene sorbitan hexaoleate; and 70% of higher aliphatic hydrocarbon oil. The components were ground together in a sand mill until sizes of solid particles were 5 μm or less. The viscous suspension obtained could either be used directly, or used after being emulsified in water.


(2) Aqueous Suspension.


The following components were prepared in proportion: 25% of any one of the above compounds; 3% of hydrated attapulgite; 10% of calcium lignosulfonate; 0.5% of sodium dihydrogenphosphate; and 61.5% of water. The components were ground together in a ball mill until sizes of solid particles were approximately 10 μm or less. The aqueous suspension could be used directly.


(3) Bait.


The following components were prepared in proportion: 0.1 to 10% of any one of the above compounds; 80% of wheat flour; and 19.9 to 10% of molasses. These components were completely mixed to form a bait shape as required. The edible baits could be dispersed to places infested by sanitary insect pests, for example, furniture or industrial places, such as kitchens, hospitals or shops or outdoor areas, so as to control the pests by oral ingestion.


Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, but are not intended to limit the scope of protection of the present invention. Those of ordinary skill in the art can make other different forms of transformations or changes based on the above description and ideas. All the embodiments need not and cannot be exhaustive here. Any modifications, equivalent substitutions, and improvements made within the spirit and principle of the present invention shall all fall within the scope of protection of the claims of the present invention.

Claims
  • 1. A fused heterocyclic compound, and an optical isomer, cis and trans isomers or an agromedically acceptable salt thereof, the fused heterocyclic compound has a structure shown in formula (I):
  • 2. The compound according to claim 1, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein; R11 is halogen, —CN, —COR17, —CONR17R18, —S(O) R17, —N R17 R18,—N R17CO R18, aryl, heterocyclyl or heteroaryl; wherein the aryl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;R12 is hydrogen, —COR17, —CONR17R18, —S(O)R17, —S(O)2R17, —N R17 R18, —N R17CO R18, —NR17CONR18R19, —NR17CO2R18, aryl, heterocyclyl or heteroaryl; wherein the aryl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;R13 is hydrogen, —COR17, alkyl, heteroalkyl or alkenyl;R14 is halogen, —CN, —N R17 R18, —O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl, the heteroalkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10; andR15 is hydrogen, halogen, —CN, —N R17 R18,—O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl, the heteroalkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10.
  • 3. The compound according to claim 1, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein when Z1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently hydrogen, halogen, alkyl, heteroalkyl, alkenyl, —S(O) R17, —S(O)2 R17, —COR17, —N R17 R18, —CONR17R18, —N R17CO R18 or —NR17S(O)2R18; R11 is halogen, —CN, —COR17, —CONR17R18, —S(O) R17, —N R17 R18, —N R17CO R18, aryl, heterocyclyl or heteroaryl; wherein the aryl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;R12 is —CONR17R18, —S(O) R17, —S(O)2 R17, —N R17 R18, —N R17CO R18, —N R17CON R18R19, aryl, heterocyclyl or heteroaryl; wherein the aryl, the heterocyclyl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;R13 is hydrogen, —COR17, alkyl or alkenyl; andR14 and R15 are each independently halogen, —CN, —N R17 R18, —O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CO2R18, alkyl, heteroalkyl and alkenyl;wherein the alkyl, the heteroalkyl and the alkenyl is unsubstituted or substituted with one or more substituents R10.
  • 4. The compound according to claim 1, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein, R11 is halogen, —CN, —COR17, —CONR17R18, —S(O) R17, —N R17 R18 or —N R17CO R18;R12 is —S(O) R17, —S(O)2 R17, —N R17 R18, —N R17CO R18, aryl or heteroaryl; wherein the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;R13 is hydrogen, —COR17, alkyl or alkenyl;R14 and R15 are each independently halogen, —CN, —N R17 R18, —O R17, —CO R17, —CO2 R17, —CONR17R18, —N R17CO R18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl;wherein the alkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10; andZ1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently halogen, alkyl, heteroalkyl, —S(O) R17, —S(O)2 R17, —COR17, —N R17 R18, —N R17CO R18 or —NR17S(O)2R18.
  • 5. The compound according to claim 4, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein, R11 is halogen, —CN, —COR17 or —CONR17R18;R12 is —s(o)R17, —S(O)2R17, —NR17COR18, aryl or heteroaryl; wherein the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R10;R13 is hydrogen, —COR17 or alkyl; andZ1, Z2, and Z4 are all C, one or more R16 are provided, and each R16 is independently halogen, heteroalkyl, —S(O)R17, —NR17R or —NR17COR18.
  • 6. The compound according to claim 4, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein R11 —CN or —COR17;R12 is —S(O)R17 or aryl; wherein the aryl is substituted with one or more substituents R10;R13 is hydrogen, —COR17, methyl or ethyl;R14 and R15 are each independently halogen, —OR17, —COR17, —CO2R17, —CONR17R18, —NR17COR18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10; andZ1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently halogen or heteroalkyl.
  • 7. The compound according to claim 4, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein, R11 is —CN or —COR17, and R17 is alkyl or heteroalkyl;R12 is —S(O)R17, and R17 is alkyl or heteroalkyl;R13 is hydrogen, —COR17, methyl or ethyl, and R17 is alkyl;R14 and R15 are each independently halogen, —OR17, —COR17, —CO2R17, —CONR17R18, —NR17COR18, —NR17CO2R18, alkyl, heteroalkyl or alkenyl; wherein the alkyl or the alkenyl is unsubstituted or substituted with one or more substituents R10; andZ1, Z2, Z3 and Z4 are all C, one or more R16 are provided, and each R16 is independently halogen or heteroalkyl.
  • 8. A pyrazole-ring-containing fused heterocyclic compound, and an optical isomer, cis and trans isomers or an agromedically acceptable salt thereof, the pyrazole-ring-containing fused heterocyclic compound having a structure shown in formula (II):
  • 9. The compound according to claim 8, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein, when Z1 is N and Z2 is C, R6 is a monosubstituent —CF3 at a 5-position of a pyridine ring, and the general formula of the compound is shown in formula (a):
  • 10. The compound according to claim 9, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl or heteroalkyl; wherein R7 is hydrogen, hydroxyl, C1-4 alkyl, C1-4 haloalkyl, or amino.
  • 11. The compound according to claim 9, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein when the compound is shown in the formula (a) or the formula (b), and any one of R4 and R5 is hydrogen, R1 is —CN, and R2 is —SOCF3 or —OCF3; or R1 is —CF3, and R2 is —SOCF3; or, when neither R4 nor R5 is hydrogen, R1 is —CN or —CF3; and R2 is —SOCF3, —SOCH2CH3, —OCF3, —CF3, —CN or halogen.
  • 12. The compound according to claim 9, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein when the compound is shown in the formula (c), R3 is —CH3, —Ac or —CH2CH2Cl, R2 is —SOCF3, R1 is —CN, and both R4 and R5 are —CO2Me; or, when R3 is hydrogen, and R2 is —CN, —CF3 or —SOCH2CH3, R1 is —CN or —CF3, and R4 and R5 are each independently —CO2Me or —CH2CO2Me;or, when R3 is hydrogen, and R2 is —OCF3 or —SOCF3, R1 is —CN or —CF3, R4 and R5 are each independently hydrogen, halogen, —CN, —COR7, —CO2R7, —CH2COR7, —CH2COOR7, amino, alkyl, heteroalkyl, aryl or heteroaryl; wherein the amino, the alkyl, the aryl or the heteroaryl is unsubstituted or substituted with one or more substituents R9.
  • 13. The compound according to claim 9, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein when the compound is shown in the formula (d), R3 is hydrogen, and R2 is —CN, —CF3, —SOPh, —SOCH2Ph, —SOC6H13, or
  • 14. The compound according to claim 9, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt of the compound, wherein when the compound is shown in the formula (e), R6 is 3-Cl and 6-CF3, 3-Cl and 4-CF3, 4-Cl and 5-CF3, or 5-Cl and 6-CF3 on the benzene ring; and R4 and R5 are each independently —CO2Me, —CH2CO2Me, —CO2Et, —CH2CO2Et, —CH2CO2CH2CF3 or —CH2CO2CH2CHF2.
  • 15. An agricultural composition, comprising: (a) 0.001 to 99.99% by weight of the compound according to claim 1, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt thereof, or a combination thereof; and(b) an agromedically acceptable carrier and/or excipient.
  • 16. A method of killing or preventing agroforestry pests, sanitary insect pests and pests harmful to animal health comprising directly applying the agricultural composition according to claim 15 to the pests or places contacted by the pests.
  • 17. An agricultural composition, comprising: (a) 0.001 to 99.99% by weight of the compound according to claim 8, or the optical isomer, the cis and trans isomers or the agromedically acceptable salt thereof, or a combination thereof; and(b) an agromedically acceptable carrier and/or excipient.
  • 18. A method of killing or preventing agroforestry pests, sanitary insect pests and pests harmful to animal health comprising directly applying the agricultural composition according to claim 17 to the pests or places contacted by the pests.
Priority Claims (2)
Number Date Country Kind
201711069917.7 Nov 2017 CN national
201810219338.4 Mar 2018 CN national
PCT Information
Filing Document Filing Date Country Kind
PCT/CN2018/113811 11/2/2018 WO 00
Publishing Document Publishing Date Country Kind
WO2019/086009 5/9/2019 WO A
US Referenced Citations (3)
Number Name Date Kind
4072680 Denzel et al. Feb 1978 A
20130150414 Kagabu et al. Jun 2013 A1
20150173359 Frackenpohl Jun 2015 A1
Foreign Referenced Citations (20)
Number Date Country
102892290 Jan 2013 CN
103254125 Aug 2013 CN
103960242 Aug 2014 CN
107108626 Aug 2017 CN
108003162 May 2018 CN
108129481 Jun 2018 CN
102006015467 Oct 2007 DE
0580374 Jan 1994 EP
2305678 Apr 2011 EP
2003201280 Jul 2003 JP
2016040826 Apr 2016 KR
9805638 Feb 1998 WO
0214263 Feb 2002 WO
2004067528 Aug 2004 WO
2007095229 Aug 2007 WO
2007144669 Dec 2007 WO
2007149907 Dec 2007 WO
2010069266 Jun 2010 WO
2013174822 Nov 2013 WO
2016046404 Mar 2016 WO
Non-Patent Literature Citations (22)
Entry
Yang; Pest Management Science 2021, 77, 1013-1022. DOI: 10.1002/ps.6113 (Year: 2021).
National Center for Biotechnology Information. PubChem Substance Record for SID 344180132, SCHEMBL19134571, Source: SureChEMBL. Deposit Date Oct. 7, 2017. Downloaded Dec. 9, 2021 from: https://pubchem.ncbi.nlm.nih.gov/substance/344180132 (Year: 2017).
Supplemental European Search Report in Application EP18873292, dated Jul. 20, 2020. 5 pages. (Year: 2020).
John E. Casida, et al., “Novel GABA receptor pesticide targets,” Pesticide Biochemistry and Physiology, vol. 121, Nov. 2014, pp. 22-30.
Jaime Gálvez, et al., “Design, facile synthesis, and evaluation of novel spiro- and pyrazolo[1,5-c]quinazolines as cholinesterase inhibitors: Molecular docking and MM/GBSA studies,” Computational Biology and Chemistry, vol. 74, Mar. 2018, pp. 218-229.
Zhen Fang, et al., “Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 27, May 2017, pp. 3201-3204.
Gabriella Guerrini, et al., “Identification of a New Pyrazolo[1,5-a]quinazoline Ligand Highly Affine to y-Aminobutyric Type A (GABAA) Receptor Subtype with Anxiolytic-Like and Antihyperalgesic Activity,” J Med Chem., Nov. 2017, pp. 1-12.
Gabriella Guerrini, et al., “Synthesis and Pharmacological Evaluation of Novel GABAA Subtype Receptor Ligands with Potential Anxiolytic-like and Anti-hyperalgesic Effect,” Journal of Heterocyclic Chemistry, vol. 54, Sep. 2017, pp. 2788-2799.
Carson Wiethan, et al., “Synthesis of pyrazolo[1,5-a]quinoxalin-4(5H)-ones via one-pot amidation/N-arylation reactions under transition metal-free conditions,” Organic & Biomolecular Chemistry, Aug. 2016, pp. 1-7.
Gabriella Guerrini, et al., “Pyrazolo[1,5-a]quinazoline scaffold as 5-deaza analogue of pyrazolo[5,1-c][1,2,4] benzotriazine system: synthesis of new derivatives, biological activity on GABAA receptor subtype and molecular dynamic study,” J Enzyme Inhib Med Chem., Mar. 2015, pp. 1-21.
Miaomiao Niu, et al., “An in silico protocol for identifying potential poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors from chemical databases,” New Journal of Chemistry, Oct. 2014, pp. 1-7.
Takeo Fukuzumi, et al., “Exploratory Study on the RNA-Binding Structural Motifs by Library Screening Targeting pre-miRNA-29a,” Chemistry—A European Journal, Oct. 2015, pp. 16859-16867.
Cody J. Wenthur, et al., “Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu2/mGlu3 NAMs,” Bioorganic & Medicinal Chemistry Letters, vol. 24, Apr. 2014, pp. 2693-2698.
Sabrina Taliani, et al., “Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: A Suitable Scaffold for the Development of Noncamptothecin Topoisomerase I (Top1) Inhibitors,” J Med Chem., Aug. 2013, pp. 1-24.
Federica Orvieto, et al., “Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 19, May 2009, pp. 4196-4200.
Michael B. Tropak, et al., “High-Throughput Screening for Human Lysosomal b-N-Acetyl Hexosaminidase Inhibitors Acting as Pharmacological Chaperones,” Chemistry & Biology, vol. 14, Feb. 2007, pp. 153-164.
Sandriyana Soelaiman, et al., “Structure-based Inhibitor Discovery against Adenylyl Cyclase Toxins from Pathogenic Bacteria That Cause Anthrax and Whooping Cough,” Journal of Biological Chemistry, vol. 278, Apr. 2003, pp. 1-9.
Flavia Varano, et al., “Synthesis and Biological Evaluation of a New Set of Pyrazolo[1,5-c]quinazoline-2-carboxylates as Novel Excitatory Amino Acid Antagonists,” Journal of Medicinal Chemistry, vol. 45, May 2002, pp. 1035-1044.
Krishna Kumar Gnanasekaran, et al., “Pyrazoloquinazolinones and pyrazolopyridopyrimidinones by a sequential N-acylation-SNAr reaction,” Tetrahedron Letters, vol. 56, Jan. 2015, pp. 1367-1369.
Xinying Zhang, et al., “Water-Mediated Selective Synthesis of Pyrazolo[1,5-a]quinazolin-5(4H)-ones and [1,2,4]Triazolo[1,5-a]quinazolin-5(4H)-one via Copper-Catalyzed Cascade Reactions,” Synthetic Communications, vol. 45, Aug. 2015, pp. 1-11.
Lin Gao, et al., “Copper-catalyzed tandem reactions of 2-bromobenzaldehydes/ ketones with aminopyrazoles toward the synthesis of pyrazolo [1,5-a]quinazolines,” Tetrahedron Letters, vol. 55, Jul. 2014, pp. 4997-5002.
Hyun, S.Y. et al., “Aromatic compound as electroluminescent host or hole transport material,” Chemical Abstract, Dec. 2016, pp. 1-5.
Related Publications (1)
Number Date Country
20210188853 A1 Jun 2021 US